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ABSTRACT 
 
Non-alcoholic fatty liver disease (NAFLD) prevalence is growing dramatically with 
epidemic of obesity. A subset of patients with NAFLD is lean, but the 
pathophysiology of this sub-group is still not well known. This project aims to 
investigate the roles of metabolic health and metabolic adaptation in the pathogenesis 
of lean NAFLD, using well-characterised Caucasian subjects with lean and non-lean 
NAFLD, and comparing them with the lean and non-lean healthy controls, and murine 
models.  We investigated in detail their demographics, genetic background, bile acid 
profile, gut microbiota and their bile acid regulatory activity to further understand the 
underlying pathophysiology governing the development and progression of lean 
NAFLD. We then compared our findings in humans with that of mice models of lean 
and non-lean NAFLD. Finally, we performed an untargeted metabolomics analysis on 
lean and non-lean NAFLD patients to determine other metabolic pathways and 
biomarkers, which may be relevant to lean NAFLD.  
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 
The majority of this chapter has been submitted for 
publication in Nature Reviews Gastroenterology and 
Hepatology, and is currently in revision: 
Chen, F, et al.; The role of metabolic health and metabolic 
adaptation in lean NAFLD; invited review and submitted for 
publication in Nature Reviews Gastroenterology and Hepatology, 
28 January 2020; manuscript no: NRGH-19-237V1 
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1 INTRODUCTION 
1.1 BURDEN OF LIVER DISEASE 
Chronic liver disease affects a major proportion of the global population and accounts 
for about 2 million deaths worldwide, which is roughly 3.5% of all deaths, an increase 
in rate from the previous reported rate of 3% in the year 2000 (Asrani et al. 2019). At 
least half of the mortalities caused by chronic liver disease is contributed by liver 
cirrhosis, where it ranks within the top 20 causes of deaths globally (Asrani et al. 2019). 
The aetiology and distribution of chronic liver disease varies geographically, where 
non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease account for the 
majority of causes of cirrhosis in Western countries and viral hepatitis still remains the 
predominant cause of cirrhosis in Asian countries (Lozano et al. 2012). In addition, 
NAFLD represents a significant economic burden to society that reduces quality of life 
including through increased symptoms of fatigue and decreased mental well-being. This 
affects how well a person is able to function in their daily activities (Sayiner et al. 
2016). In the United States alone, patients with NAFLD are reported to have higher 
annual health care expenditure ($19,390 versus $5,567) with higher rates of 
unemployment (55% versus 30%) and disability related unemployment (30.5% versus 
6.6%) compared to those without chronic liver disease. In Europe, NAFLD is estimated 
to have an annual cost of about €35billion (from €354 to €1,163 per patient; highest in 
patients aged 45-65) (Stepanova et al. 2017; Z. M. Younossi et al. 2016b). 
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1.2 EPIDEMIOLOGY AND DEFINITION OF NAFLD 
 
Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause for 
liver disorder in Western industrialized nations, with a prevalence ranging between 6 – 
35% (median 20%) worldwide (Bellentani 2017). NAFLD can be defined as the 
presence of more than 5% hepatic steatosis without evidence of hepatocellular injury in 
the form of hepatocyte ballooning, in the absence of other causes for secondary hepatic 
fat accumulation such as excessive alcohol consumption or use of steatogenic 
medications (Chalasani et al. 2012; Le et al. 2017).  The majority of NAFLD cases are 
associated with presence of metabolic risk factors such as obesity, diabetes, 
hypertension and dysipidaemia (Le et al. 2017). This is reflected with the parallel 
increase of metabolic syndrome (the Adult Treatment Panel III diagnosis of metabolic 
syndrome requires the presence of at least three of: waist circumference >102cm in men 
and >88cm in women, triglyceride level of 150 mg/dL (or 1.7 mmol/L) or greater, high 
density lipoprotein (HDL) level of less than 40 mg/dL (or 1.0 mmol/L) in men and less 
than 50 mg/dL (or 1.3 mmol/L) in women or use of lipid medications, systolic blood 
pressure greater than 130mmHg or diastolic blood pressure greater than 85mmHg or use 
of anti-hypertensive medications, and fasting plasma glucose level of 110 mg/dL (or 5.6 
mmol/L) or greater or use of diabetic medications (Chalasani et al. 2012)) with NAFLD 
in Western countries (Le et al. 2017).  
 
Although the majority of NAFLD is associated with obesity, a small but significant 
proportion of patients with NAFLD do not have obesity. This sub-group, also known as 
“lean NAFLD” has been understudied in the literature and will be the focus of this 
thesis. 
  4 
1.3 FACTORS AFFECTING NAFLD DEVELOPMENT 
 1.3.1 Modifiable risk factors 
 Lifestyle factors 
 
Studies have shown that lifestyle habits may partially explain the heterogeneity of 
metabolic health and non-alcoholic fatty liver disease. Even overweight and obese 
individuals may have the same overall mortality risk as normal weight people. 
Population cross-sectional studies have shown that metabolically healthy obesity is 
more prevalent in younger and female adults, and that these individuals are more likely 
to exercise and less likely to smoke or drink heavily (Goday et al. 2016; Matheson et al. 
2012). A recent study estimated the prevalence of insufficient physical activity at 
around 23.3% in 2010 (Hallal et al. 2012). Alarmingly, a more recent report on 
worldwide trends in physical inactivity between 2001-2016 suggested that the 
prevalence of physical inactivity has not altered since 2001, with the rate being twice as 
high in high income countries, and rising over time (Guthold et al. 2018). 
 
The possible underlying mechanism governing this may lie in how individuals modulate 
whole body energy metabolism, as evidenced by the fact that concurrent physical 
activity increases fatty acid oxidation during high calorie intake period (S. R. Smith et 
al. 2000). In addition, lower fasting respiratory quotient has been shown to be positively 
associated with the ability to extract energy from fat (Pujia et al. 2016). Other lifestyle 
factors which have been shown to contribute to cardiometabolic health risk include 
sleep duration and sleep quality factors (Koren and Taveras 2018). A study in China has 
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found that patients with NAFLD have shorter duration of sleep compared to healthy 
controls (C. Li et al. 2019). The most commonly used definition of healthy lifestyle 
include the adaptation of four healthy habits which include moderate alcohol intake, not 
smoking, 30 minutes of exercise daily and eating five or more servings of vegetables 
and fruits daily (Matheson et al. 2012). 
 
Role of diet and microbiome 
 
About 10-100 trillion micro-organisms composed of bacteria, fungi, archae, and viruses 
live inside or on the human body. The majority of these microbial symbionts 
(collectively known as the microbiota) reside within the digestive tract (Turnbaugh et al. 
2007). Four main phyla of bacteria make up the human microbiome: Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria. The gut microbiome plays a role in 
the bile acid pathway in the conversion of primary to secondary bile acids (bile acids 
will be discussed in more detail in later section). The conversion of primary bile acids to 
secondary bile acids require the initial deconjugation by Bile Salt Hydrolase (BSH) 
before downstream modifications by 7-alpha dehydroxylase to produce deoxycholic 
acid (DCA) and lithocholic acid (LCA) or by 7-alpha hydroxysteroid dehydrogenase to 
produce ursodeoxycholic acid (UDCA) (Jiao et al. 2017; Ridlon et al. 2006). BSH 
activity is present in all major gut bacterial species, however the conversion of primary 
to secondary bile acid by 7-dehydroxylation are carried out only by bacteria with bile 
acid inducible genes. These include those belonging to the genera Clostridium (clusters 
XIVa and XI), Eubacterium, Blautia, Ruminococcaceae and Lachnospiraceae, all of 
which belong to the Firmicutes phylum (Wahlstrom et al. 2016a; Yokota et al. 2012).  
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Given the anatomical link between the intestine and the liver, the microbiota has been 
proposed to play a role in the pathogenesis of various hepatic pathologies. A number of 
studies have demonstrated the role of intestinal dysbiosis in a variety of human diseases, 
including NAFLD (Wieland et al. 2015). These studies have been performed using both 
murine models as well as in humans. Unfortunately, due to the large variation in the 
study design, population, sample sizes, and clinical endpoints, the results remain 
controversial and difficult to interpret. Common to all published studies in the literature 
on the role of microbiome in NAFLD, however, is that these studies have demonstrated 
a measurable difference in the microbiome between different stages of NAFLD and 
NASH, compared to their healthy controls. However, causality has not been proven and 
further studies are required to delineate mechanistic links. 
 
Multiple factors influence microbiome composition. These include age, BMI, genetics 
and diet (Wu et al. 2011). Diet has been shown to exert predominant effect on 
microbiome composition, irrespective of the host’s genotypes (Carmody 2015). Studies 
have shown that long-term dietary habits are strongly associated with specific 
enterotype clustering of microbiota, where Bacteroides enterotype was associated with 
subjects who have diet rich in animal fat and protein and the Prevotella enterotype with 
individuals with carbohydrate rich diet (De Filippo et al. 2010; Wu et al. 2011). Of 
interest, it has been suggested that cholesterol intake is higher in lean compared to obese 
NAFLD (Enjoji et al. 2012; Musso et al. 2003; Yasutake et al. 2009b). Furthermore, 
although alterations in diet have been shown to change the microbiota composition 
within 24 hours, an individual’s enterotype identity is only affected by their long-term 
dietary habit (Wu et al. 2011). Few studies on the microbiota profile of patients in lean 
and non-lean NAFLD have demonstrated evidence of microbial dysbiosis in lean 
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NAFLD compared with non-lean NAFLD and healthy controls, but the specific 
changes, as well as the role of these changes in the pathophysiology of lean NAFLD 
remain controversial (B. Wang et al. 2016; Wieland et al. 2015). 
 
Role of bile acids and its regulators 
 
The pathogenesis of NAFLD and the progression of NAFLD from simple steatosis have 
not been fully understood. It has been thought that certain factors such as genetic 
predisposition, insulin resistance, inflammatory events involving mediators such as 
endotoxins, adiponectin, oxidative stress as well as hepatotoxic bile acid played a role in 
the disease progression (Arab et al. 2017; Perez and Briz 2009). Bile acids are steroid 
molecules synthesized in the liver from cholesterol. The primary bile acids 
chenodeoxycholate (CDCA) and cholate (CA) are synthesized from the cholesterol in 
the liver, conjugated into their taurine or glycine conjugates and excreted into the bile, 
where they assist in fat emulsification and absorption. Primary bile acids also undergo 
conversion into the secondary bile acids deoxycholate (DCA), lithocolic acid (LCA) 
and ursodeoxycholic acid (UDCA) by the intestinal bacteria and mostly reabsorbed in 
the distal ileum via the enterohepatic circulation (Arab et al. 2017; Khalid et al. 2015). 
Besides their role in the digestion and absorption of fat and fat soluble vitamins, bile 
acids have also been recognised as signalling molecules involved in the regulation of 
lipid and glucose metabolism, as well as inflammatory modulators in the liver and 
several other tissues (Arab et al. 2017; Chavez-Talavera et al. 2017; Khalid et al. 2015). 
This is mediated through their actions on specific bile acid receptors, including 
members of the farsenoid X receptor (FXR), pregnane X receptor (PXR), Vitamin D 
receptor and Takeda G protein coupled receptor 5 (TGR5) (Arab et al. 2017). The 
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binding of bile acids to the FXR in the ileocytes trigger the transcription and production 
of Fibroblast Growth Factor 19 (FGF-19), which is then transported to the liver where it 
binds to the tyrosine kinase FGF receptor 4 (FGF4R4) (Khalid et al. 2015). This then 
activates the c-Jun N terminal-kinases 1/2 signalling pathways which subsequently 
down regulates the CYP7A1, a key cytochrome P450 enzyme in the bile acid synthesis 
pathway (Khalid et al. 2015). FXR can be stimulated by most bile acids, although at 
varying potency, with CDCA displaying the highest potency, followed by LCA and 
DCA then CA (Khalid et al. 2015). In addition to regulating bile acid synthesis, the 
FGF-19 have also been shown to play a significant role in the glucose and cholesterol 
homeostasis, by promoting hepatic glycogen storage, fatty acid beta oxidation and 
decreasing hepatic lipogenesis (Arab et al. 2017; Khalid et al. 2015). The enzymes 
involved in bile acid synthesis are controlled tightly in response to the changing 
metabolic conditions, and dysregulation of bile acid synthesis and metabolism is often 
an indication of liver dysfunction. Bile acid levels, therefore, have been recognized as 
sensitive indicators of hepatobiliary diseases and have been implicated to play a role in 
several diseases including alcoholic and non-alcoholic fatty liver diseases (Xie et al. 
2015).  
 
Given the limited resources in the drug treatment of NAFLD other than promotion of 
lifestyle changes in diet and exercise habits as well as control of comorbidities (type 2 
diabetes, hypertension and dyslipidaemia), bile acid (BA) derivatives and compounds 
that influence BA-related signalling pathways are emerging as potentially useful 
therapeutic agents for NAFLD and NASH.  
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For metabolic homeostasis, in addition to the neuroendocrine axis, caloric intake and 
physical activity, the enterohepatic circulation, including bile acids (BA) and their 
metabolites, and gut microbiota are intimately involved. Bile acids are the principal 
route for cholesterol catabolism, and recent evidence demonstrates that a high intake of 
dietary cholesterol (Ioannou et al. 2009), elevated levels of hepatic cholesterol (Min et 
al. 2012; Puri et al. 2007; Simonen et al. 2013; Van Rooyen et al. 2011) and disrupted 
hepatic cholesterol homeostasis are pivotal drivers of the pathogenesis of NAFLD (Arab 
et al. 2017; Puri et al. 2007; Simonen et al. 2013). Despite the increasing number of 
studies, our knowledge into the role of bile acids in NAFLD pathogenesis and 
progression is still incomplete. A number of studies looking at the metabolomics profile 
of patients with NAFLD/NASH have shown that the progression from NAFLD to 
NASH is characterised by increase in total serum bile acid concentration as well as 
variations in the level of primary and secondary bile acid compositions (Ferslew et al. 
2015; Jiao et al. 2017; Kalhan et al. 2011; Puri et al. 2017). Interestingly, total bile acid 
concentration was also found to be higher in patients who have achieved weight loss 
through previous gastric bypass as compared to those without previous gastric bypass 
with similar preoperative or current BMI, possibly through improved insulin sensitivity 
(Dutia et al. 2015; Kohli et al. 2013; Legry et al. 2017; Patti et al. 2009; Sachdev et al. 
2016; Werling et al. 2013). There is strong evidence that activation of bile acid 
signalling induces improvements in metabolic (glucose and lipid) phenotype in 
murine models (Pierre et al. 2016). Furthermore, in human and murine models, 
elevated bile acids play a role in the metabolic improvements after bariatric surgery, 
including in type 2 diabetes, dyslipidaemia and NASH resolution, even before 
significant weight loss (A. P. Chambers et al. 2011; Kohli et al. 2015; Patti et al. 
2009; Pournaras et al. 2012). The role and regulation of bile acid, through its specific 
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nuclear receptors such as the Farsenoid X receptor (FXR), in the pathogenesis and 
treatment of NAFLD has been described in multiple studies (Khalid et al. 2015; 
Mudaliar et al. 2013; Puri et al. 2017). Activation of FXR receptors by binding of bile 
acids or with FXR agonists has been shown to result in improvement of lipid and 
glucose metabolism through the release of Fibroblast Growth Factor 19 (FGF-19), 
which not only results in down regulation of CYP7A1, the rate-limiting enzyme in bile 
acid synthesis but also in promotion of fatty acid beta oxidation and inhibition of 
glycogen synthesis (Arab et al. 2017; Khalid et al. 2015).  Activation of FXR activity on 
the hepatic stellate cells has also been shown to provide protection against liver fibrosis 
in murine models (Schumacher et al. 2020).A number of drugs targeting the bile acid 
pathways such as the FXR agonists Obeticholic acid and FGF-19 analogue NGM282, 
are currently in phase 3 and 2 clinical trials respectively for the treatment of NAFLD, 
and have been shown to improve liver histology in patients with NAFLD (Harrison et 
al. 2018; Mudaliar et al. 2013; Neuschwander-Tetri et al. 2015).  
 
Interestingly, insulin resistance improved only with FGF-19 analogue treatment, but not 
with FXR agonist treatment (Harrison et al. 2018; Neuschwander-Tetri et al. 2015). 
This suggests that there may be another receptor which, together with the FXR 
receptors, play a role in regulating metabolic pathways involved in mediating glucose 
homeostasis and insulin resistance. Indeed, recent studies looking at the role of bile acid 
in murine models undergoing bile acid diversion surgery to mimic Roux-en-Y gastric 
bypass described the importance of FXR receptors and Takeda G-protein coupled 
receptors 5 (TGR 5) in metabolic improvements post bariatric surgery, through the 
down-stream production of Glucagon-like-peptide 1 (GLP-1) (Albaugh et al. 2019; 
Pierre et al. 2019).  Studies regarding the effect of weight loss after bariatric surgery on 
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the intestinal FXR and TGR5 activities have been controversial. Some mice studies 
have shown that intestinal FXR and TGR5 are inversely related, however studies on the 
effect of intestinal FXR agonist Fexaramine have shown increased GLP-1 secretion and 
improved glucose tolerance in mice (Browning et al. 2019; Pathak et al. 2018; Trabelsi 
et al. 2015). Due to inter-species differences in BA physiology, these findings have not 
been directly extended into human studies, and findings regarding BA physiology 
changes post bariatric surgery in humans also remain conflicting. Previous studies have 
shown that the gene expression of the major BA target, the FXR, is increased in the 
liver but decreased in the small intestine, whereas the intestinal TGR5 receptor is 
increased after Roux-en-Y gastric bypass in obese patients (Browning et al. 2019). 
However, along with the increased BA levels, both FGF-19 and GLP-1 levels have also 
been shown to increase post bariatric surgery, which are presumed to support the 
metabolic benefits post bariatric surgery (Browning et al. 2019; Cole et al. 2015).  
 
FXR and TGR5 receptors are also differentially expressed in adipocytes, FXR in white, 
and TGR5 in brown adipocytes, respectively, as well as in certain immune-
inflammatory cells in adipocytes (E. P. Broeders 2015). In adipocytes, FXR regulates 
the differentiation and functions of adipocytes and promotes peroxisome proliferator-
activated receptor-γ (PPARγ) activity which interferes with the Wnt/β-catenin pathway, 
while TGR5 activates the thyroid hormone receptor to uncouple mitochondrial function 
and increase thermogenesis in brown adipose tissue, which further contributes to their 
anti-inflammatory and insulin-sensitizing effects (Abdelkarim et al. 2010; Watanabe et 
al. 2006). The enzymes involved in bile acid synthesis are controlled tightly in response 
to changing metabolic conditions and metabolic alterations, along with chronic low-
  12 
grade inflammation, which are characteristics of meta-inflammatory disorders such as 
obesity, type 2 diabetes and NAFLD (Chavez-Talavera et al. 2017; Xie et al. 2015).  
 
Therefore, the interplay between an individual’s lifestyle factors, combined with their 
microbiota and bile acid profile, shaped in part by their dietary composition and genetic 
as well as epigenetic backgrounds, has a significant impact on an individual’s overall 
metabolic health. This in turn governs the risk for metabolic disorders, including 
NAFLD. 
 1.3.2 Non-modifiable risk factors 
 Genetic factors 
 
Genetic factors in NAFLD 
 
NAFLD is a complex disease phenotype. Multiple twins and familial studies have 
shown that first degree relatives of NAFLD patients are at increased risk of the disease 
than the general population and that about 50% of hepatic fat are inherited. The hepatic 
fat content subsequently affects the risk of metabolic disease and liver fibrosis (Eslam et 
al. 2018a; Schwimmer et al. 2009).   
 
In addition, NAFLD also demonstrates interethnic variability as shown in multiple 
epidemiological studies. Individuals from South America, Asia, Hispanic descents in 
the United States are at increased risk of NAFLD, whereas those of European and 
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African descent showed lower NAFLD prevalence, irrespective of the socioeconomic 
status, insulin resistance and adiposity (Guerrero et al. 2009; Z. M. Younossi et al. 
2016a).  
 
Various genome-wide association studies (GWAS) in the last decade have been the 
focus of extensive research to elucidate the role of genetic influence in many disease 
processes, including NAFLD. The discovery of the single nucleotide polymorphism 
(SNP) rs738409 C/G variant in PNPLA3 (patatin-like phospholipase domain containing 
3, also known as adiponutrin or calcium-independent phospholipase A2-epsilon), which 
is now regarded as a major genetic component of NAFLD/NASH in the first GWAS of 
NAFLD has significantly contributed to our understanding of the genetic component of 
the disease. This SNP encodes for the amino acid substitution I148M and is 
significantly associated with the accumulation of fat in the liver as well as histological 
severity and progression of NAFLD (Romeo et al. 2008; Sookoian and Pirola 2011). 
This substitution induces loss of function of the enzymatic hydrolase activity, resulting 
in entrapment of triglycerides and retinyl esters in lipid droplets of hepatocytes and 
hepatic stellate cells, and subsequently leading to liver damage and accumulation of 
extracellular protein, with the end result being liver fibrosis development (Eslam et al. 
2018a). The expression of rs738409 C>G in PNPLA3 allele was found to be higher in 
Asian lean NAFLD compared to obese NAFLD, although in another study involving 
Western lean NAFLD, there was no significant difference found in the frequency of the 
allele expression between lean and non-lean group(Fracanzani et al. 2017; Wei et al. 
2015). Nevertheless, studies have demonstrated independent association of this allele 
with NASH development and higher degree of fibrosis (grade 2 or more) in lean 
NAFLD (Fracanzani et al. 2017; Wei et al. 2015). In addition, the rs738409 variant also 
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explains some sexual dysmorphism in NAFLD, with higher effect seen in women 
compared with men (Sookoian and Pirola 2011).   
 
Aside from the discovery of highly replicated variant such as rs738409, other variants in 
multiple loci with diverse functions in NAFLD have also been uncovered through 
GWAS.  These include variants in multi-gene locus called 
NCAN/TM6SF2/CILP2/PBX4 located in the TM6SF2 (transmembrane 6 superfamily 
member 2) gene, which is non-synonymous for the rs58542926 variant, which encodes 
the amino acid substitution p.Glu167Lys (E167K) involved in the enrichment of 
triglycerides to apolipoprotein B100 in the pathway of very low density lipoprotein 
secretion from hepatocytes (Eslam et al. 2016b). Carriers of this mutation has been 
shown to have higher liver triglyceride content and lower circulating lipoproteins, 
resulting in greater risk of NAFLD progression but interestingly lower risk of 
cardiovascular diseases (Eslam et al. 2018a). Additionally, in a recent study, carriers of 
this variant were significantly associated with increased endotoxemia and elevated 
alanine transaminase level as well as increased hepatic triglyceride content independent 
of obesity, insulin resistance and alcohol intake (Kozlitina et al. 2014; Pang et al. 2017). 
Compared to obese NAFLD, lean NAFLD has been shown to carry higher prevalence 
of rs58542926 C>T in TM6SF2 allele (Fracanzani et al. 2017). 
 
Another variant discovered through NAFLD-GWAS was the variant rs780094 in the 
GCKR (glucokinase regulatory gene), whose missense is associated with a modest risk 
of having a fatty liver, with pooled odds ratio of 1.25 (Speliotes et al. 2011; Zain et al. 
2015). A number of other variants have been found to be associated with NAFLD 
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disease severity and progression, but all these variants have quite a diverse effect on 
NAFLD susceptibility, conferring only a small to moderate increment in risk, and 
explaining only a minor proportion of familial clustering (Manolio et al. 2009).  
 
Recently, the membrane bound O-acyltransferase domain-containing 7 (MBOAT7) 
rs641738 C>T variant was found to be associated with the risk of NAFLD, 
inflammation and fibrosis, as well as risk of NAFLD progression to hepatocellular 
carcinoma (HCC). This protein is involved in the remodelling of phosphatidylinositol 
with arachidonic acid as part of the Land’s cycle. The rs641738 C>T variant results in 
downregulation of MBOAT7 at an mRNA and protein level, which subsequently 
reduces the level of phosphatidyl-inositol containing arachidonic acid in hepatocytes 
and in the circulation (Mancina et al. 2016).  
 
While gene polymorphisms undoubtedly play a role in development of liver fibrosis in 
NAFLD, it does not fully explain the inter-individual variability in the rate of fibrosis 
development (Zeybel et al. 2015). In the recent study looking into the role of genetic 
polymorphism on the pathogenesis of NAFLD in non-obese patients, for example, no 
significant association has been found between the presence of the alleles PNPLA3 and 
TM6SF2 with histological severity (J. C. Leung et al. 2017a). Furthermore, there is 
increasing understanding that in most complex disease and phenotype, the predictive 
value of these genetic variants towards clinical practice outcome is only limited (Hardy 
and Mann 2016). It has become more apparent that studies looking at the gene-gene or 
gene-environment factors may improve our understanding of the inter-patient variability 
on the disease progression (Eslam and George 2016; Hardy et al. 2016).   
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Genetic contribution of obesity and fat distribution 
 
Considerable inter-individual variation exists with regards to metabolic risk for a given 
BMI. The evidence for the role of genetics in determining how an individual respond to 
excess energy dates back to more than 25 years ago where a study involving 12 pairs of 
identical twins showed variations in weight gain and fat distribution among the pairs in 
response to overfeeding(Bouchard et al. 1990). The waist hip ratio, which has been used 
as surrogate measure of regional fat distribution is estimated to be heritable in up to 
60%, independent of the risk for overall obesity (Schleinitz et al. 2014). With the era of 
genome wide association studies (GWAS), several genetic loci have been identified to 
be involved in regulating obesity and controlling body extra fat distribution as well as 
the metabolic profile of excess adiposity (i.e. metabolically healthy obesity vs 
metabolically unhealthy obesity)(Iacobini et al. 2019). The single nucleotide 
polymorphism (SNP) near MC4R gene has been involved in obesity and remained one 
of the major loci associated with waist circumference (J. C. Chambers et al. 2008).  A 
meta-analysis of GWAS in 2010 have uncovered 13 loci associated with WHR adjusted 
for BMI (RSPO3, VEGFA, NISCH-STAB1, TBX15-WARS2, NFE2L3, GRB14-COBLL1, 
DNM3-PIGC, ITPR2-SSPN, LY86, HOXC13, ADAMTS9, ZNRF3-KREMEN1, CPEB4) 
and the known association signal  at LYPLAL1 involved in lipase activity was also 
confirmed, with effect sizes reaching 0.059 per risk allele in women (Heid et al. 2010). 
Many of these loci have also been showed to be associated with metabolic traits such as 
fasting glucose, insulin, adiponectin levels and BMI, as well as with metabolic 
conditions such as type 2 diabetes, hypertension and coronary artery disease 
(Kilpelainen et al. 2011; Schleinitz et al. 2014). Several genetic variants have also been 
associated with lower risk of metabolic abnormalities despite BMI in the obese range 
(Yaghootkar et al. 2016). Interestingly, the same genetic variants have also been shown 
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to share similar pattern of metabolic trait association with the monogenic lipodystrophy 
phenotype, including lower BMI, higher VAT to SAT ratio, impaired insulin sensitivity 
and increased risk of type 2 diabetes (Iacobini et al. 2019; Yaghootkar et al. 2014). This 
suggests that unlike in specific altered fat distribution condition like lipodystrophy 
where there is a clear genetic mutation involved, there seems to be a polygenic nature 
influencing fat distribution (visceral vs subcutaneous) and metabolic trait, with further 
influence from other factors such as epigenetic, environmental and biologic factors 
(Schleinitz et al. 2014). 
 
Epigenetic factors 
 
Despite the advances of genetic analyses to identify polymorphisms associated with 
WHR and fat distribution, these can only explain a small proportion of phenotypic 
variance and genetic heritability. Therefore, other factors linking genetic to 
environmental factors such as epigenetics need to be considered. The study of 
epigenetics encompasses the study of how non-genetic factors act on the gene and affect 
its expression and phenotype (Hardy and Mann 2016). The epigenetic mechanisms act 
as interphase between an individual’s genetic background and his environmental cues 
and are dynamically regulated throughout the individual’s lifetime (Hardy and Mann 
2016). These mechanisms comprise of DNA methylation, histone modifications and 
chromatin remodeling, and non-coding RNAs (Hardy and Mann 2016).  
 
DNA methylation refers to the addition of a methyl group to the fifth carbon position on 
the cytosine base in the cytosine-phosphoguanine (CpG) dinucleotide region to form 5-
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methylcytosine. This process occurs throughout the genome, but when it occurs in the 
gene promoter region, in the region rich in CpG dinucleotides (CpG islands), this then 
causes gene repression by affecting its ability to affect transcription factor binding and 
chromatin structure (Bergman and Cedar 2013; Bian et al. 2013). DNA methylation 
profile is not inherited from the gametes, but rather re-established at the time of 
implantation at the very early embryo stage. This profile is then maintained through 
every cell division and plays an important role in various important processes including 
genomic imprinting, embryonic development, cellular differentiation and chromosomal 
stability (Bergman and Cedar 2013; Zeybel et al. 2015).   
 
Two distinct classes of enzymes, namely the DNA methyltransferase (DNMT1, 
DNMT3a and DNMT 3b) and the Ten-Eleven Translocation (TET1-3) enzymes, 
regulate the process of DNA methylation (Hardy and Mann 2016). DNA 
methyltransferase 1 (DNMT1) is responsible for maintaining DNA methylation profile 
in daughter cells during mitosis, whereas DNMT3a and DNMT3b are responsible for 
regulating de novo DNA methylation in the absence of cell division. TET enzymes, on 
the other hand, are responsible for restoring unmodified cytosine residue by catalysing 
oxidation of methyl groups on DNA (Hardy and Mann 2016; Mann 2014).   
 
Histone modifications include methylation (mono-, di- or tri-), acetylation and 
citrullination of one or more amino acids in the N-terminal tails of core histones. Non-
coding RNAs (ncRNA), including short micro RNA (miRNA), Piwi-interacting RNA 
(piRNA) and large intervening non-coding RNA (lincRNA), can self-propagate and 
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transmit regulatory information independent of the underlying DNA (Bernstein et al. 
2007; Zaratiegui et al. 2007). 
 
DNA methylation is the most common and best-studied epigenetic mark. One of the 
earliest study of the role of DNA methylation in human disease involved the work by 
Feinberg et al in 1983 where they discovered global methylation changes of DNA in 
human tumours (Feinberg and Vogelstein 1983).  Subsequently, a number of studies 
have followed demonstrating the roles of DNA methylation in tumorigenesis, such as 
hypermethylation of tumour-suppressor genes as well as the role of DNA methylation in 
the inactivation of microRNA (miRNA) (Esteller 2008).  Studies into the roles of DNA 
methylation in many other non-malignant human diseases have also emerged over the 
next decade, including the role of DNA methylation in aging process, as well as in a 
number of complex diseases such as Type 1 Diabetes, liver fibrosis, many autoimmune 
conditions.      
 
The role of DNA methylation in NAFLD patients has also been the focus of a number 
of studies in the past decade. Methylation in the promoter region of anti-fibrogenic gene 
such as peroxisome proliferator-activated receptor α (PPARα) has been correlated with 
peripheral insulin resistance, fasting insulin level and homeostasis model assessment of 
insulin resistance (HOMA-IR) in patients with NAFLD (Sookoian et al. 2010; Zeybel et 
al. 2015). In a study comparing DNA methylation level within several fibrosis related 
genes, Zeybel et al has shown that DNA methylation level at specific CpGs within 
genes known to affect fibrosis differ between patients with mild versus severe NAFLD. 
In this study, there was more methylation seen in anti-fibrogenic genes such as PPARα 
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and PPARδ, and less methylation in profibrogenic genes such as transforming growth 
factor β1 (TGFβ1), Collagen 1A1 and platelet derived growth factor α (PDGFα) in 
patients with severe NAFLD compared to those with mild NAFLD (Zeybel et al. 2015). 
 
The strong adipose tissue-specific expression patterns of genes playing important role in 
early development have been found to be preserved from one pre-adipocyte to the next 
over several generations, suggesting the existence of yet unknown mechanism to 
maintain expression profiles over time (Schleinitz et al. 2014). Genome-wide 
methylation analysis using methylated DNA immunoprecipitation sequencing of eight 
different adipose depots in three pig breeds displaying different fat levels despite living 
in comparable environments demonstrated functionally relevant methylation differences 
between different adipose depots. These differences were reflected in the visceral 
adipose tissue, which carries the metabolic risk factors associated with impaired 
inflammatory and immune responses (M. Li et al. 2012). 
 
Several human studies have also supported the role of epigenetics in the regulation of 
fat distribution. DNA methylation levels at the LEP promoter encoding for the protein 
leptin, which is the main player in regulation of energy homeostasis, were shown to be 
related to its tissue distribution. Furthermore, dynamic changes in adipose tissue leptin 
expression as a result of weight loss are not associated with alterations in leptin 
promoter methylation patterns (Marchi et al. 2011). In addition, in another recent study, 
altered DNA methylation at the IGF2/H19 locus as a result of adverse in-utero 
environments have been associated with changes in subcutaneous fat measures, but not 
visceral or central adiposity (Huang et al. 2012). 
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It has been widely shown in multiple studies involving several species that oscillations 
of intrauterine and early postnatal nutritional, metabolic and hormonal environments 
may increase susceptibilities to the development of metabolic disorders and diseases in 
later life (Plagemann 2004). Furthermore, maternal nutrition during pregnancy 
contributes to the perinatal programming of the genome which has influence on fetal 
body composition and adverse fat distribution, and ultimately risk of obesity and 
metabolic diseases later in life (Blumfield et al. 2012). These ‘embryonic or fetal 
programming’ suggests that metabolic health and adiposopathy is a transgenerational 
disease (H. Bays and Scinta 2015). 
 
1.4 FACTORS AFFECTING NAFLD PROGRESSION 
 
NAFLD covers a spectrum of liver condition ranging from simple steatosis (non-
alcoholic fatty liver) to non-alcoholic steatohepatitis (NASH) involving hepatocyte 
injury and inflammation with or without fibrosis (Bedossa 2016).  The histologic 
diagnosis of NASH requires the presence of more than 5% hepatic steatosis and 
inflammation with hepatocyte injury (eg ballooning), with or without any fibrosis 
(Kleiner et al. 2005a).  Although steatosis is the hallmark of NAFLD, it can be absent in 
some cases, including advanced stages of the disease (van der Poorten et al. 2013). This 
phenomenon of “burnt out” NASH was thought to be due to increased adiponectin 
levels in individuals with advanced NASH fibrosis. Adiponectin is the most abundant 
human adipocytokine, which acts directly on hepatocytes to upregulate fatty acid 
oxidation, inhibit fatty acid synthesis and improve insulin sensitivity, and hence plays a 
key role in hepatic steatosis (van der Poorten et al. 2013; Xu et al. 2003).  
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In multiple previous studies including a study by Angulo et al, it was demonstrated that 
presence and degree of fibrosis independently predict the overall and liver-related 
mortality/ liver transplantation or liver-related events, regardless of the presence of 
other histologic features (Angulo et al. 2015). Several studies have shown that 
compared with non-lean NAFLD, patients with lean NAFLD tend to show less severe 
histological features (Sookoian and Pirola 2018). However, despite the more favourable 
histological features at baseline, several long-term studies on lean NAFLD patients have 
demonstrated worse prognosis with respect to development of severe liver disease, 
independent of other confounders (A. C. e. a. Dela Cruz 2014; Hagstrom et al. 2018). 
 
1.5 METABOLIC HEALTH 
 1.5.1 Definition 
 
Although there has been no universally accepted definition of metabolic health in the 
literature, the most widely accepted and perhaps one of the first definition of metabolic 
health is the absence of insulin resistance, no evidence of subclinical inflammation as 
determined by high sensitivity C-reactive protein (CRP), together with only one 
component of the metabolic syndrome according to the Adult Treatment Panel III 
criteria (Table 1) (Lorenzo et al. 2007; Wildman et al. 2008).  
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Table 1. Clinical parameters used for the diagnosis of metabolic 
health 
Systemic inflammation hs-CRP level < 0.1mg/L 
Insulin resistance HOMA-IR < 5.13 
Plus only one (or none) of the following components: 
Clinical parameter Criteria for metabolic abnormality 
Blood pressure Systolic/diastolic blood pressure ≥ 130/85 mmHg or anti-
hypertensive drug use 
Triglyceride level Fasting triglyceride level ≥ 150mg/dL (or ≥ 1.7 mmol/L) 
HDL-C level HDL-C level < 40mg/dL (or < 1.0 mmol/L) in men or < 
50mg/dL (or < 1.3 mmol/L) in women or use of lipid 
lowering medication 
Glucose level Fasting glucose level ≥ 100mg/dL (or ≥ 5.6 mmol/L) or use 
of anti-diabetic medication 
Metabolic health is defined as absence of systemic inflammation with only one (or 
none) other component of metabolic syndrome. Abbreviations: hs-CRP, high sensitivity 
C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, 
homeostatic model of insulin resistance. 
 
More recently, a more rigorous definition for metabolic health, especially metabolically 
healthy obesity, was suggested so as to determine the true prevalence and outcome of 
this group of people. This new definition is based on the absence of cardiometabolic 
diseases, a healthy cardiometabolic blood profile, normal blood pressure and 
intrahepatic triglyceride content and normal insulin sensitivity (G. I. Smith et al. 2019). 
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1.5.2 Adiposopathy 
 
While it is not entirely clear as to the underlying mechanisms explaining individual 
variation in metabolic health, the term “adiposopathy” or defective/sick adipose tissue 
has been introduced. Adiposopathy governs an individual’s cardiometabolic risk, above 
and beyond BMI alone (H. E. Bays 2011) and refers to the pathogenic enlargement of 
fat cells and fat tissue, resulting in anatomic and functional disturbances leading to 
altered lipid metabolism, adipose inflammation and adverse clinical outcomes (H. E. 
Bays et al. 2008).  
However, given that adipose tissue is not a single, functionally uniform organ, it is not 
only how fat is stored (adipocyte proliferation versus adipocyte hypertrophy) that 
matters, but where the fat is stored (visceral versus subcutaneous, upper body versus 
lower body) and the type of fat (brown versus white). The ‘where’ and ‘type’ of 
adiposity has a greater impact on an individual’s metabolic health than total fat mass 
(Iacobini et al. 2019). Thus, visceral and subcutaneous adipose tissues differ with 
regards to their contribution for metabolic risk. Visceral adipose tissue (VAT) as well as 
ectopic fat in or around the liver, heart and skeletal muscle lipid content 
(intramyocellular) have been linked to impaired glucose homeostasis, insulin resistance 
and cardiovascular disease (Lim and Meigs 2013). On the other hand, subcutaneous 
adipose tissue (SAT), especially lower body SAT (gluteofemoral body fat) which is a 
characteristic of metabolically healthy individuals is associated with lower risk for 
metabolic diseases (Goodpaster et al. 2005; Manolopoulos et al. 2010). The only 
exception is upper body subcutaneous fat which has been shown to be the primary 
source of circulating free fatty acids and hence plays an important role in determining 
insulin resistance and metabolic impairment. This has been demonstrated in several 
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disease states associated with accumulation of upper body fat, including Cushing’s 
syndrome, lipodystrophy and human immunodeficiency virus associated lipodystrophy 
(Ebbert and Jensen 2013; J. J. Lee et al. 2017).  
 
The adipocyte responds to positive energy balance through adipocyte hypertrophy as 
well as adipocyte hyperplasia (i.e. recruitment and proliferation of adipocyte 
precursors). Adipose tissue expandability and the increase in fat mass, especially SAT 
expansion, has been linked in previous studies to metabolic improvement and protection 
from type 2 diabetes (J. Y. Kim et al. 2007; McLaughlin et al. 2011). Whereas SAT 
expansion protects from metabolic risk, expansion of VAT or limited expansion of SAT 
is strongly associated with insulin resistance due to its hyperlipolytic state that is 
resistant to the anabolic actions of insulin, thereby producing larger amounts of 
circulating free fatty acids (Despres and Lemieux 2006; O'Connell et al. 2010). 
Although both SAT and VAT sizes correlate with the degree of fatty liver, only VAT 
size is related to metabolic health and progression from hepatic steatosis to fibrosis 
(O'Connell et al. 2010). Previous studies have shown that surgical removal of 
abdominal SAT through liposuction does not improve insulin resistance in obese 
individuals, whereas transplantation of SAT into the abdominal cavity results in 
improved insulin sensitivity and glucose metabolism. This supports the notion that 
differences in metabolic health appear to be reflected by the “fitness” of SAT, while 
dysfunctional SAT (adiposopathy) is characteristic of the metabolically unhealthy state 
(Iacobini et al. 2019; Klein et al. 2004; Tran et al. 2008). Figure 1 shows a schematic 
representation of the different adiposity phenotype based on metabolic health status and 
body weight. 
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Figure 1. Adiposity phenotype based on metabolic health status 
and body weight 
The difference in fat depots, insulin sensitivity, inflammatory marker and hepatic fat 
content in individuals with metabolically healthy lean, metabolically unhealthy lean 
(lean NAFLD), metabolically healthy obese and metabolically unhealthy obese 
phenotypes. Abbreviations: SAT – Subcutaneous adipose tissue; VAT – Visceral adipose 
tissue; NAFLD – Non-alcoholic fatty liver disease. 
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1.5.3 Effect of metabolic health on NAFLD 
 
Given that metabolic health status (defined as per Table 1) is an integral aspect of 
NAFLD pathophysiology, several studies have investigated the relationship between 
metabolic health and NAFLD. In these, the risk of developing steatohepatitis and 
significant fibrosis increases progressively as the number of metabolic risk factors 
increases (Ampuero et al. 2018). Consistently, a cross-sectional study of more than 
1,000 patients with biopsy proven NAFLD demonstrated that metabolic health has a 
greater impact on the risk of NASH development, significant fibrosis, atherogenic 
dyslipidaemia and kidney dysfunction than obesity or BMI alone(Ampuero et al. 2018). 
That study also found a similar risk for steatohepatitis and fibrosis in a metabolically 
unhealthy group, regardless of their body weight, suggesting that metabolic health has a 
greater impact on the severity of liver disease than BMI, possibly through unfavourable 
body fat distribution (and/or as yet unknown factors) with a long but important period 
of subclinical systemic inflammation (Ampuero et al. 2018). Similar findings have been 
demonstrated in Asian and Mexican populations (Gutierrez-Grobe et al. 2017; M. K. 
Lee et al. 2015; Sung et al. 2014).  
 
Despite this data, metabolically healthy obesity cannot be considered entirely benign as 
it carries almost double the risk of steatohepatitis compared to individuals who are 
metabolically healthy and normal weight(Sung et al. 2014). This implies that healthy 
obesity (acting through subclinical or as yet be discovered impacts on metabolic health) 
perhaps represents a “honeymoon phase” that in some individuals eventually progresses 
to a metabolically unhealthy obese state (Kramer et al. 2013). A decline in insulin 
sensitivity and increased fasting blood glucose levels, especially in those with higher 
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BMI, older age, presence of more severe metabolic dysfunction and poor lifestyle index, 
have been identified to be major factors associated with the conversion from 
metabolically healthy obesity to metabolically unhealthy obesity (G. I. Smith et al. 
2019). In addition, the presence of NAFLD can promote (or at least be associated with) 
the conversion of an individual’s metabolic health from metabolically healthy to 
metabolically unhealthy, independent of age, sex, BMI, lifestyle factors, individual 
components of metabolic syndrome and insulin resistance. The effect is greater in those 
with a lower BMI and body fat mass compared to those with high BMI and body fat 
mass (Hwang et al. 2019). 
 
 
1.6 METABOLIC ADAPTATION 
 
The human body has great capacity to maintain body weight homeostasis through 
effects on food intake and energy expenditure. The ability of the body to increase or 
decrease energy expenditure beyond the obligatory energy costs of depositing and 
maintaining new tissues, digesting food, moving and maintaining body mass, without 
any change in body mass is defined as metabolic adaptation (Johannsen et al. 2019). 
Adaptation is achieved through a fine balance of regulatory systems through the 
interaction of hormones, chemokine signals and the neuroendocrine axis (Johannsen et 
al. 2019). In response to certain nutrition and/or physical activity conditions, several 
cytokines or peptides secreted from muscles (myokines), adipose tissue (adipokines) 
and liver (hepatokines) engage in cross-talk to maintain energy homeostasis by 
governing lipid and glucose metabolism as well as mediating local and systemic 
inflammation. Any perturbations in the systems involved results in loss of metabolic 
29 
adaptation, resulting in abnormal expansion of adipose tissue and obesity, hepatic fat 
accumulation, and insulin resistance (Oh et al. 2016).  
In addition, the enterohepatic circulation including bile acids (BA) and their 
metabolites, as well as gut microbiota play important roles in metabolic 
adaptation which occurs in part due to genetic and developmental influences 
(Wahlstrom et al. 2016a). A number of early experiments involving protein 
overfeeding have shown large variations in weight gain among nonrelated subjects 
but high correlation within twin pairs (Bouchard et al. 1990). Further, studies have 
shown that the change in energy expenditure was due to a change in non-exercise 
activity thermogenesis (Diaz et al. 1992; Leibel et al. 1995). This concept of 
metabolic adaptation may explain why some individuals appear to be obesity 
resistant while others gain weight easily when challenged with caloric abundance.  
Given the complex and multifactorial pathogenesis of NAFLD (Buzzetti et al. 2016) 
and knowing that not all obese people have NAFLD and not all NAFLD patients 
are obese(Younes and Bugianesi 2019), how an individual adapts to an unfavorable 
set of metabolic circumstances will govern when he/she will manifest fatty liver 
disease. This adaptive ability is the capability of the body to increase or decrease 
energy expenditure beyond obligatory energy requirements without any change in body 
mass.  
  30 
1.7 LEAN NAFLD 
 1.7.1 Definition and epidemiology 
 
NAFLD classically presents in close association with metabolic syndrome or one of its 
components, including obesity, hypertension, type 2 diabetes mellitus and 
dyslipidaemia (Chalasani et al. 2012; Z. M. Younossi et al. 2016a). The prevalence of 
NAFLD has risen in parallel with obesity recently, with nearly a third of adults in the 
USA having BMI more than 30kg/m2 (Ng et al. 2014). A meta-analysis of 21 cohort 
studies in 2016 found obesity to be a 3.5-fold increased risk of developing NAFLD, 
with a dose-dependent relationship between BMI and NAFLD risk (L. Li et al. 2016). 
However, not all obese patients suffer from the metabolic disturbances related to 
obesity, including NAFLD. This concept of “metabolically healthy obesity”, present in 
up to 30% of all obese individuals, refers to obese individuals with no evidence of 
metabolic or cardiovascular complications (Wildman et al. 2008). Similarly, a fair 
proportion of patients (10-30%) develop NAFLD despite having normal body mass 
index (BMI < 25 kg/m2) (Das and Chowdhury 2013; Z. M. Younossi et al. 2012). This 
subset of individuals is known as lean NAFLD, which is most commonly defined as 
NAFLD in the population with BMI less than 25 kg/m2 in Western studies and less than 
23 kg/m2 in Eastern studies (D. Kim and Kim 2017). Lean NAFLD was first reported in 
Asian countries and may represent the other end of the spectrum known as the 
“metabolically unhealthy normal weight” NAFLD (D. Kim and Kim 2017; J. C. Leung 
et al. 2017a; Sookoian and Pirola 2017; Stefan et al. 2017). 
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The first population study describing lean NAFLD was conducted in Korea in 2004, 
where lean NAFLD was present in 23.4% of the non-obese population with associated 
metabolic disorders (H. J. Kim et al. 2004). Since then, lean NAFLD has been described 
in several Asian and Caucasian reports. Figure 2 shows geographical data on available 
lean NAFLD prevalence worldwide. These data indicate that there are patients with 
fatty liver who are lean by BMI criteria and secondly that disease prevalence is between 
5 - 26% in Asian and 7 - 20% in Western populations (Younes and Bugianesi 2019). In 
one study, up to 75% of patients with NAFLD and significant liver disease prevalence 
was shown to have normal BMI in a non-obese Asian population (Das et al. 2010). 
However, owing to the lack of a widely accepted definition of “lean” across studies, as 
well as the heterogeneity in NAFLD diagnostic criteria, the current data suffers from 
many limitations.  
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Figure 2. Worldwide prevalence of NAFLD and of lean NAFLD as a 
proportion of total NAFLD 
Worldwide distribution of NAFLD with data on the prevalence of lean NAFLD (light 
blue; where available). Abbreviation: NAFLD – Non-alcoholic fatty liver disease 
1.7.2 Histological characteristics 
The histological characteristics of NAFLD vary between ethnic groups including for the 
subgroup with lean disease.  A recent systematic review from cross sectional studies 
shows that liver fibrosis stage is significantly lower in lean compared to 
overweight/obese NAFLD (Sookoian and Pirola 2018). Similarly, the NAFLD activity 
scores and presence of steatohepatitis are lower compared to overweight/obese patients, 
although there was substantial heterogeneity in the results (Sookoian and Pirola 2018). 
Some studies however have reported a more severe histological picture in lean patients 
with higher rates of advanced fibrosis, ballooning and lobular inflammation, as well as 
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greater steatohepatitis compared to their non-lean counterparts (Denkmayr et al. 2018; 
Q. Wang et al. 2019).  
 1.7.3 Pathogenesis 
 
Over the past decade, there has been a surge in the number of studies describing lean 
NAFLD and its characteristics. However, studies looking into the pathogenesis of lean 
NAFLD are lacking. Table 2 lists selected published studies on lean NAFLD, including 
the number of patients included, definition of lean NAFLD and main findings. Although 
lean NAFLD has been shown to share metabolic features and hepatic pathology as the 
classical obese NAFLD, patients with lean NAFLD lack any linear association with 
adiposity. This suggests that the distribution of adipose tissue in the body has more 
relevance in the pathogenesis of lean NAFLD (Das and Chowdhury 2013). In a recent 
cross-sectional study of lean and overweight individuals with and without NAFLD, 
insulin resistance was positively and significantly associated with hepatic triglyceride 
content, which has been shown to be closely associated with NAFLD, above and 
beyond their BMI and waist circumference measurements (Gonzalez-Cantero et al. 
2018). These findings indicate that it is likely that factors other than adiposity may 
come into play in the pathogenesis of NAFLD (F. Chen et al. 2019). 
 1.7.4 Prognosis 
 
In contrast to studies that examine the prevalence and presentation of lean NAFLD, data 
on its long-term prognosis have been scarce and conflicting. Some reports suggest that 
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clinical events and prognosis are worse in the obese compared to the lean NAFLD 
population, with higher cardiovascular events and death (Fracanzani et al. 2011; J. C. 
Leung et al. 2017a). One recent study with a median follow up of 49 months reported a 
clinical event rate of 11.9% in obese compared to 8.3% in the lean NAFLD population 
(J. C. Leung et al. 2017a).  However a study in 2014 by Delacruz et al. looking at the 
long-term prognosis of lean patients with NAFLD and a median follow up of 11 years 
has challenged this finding (A. C. e. a. Dela Cruz 2014). This international cohort study 
included 483 patients with biopsy-proven disease and suggested that the median 
survival free of liver transplantation was in fact lower in those who were lean compared 
to obese. This occurred despite having a better metabolic profile and less advanced liver 
fibrosis (A. C. e. a. Dela Cruz 2014). This result was supported by another report of 646 
patients with biopsy proven NAFLD and a median of 19.9 years follow up. The study 
showed that although patients with lean disease did not have increased mortality, they 
had an increased risk for the development and progression to severe liver disease 
compared to obese patients (hazard ratio 2.69, p = 0.007) (Hagstrom et al. 2018). 
 
While lean NAFLD reflects the hepatic manifestation of a metabolically unhealthy 
normal weight, studies involving other organ systems also indicate that individuals with 
a metabolically unhealthy phenotype may suffer a worse prognosis despite a normal 
BMI. Studies of diabetes mellitus in underweight or normal weight people suggest a 
distinct, albeit less characterized pathophysiology to disease in the overweight/obese 
population, with higher mortality rates(George et al. 2015). Similarly, metabolic health 
(as measured by the number of components of metabolic syndrome) has been shown to 
be a stronger predictor for myocardial dysfunction than simply BMI or fat mass alone 
(Dobson et al. 2016). 
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Table 2. Summary of a selection of published studies on lean NAFLD 
Author, year, country Definition of lean NAFLD Sample size Main findings 
Kim, HJ, 2004, Korea (H. J. 
Kim et al. 2004) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound  
74 lean and 106 non-lean NAFLD; 
386 lean healthy and 202 non-lean 
healthy controls 
Metabolic disorders are present in NAFLD 
subjects with normal weight 
Chen, CH, 2006, Taiwan (C. 
H. Chen et al. 2006) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
61 lean and 291 non-lean NAFLD; 
1383 lean healthy and 654 non-lean 
healthy controls 
Hypertriglyceridaemia was related to 
NAFLD in non-obese subjects  
Das, K, 2010, India (Das et 
al. 2010) 
Lean BMI  < 25 kg/m2, hepatic 
steatosis on liver ultrasound, 
confirmed on CT 
123 lean and 41 non-lean NAFLD; 
1660 lean healthy and 87 non-lean 
healthy controls 
Lean NAFLD is present in 75% of this 
predominantly non-obese population, with 
potentially significant liver disease 
Younossi, 2012, USA (Z. M. 
Younossi et al. 2012) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
431 lean and 2061 non-lean 
NAFLD; 
4026 lean healthy and 5095 non-
lean healthy controls 
Lean NAFLD patients (20.9%) are younger, 
have lower metabolic syndrome and is more 
common in females 
Margariti, 2012, Greece 
(Margariti et al. 2012) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
19 lean and 143 non-lean NAFLD Lean NAFLD patients (12%) have lower 
metabolic syndrome and higher ALT/AST 
than non-lean NAFLD 
Bhat, 2013, India (Bhat et al. 
2013) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
30 lean and 120 non-lean NAFLD Lean NAFLD present in 20% of patients. 
Insulin resistance is common amongst 
patients with NAFLD, including lean 
NAFLD (80%) 
Kumar, 2013, India (Kumar 
et al. 2013) 
Lean BMI < 23 kg/m2, biopsy 
proven NAFLD 
27 lean and 141 non-lean NAFLD Lean NAFLD patients (13.2%) have less 
severe histology and lower insulin resistance 
than non-lean NAFLD 
Delacruz, 2014, Australia 
(A. C. e. a. Dela Cruz 2014) 
Lean BMI < 25 kg/m2, biopsy 
proven NAFLD 
125 lean and 965 non-lean NAFLD Lean NAFLD patients (11.5%) have higher 
mortality than patients with non-lean 
NAFLD despite presenting with healthier 
metabolic profile 
Alam, 2014, India (Alam et 
al. 2014) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound, 
biopsy in some (220/465) 
119 lean and 346 non-lean NAFLD Lean NAFLD patients (25.6%) were 
metabolically and histologically similar to 
non-lean NAFLD patients, with similar rates 
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of NASH and fibrosis 
Feng, 2014, China (Feng et 
al. 2014) 
Lean BMI < 24 kg/m2, hepatic 
steatosis on liver ultrasound 
134 lean and 764 non-lean NAFLD; 
597 lean healthy and 284 non-lean 
healthy controls 
Lean NAFLD patients (14.9%) had higher 
visceral adiposity index and comparable 
metabolic risk profile to non-lean NAFLD  
Vendhan, 2014, India 
(Vendhan et al. 2014) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
48 lean and 125 non-lean NAFLD Lean NAFLD patients (27.7%) had better 
metabolic profile but similar association to 
coronary artery disease as non-lean NAFLD  
Wei, 2015, Hong Kong (Wei 
et al. 2015) 
Lean BMI < 25 kg/m2, liver fat 
assessed by proton-magnetic 
resonance spectroscopy 
135 lean and 127 non-lean NAFLD Lean NAFLD patients (19.3%) had similar 
intrahepatic triglyceride content, but lower 
cytokeratin-18 fragments and liver fibrosis. 
PNPLA3 G allele was more common in lean 
NAFLD. 
Nishioji, 2015, Japan 
(Nishioji et al. 2015) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
411 lean and 394 non-lean NAFLD; 
2285 lean healthy and 181 non-lean 
healthy controls 
Lifestyle and metabolic factors (higher 
triglycerides and waist circumference) 
increases the risk of NAFLD, even in lean 
patients (15.2%) 
Cho, 2016, Korea (Cho 
2016) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
213 lean and 347 non-lean NAFLD; 
1498 lean healthy controls 
Lean NAFLD patients (12.4%) had higher 
proportion of females, lower insulin 
resistance and fewer metabolic risk factors 
than non-lean NAFLD 
Feldman, 2017, Austria 
(Feldman et al. 2017b) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
55 lean and 61 non-lean NAFLD;  
71 lean healthy controls 
Lean NAFLD patients (29.4%) had impaired 
glucose tolerance, low adiponectin 
concentrations and a distinct metabolic 
profile with increased PNPLA3 risk allele 
carriage 
Leung, 2017, Hong Kong (J. 
C. Leung et al. 2017a) 
Lean BMI < 25 kg/m2, biopsy-
proven NAFLD 
72 lean and 235 non-lean NAFLD Lean NAFLD patients (23.5%) had less 
severe disease and better prognosis than 
non-lean NAFLD. Hypertriglyceridaemia 
and high creatinine were associated with 
advanced liver disease in lean NAFLD 
Fracanzani, 2017, Italy 
(Fracanzani et al. 2017) 
Lean BMI < 25 kg/m2, biopsy-
proven NAFLD 
143 lean and 526 non-lean NAFLD Lean NAFLD patients (21.4%) had higher 
TM6SF2 risk allele carriage and lower 
metabolic syndrome, less NASH and lower 
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fibrosis but thinner carotid intima compared 
to non-lean NAFLD 
Sookoian, 2017, Argentina 
(Sookoian and Pirola 2018) 
Systematic review, lean BMI ≤ 
25 kg/m2 
493 lean and 2209 non-lean 
NAFLD 
Lean patients tended to have milder 
histological features compared to non-lean 
NAFLD 
Sookoian, 2017, Argentina 
(Sookoian and Pirola 2017) 
Systematic review with meta-
analysis, lean BMI ≤ 25 kg/m2, 
hepatic steatosis on liver 
ultrasound 
1966 lean and 5938 non-lean 
NAFLD; 9946 lean healthy and 
6027 obese healthy controls 
Lean NAFLD shared common altered 
metabolic and cardiovascular profile 
compared to non-lean NAFLD, although the 
effect is less severe in lean NAFLD 
Hagstorm, 2017, Sweden 
(Hagstrom et al. 2018) 
Lean BMI < 25 kg/m2, biopsy 
proven NAFLD 
123 lean, 335 overweight and 188 
obese NAFLD  
Lean NAFLD patients (19%) had lower 
fibrosis at better metabolic profile at 
baseline but increased risk of development 
of severe liver disease 
Denkmayr, 2018, Austria 
(Denkmayr et al. 2018) 
Lean BMI ≤ 25 kg/m2, biopsy 
proven NAFLD 
72 lean, 242 overweight and 150 
obese NAFLD 
Lean NAFLD patients (15.9%) had severe 
histological features similar to obese but 
more progressed than overweight NAFLD 
Tobari, 2018, Japan (Tobari 
et al. 2018) 
Lean BMI < 25 kg/m2, biopsy 
proven NAFLD 
116 lean, 173 overweight and 115 
obese NAFLD 
Advanced fibrosis was not associated with 
BMI but histological steatosis was more 
common in lean NAFLD 
Li, 2019, China (C. Li et al. 
2019) 
Lean BMI < 24 kg/m2, hepatic 
steatosis on liver ultrasound 
84 lean and 85 non-lean NAFLD;  
90 lean healthy and 92 non-lean 
healthy controls 
Lean NAFLD patients had comparable total 
caloric, calorigenic nutrition, iron, sleep 
duration and overtime work as obese 
NAFLD 
Niriella, 2019, Srilanka 
(Niriella et al. 2019) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
120 lean and 816 non-lean NAFLD; 
1206 healthy controls 
Lean NAFLD patients (4%) had similar risk 
of developing metabolic comorbidities 
compared to non-lean NAFLD, with higher 
NAFLD associated with PNPLA3 incidence 
Yilmaz, 2019, Turkey 
(Yilmaz et al. 2019) 
Lean BMI < 25 kg/m2, biopsy 
proven NAFLD 
30 lean and 428 non-lean NAFLD Lean NAFLD was present in 6.4% of the 
study sample, with metabolic syndrome 
present in 63% of the sample population 
Wang, 2019, China (Q. 
Wang et al. 2019) 
Lean BMI < 25 kg/m2, biopsy 
confirmed NAFLD 
36 lean and 48 non-lean NAFLD Lean NAFLD patients (42.9%) have a 
female predominance and more advanced 
fibrosis compared to non-lean NAFLD 
patients 
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1.8 HYPOTHESIS AND AIMS 
We hypothesize that there is a distinct underlying metabolic adaptation governing the 
pathophysiology of lean NAFLD, which may explain its unique baseline 
characteristics and long-term prognosis. 
The aims of this project are to: 
1. Compare the characteristics of lean NAFLD patients to lean and non-lean 
healthy controls 
2. Compare the characteristics of lean NAFLD compared to non-lean NAFLD 
patients in terms of their bile acid profile and regulation, gut microbiota profile 
and metabolic adaptation capacity 
3. Explore murine models of lean and non-lean NAFLD to investigate the 
replicability of our hypothesis from the human results 
4. Explore the metabolomic characterisation of patients with lean NAFLD 
compared to patients with non-lean NAFLD to investigate if there are other 
metabolic pathways other than that of bile acid pathways which are 
significantly different 
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2 MATERIALS AND METHODS 
 
2.1  MATERIALS 2.1.1 Polymerase chain reaction (PCR) primers 
 
The real-time polymerase chain reaction (PCR) primers were ordered from 
GeneWorks. The primers were designed using the Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) and reaction conditions were 
optimised for a standard curve of pooled cDNA. Table 3 shows the sequence of 
primers used for qPCR in this thesis. 
 
Table 3 List of mouse primers used for qPCR analysis 
Gene Primer sequence 
GAPDH GAAGGTGAAGGTCGGAGTC (forward) 
GAAGATGGTGATGGGATTTC (reverse) 
ASBT TGGGTTTCTTCCTGGCTAGACT (forward) 
TGTTCTGCATTCCAGTTTCCAA (reverse) 
BSEP CAGACACCATGTCTGACTCAGTGA (forward) 
GGCCACACTCAGACCTATGACGGC (reverse) 
CYP7A1 AGCAACTAAACAACCTGCCAGTACTA (forward) 
GTCCGGATATTCAAGGATGCA (reverse) 
CYP8B1 TGAATTCTTGAAGGGGATGC (forward)  
CCTTGCTCCCTCAGAAACTG (reverse) 
CYP27A1 TTCTCAGACACGATCTATGGCTGT (forward) 
 CTACTGTCTCTGCAGAAAGCGTA (reverse)  
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FGF-15 ACGGGCTGATTCGCTACTC (forward) 
TGTAGCCTAAACAGTCCATTTCCT (reverse) 
FGFR4 CGAGGCATGCAGTATCTGG (forward) 
CAAAGTCAGCGATCTTCATCACA (reverse) 
FXR CGGAACAGAAACCTTGTTTCG (forward) 
TTGCCACATAAATATTCATTGAGATT (reverse) 
HNF4A CCAAGAGGTCCATGGTGTTTAAG (forward) 
GTGCCGAGGGACGATGTAGT (reverse) 
Mrp2 TCCAGGACCAAGAGATTTGC (forward) 
TCTGTGAGTGCAAGAGACAGGT (reverse) 
NTCP GGGTCGGAGGATGGAGGCGCACAA (forward) 
GGACGTTTTGGAATCCTGTTTCCA (reverse) 
OST beta GTATTTTCGTGCAGAAGATGCG (forward) 
TTTCTGTTTGCCAGGATGCTC (reverse) 
SHP CAGCGCTGCCTGGAGTCT (forward) 
AGGATCGTGCCCTTCAGGTA (reverse) 
 
 2.1.2 Sources of Clinical Information and Human Biological 
Tissue 
 2.1.2.1 Clinical and laboratory assessments 
 
Physical examination was performed on all patients on the day of the liver biopsy 
including measurement of body mass index. Weight (in kilograms) and height (in 
centimetres) were measured by staff at the time of biopsy and used to calculate BMI, 
expressed as kg/m2. Following WHO criteria for Western populations, patients with 
BMI of less than 25kg/m2 were defined as lean, and ≥25 kg/m2 as non-lean (Z. M. 
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Younossi et al. 2012). Hypertension was defined as a registered diagnosis in patient 
medical records, a resting blood pressure of ≥140/90 mm Hg, or having any 
antihypertensive medication prescribed. Type 2 diabetes mellitus (T2DM) was defined 
as a registered diagnosis in patient medical records, a fasting plasma glucose value ≥ 7 
mmol/L (or 126 mg/dL) or having any antidiabetic medication prescribed. 
 
Venous bloods were collected on the morning of liver biopsy after an overnight 12-
hour fast for serum transaminases, bilirubin, albumin, lipid profile, glucose and 
insulin. Serum insulin was determined by a radioimmunoassay technique (Phadaseph 
Insulin RIA; Pharmacia and Upjohn Diagnostics, Uppsala, Sweden). All other 
biochemical tests were performed using conventional automated analyzers within each 
local department. Insulin resistance was calculated using the homeostasis model 
(HOMA-IR) using the formula: HOMA-IR = fasting insulin (mU/L) x plasma glucose 
(mmol/L)/22.5 (Eslam et al. 2011; Matthews et al. 1985).  
 
2.1.2.2 NAFLD cohort 
 
Patients were recruited from hepatology clinics at four centres: Australia (Storr Liver 
Centre, Westmead Hospital, Sydney and Sir Charles Gairdner Hospital Unit, 
University of Western Australia) and Italy (Unit of Metabolic Diseases and Clinical 
Dietetics, University of Bologna; Gastroenterology unit, University of Palermo, and 
Division of Gastroenterology and Hepatology, University of Turin).  
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Inclusion criteria were patients who had liver biopsy for suspected NAFLD with 
available serum samples and clinical data. Individuals with alternative diagnoses were 
excluded including excess alcohol intake (>20 g per day for women; and >30 g per day 
for men), chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune liver 
diseases, hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s disease and 
drug-induced liver injury. In addition, a phosphatidylethanol assay was performed in 
all NAFLD patients to avoid misclassification of alcoholic liver disease in this 
population. Patients with any secondary cause of steatohepatitis including previous 
gastrointestinal surgery or ingestion of medications known to impact hepatic steatosis 
or bile acid metabolism or with decompensated liver disease were excluded as 
previously described in another study (van der Poorten et al. 2013). 
 
2.1.2.3 Healthy controls 
 
Healthy Caucasians controls were recruited from volunteers if the following applied: 
age between 40-65 years, BMI < 25 kg/m2 for lean healthy controls or BMI > 25 
kg/m2 for non-lean healthy controls, alcohol intake ≤ 20g per day for women and ≤ 
30g per day for men, metabolically healthy (defined as absence or having only one 
component of the metabolic syndrome according to the Adult Treatment Panel III 
criteria, including triglyceride level of 150 mg/dL (1.7 mmol/L) or greater, high 
density lipoprotein (HDL) level of less than 40 mg/dL (1.0 mmol/L) in men and less 
than 50mg/dL (1.3 mmol/L) in women, systolic blood pressure greater than 130 
mmHg or diastolic blood pressure greater than 85mmHg and fasting plasma glucose 
level of 100 mg/dL (5.6 mmol/L) or greater (Lorenzo et al. 2007; Wildman et al. 
2008)). In addition, they also needed to have normal liver tests (normal transaminases 
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(less than 30 U/L for ALT and less than 35 U/L for AST), with normal levels of serum 
bilirubin (less than 15 umol/L) and albumin (38-50 g/L) and metabolic parameters 
(fasting blood glucose and blood cholesterol levels), as well as absence of liver 
steatosis on ultrasonography. Written informed consent was obtained from all 
participants. 
 2.1.3 Sources of mice tissue 
 
Male C57BL/6 mice obtained from Animal Resources Centre (Perth, Australia) were 
used for diet studies commencing at week 8 and were exposed to a 12-hr light/dark 
cycle with free access to food and water. Mice were fed either a 33% sucrose diet 
(SF09-079, Specialty Feed Service, Glen Forest, Australia, see Table 4A) or a diet 
containing 33% Sucrose, 2% cholesterol and 0.5% cholate (SF09-080, Specialty Feed 
Service, Glen Forest, Australia, see Table 4B) starting at 8 weeks of age for 16 weeks. 
 
In addition, a separate group of mice were fed the cholesterol rich diet containing 33% 
sucrose, 2% cholesterol and 0.5% cholate, along with a sodium dependant bile acid 
transporter (ASBT) inhibitor (ASBTi, SC-435, Lumena/Shire Pharmaceuticals) for 8 
weeks. At the time of harvest, mice were anesthetized with i.p. ketamine (100 
mg/kg)/xylazine (10 mg/kg) injection after a 4-hr fasting period. Blood was collected 
by cardiac puncture. Liver and ileum samples were harvested, rapidly snap frozen in 
liquid nitrogen and stored at -80 ºC. A thin slice of liver tissue was formalin fixed for 
histology. All procedures were approved by the Western Sydney Local Health District 
Animal Ethics Committee and conducted in accordance with Animal Experimentation 
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guidelines of the National Health and Medical Research Council (NHMRC) of 
Australia. Mice tissues were obtained through collaboration with Dr Saeed Esmaili, 
Storr Liver Centre and University of Sydney. 
Table 4. A) Diet composition and nutritional parameters for mice 
fed the high sucrose diet. B) Diet composition and nutritional 
parameters for mice fed an atherogenic diet 
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2.2  METHODS 
 2.2.1 Histopathology 
 
A single expert liver pathologist at each centre who was blinded to patient clinical 
characteristics and serum measurements interpreted the liver biopsies. All biopsies had 
a minimum of 11 portal tracts, and inadequate biopsies were excluded. Disease 
activity was assessed according to the NAFLD Activity Score; fibrosis was staged 
according to the NAFLD clinical research network (CRN) (Kleiner et al. 2005b). 
Some of these patients have been the subjects of previous publications (Eslam et al. 
2015a; Eslam et al. 2016a; Eslam et al. 2016c). The concordance between pathologists 
within this cohort was very good for steatosis and fibrosis, with coefficients for inter-
observer agreement for fibrosis stage and steatosis grade of 0.78 and 0.85, respectively 
(Kazankov et al. 2016).  
 2.2.2 Phosphatidylethanol measurement 
 
The serum phosphatidylethanol level was measure using the Human Peth 
(phosphatidylethanol) ELISA kit (Elabscience) on all lean NAFLD subjects according 
to the manufacturer’s instructions. Briefly, a standard working solution stock is 
prepared and 100uL is added to each well in the first two columns, followed by 100uL 
of serum samples. The plate is covered and incubated for 90 minutes at 370C. After 
this, the liquid is removed from the wells and 100uL of biotinylated detection antibody 
working solution is added to each well, followed by a 1-hour incubation period at 
37oC after gentle mixing. The solution is then discarded and the wells are washed 
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three times with the wash solution and patted dry. Following this, 100uL of HRP 
conjugated working solution is added to each well and the plate is covered and 
incubated at 37oC for 30 minutes. This is followed by another wash done five times as 
per previously. Next, 90uL of substrate reagent is added to each well and the plate is 
covered and incubated for 15 minutes at 37oC, protected from the light.  50uL stop 
solution is then added to each well and the optical density is determined with a micro-
plate reader at 450nm. Values above 253 ng/mL are regarded as significant alcohol 
consumption in the past few weeks (Kechagias et al. 2015). 
 2.2.3 Methods for bile acid quantification 
 2.2.3.1 Bile acid extraction 
 
Bile acids were extracted from serum samples as previously described (van der 
Poorten et al. 2013; Xie et al. 2015). Briefly, 80µL of acetonitrile containing internal 
standard (cholic2,2,4,4-d4acid, Quebec, Canada) was added to 20µL of the serum 
sample. After centrifugation, the supernatant was evaporated to dryness and stored at -
200 C until time of analysis. 
 
2.2.3.2 Bile acid measurement 
 
The dried bile acid residue was reconstituted in mobile phase containing 50:50 water 
and acetonitrile and analysed on a Ultra Performance Liquid Chromatography (UPLC, 
Shimadzu, Kyoto, Japan) system using an ACQUITY (WATERS, Milford, MA) 
column in combination with a Q-TRAP 5500 Mass Spectrometer (AB SCIEX, 
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Toronto, Canada) to quantify concentrations of 19 bile acids. The mass spectrometer 
was operated in negative ion mode. The calibration solution containing all 19 analytes 
was prepared at a series of concentrations in pooled naïve plasma depleted of bile 
acids using activated charcoal to generate the calibration curve. The detection limit for 
individual bile acids was 0.01 – 0.05 umol/L. 
 2.2.4 Method of FGF-19 measurement 
 
FGF19 level was measured using the Human FGF19 Elisa kit (EHFGF19, Thermo 
Scientific) on the serum of subjects according to the manufacturer’s instructions. 
Briefly, a series of concentrations of standard solution is prepared. 100uL of standard 
or diluted serum samples (1 in 2 using assay diluent C) or blank is added to each well, 
and the plate is covered and incubated for 2.5 hours at room temperature after gentle 
shaking. After this, the plate is washed 4-5 times with the wash buffer and patted dry 
using an absorbent towel. To each well, 100uL of diluted biotinylated antibody 
solution (1 in 80 dilution) is added and the plate covered and incubated at room 
temperature for 1 hour. The plate is then washed 3-4 times again with the wash buffer. 
After this, 20uL of diluted streptavidin solution (1 in 500 dilution) is added to each 
well and the plate is covered and incubated for 45 minutes at room temperature. This 
is followed by another 3-4 washes with the wash buffer. Next, 100uL of TMB 
substrate solution is added to each well and the plate incubated at room temperature 
for 30 minutes away from the light. After this, 50uL stop solution is added to each 
well and the plate is read within 30 minutes using a micro-plate reader at 450nm.  
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2.2.5 Method of C4 measurement 
 
7-alpha-hydroxy-4-cholesten-3-one (C4) was purchased from Toronto Research 
Chemicals (Toronto, Canada). Cortisol-1,2-d2 was purchased from CDN isotopes 
(Hornsby, NSW, Australia) and charcoal stripped serum (CSS) was purchased from 
Sigma–Aldrich (Castle Hill, NSW, Australia). Additional reagents and solvents were 
of HPLC grade. To 50µL of serum, 200µL of ice-cold acetonitrile containing 2% 
formic acid and 16 ηg of the assay internal standard, cortisol-1,2-d2 was added. The 
mixture was vortexed for 1 minute and centrifuged at 10,000 rpm for 10 minutes. 
The supernatant was collected and evaporated under vacuum at room temperature. 
The samples were then reconstituted in the assay mobile phase and transferred to a 
96 well plate for analysis. Stock solution of C4 (1µM) was prepared in CSS and 
diluted to give final concentrations of 0.01-1µM. The standards were treated in the 
same way as the samples. A Nextera UPLC (SHIMADZU, Kyoto, Japan) system 
was used in combination with a Q-TRAP 5500 Mass Spectrometer (AB SCIEX, 
Toronto, Canada) with Analyst software 1.6.2. Chromatographic separations were 
performed with an ACQUITY (WATERS, Milford, MA, USA) UPLC BEH C18 
column (1.7microns 2.1x100mm). The temperature of the column and auto sampler 
was 65oC and 12oC, respectively. Sample injection was 1µL. The mobile phase 
consisted of 10% acetonitrile and 10% methanol in water containing 0.1% formic 
acid (mobile phase A) and 10% methanol in acetonitrile 0.1% formic acid (mobile 
phase B) delivered as a gradient: 0-3-min mobile phase B 20%; 3-3.5-min mobile 
phase B 80%, 7-9min mobile phase B with a constant 80% flow rate of 0.5ml/min. 
The mass spectrometer was operated in positive electro-spray mode working in the 
multiple reaction mode (MRM). Transition MRMs for C4 and the internal standard 
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cortisol-1,2-d2 were 401.2→177.2 and 365.2→122.2 respectively. Operating 
parameters were: curtain gas 30psi; ion spray voltage 4500 V; temperature 55oC; ion 
source gas 1 60psi; ion source gas 2 65psi. Declustering potential, entrance potentials 
and collision cell exit potentials were optimised using the Analyst software. 
 2.2.6 Genotyping 
 
Genotyping for TM6SF2 rs58542926 and PNPLA3 rs738409 was performed on all 
available DNA samples (n = 471 (88%) using the TaqMan SNP genotyping allelic 
discrimination method (Applied Biosystems, Foster City, CA).  All genotyping was 
blinded to clinical variables and some was extracted from previous reports (Eslam et 
al. 2016a). 
 2.2.7 Method of RNA extraction from animal tissues 
 
RNA was extracted from animal tissues as per protocol. Briefly, a piece of animal 
tissue (about 30mg each) is cut, and 350uL FARB buffer and 3.5uL β-mercaptoethanol 
are added to the tissue, along with 1 microbead (Qiagen). The mixture is then spun 
using the rotor-stator tissue homogenizer at 3000rpm for 3 minutes and incubated for 5 
minutes at room temperature. The mixture is then passed through a filter column to a 
collection tube and centrifuged for 2 minutes at 18,000rpm. After this, the supernatant 
is collected in a new microcentrifuge tube and an equal volume of 70% RNA-ase free 
ethanol solution is added. Next, the mixture is vortexed and passed through a FARB 
mini column to a collection tube and centrifuged for 1 minute at 18,000rpm. The flow 
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through is discarded and the FARB mini column is returned to the collection tube. 
500uL of wash buffer 1 is then added to the FARB column and centrifuged for 1 
minute at 18,000rpm. Then, 750uL of wash buffer 2 is added to the FARB column 
after discarding the flow through and the mixture is centrifuged for 1 minute at 18,000 
rpm. This step is repeated again once after which the FARB mini column is 
centrifuged for an additional 3 minutes at 18,000rpm to dry the column. The FARB 
mini column is then placed to an elution tube and 45uL RNA-ase free water is added 
to the membrane centre of the FARB mini column and left for one minute before 
centrifuging at 18,000rpm for 1 minute to elute the RNA. The RNA concentration is 
then measured using Nano-drop and stored at -80oC.  
 2.2.8 Method of cDNA synthesis 
 
cDNA was reverse transcribed from total RNA using qScript® cDNA SuperMix cat# 
95048 (Quanta Biosciences, Gaithersburg, MD, USA) according to the manufacturer‘s 
instructions. In brief, 1-10 μg RNA and 4μl qScript cDNA SuperMix were added to a 
sterile RNase-free microcentrifuge tube and the volume was completed to 20 μl by 
RNase/DNase-free water. The mixture was incubated for 5 minutes at 25°C, then 30 
minutes at 42°C, 5 minutes at 85°C and finally held at 4°C using Mastercycler 
gradient 5331 (Eppendorf AG, Hamburg, Germany). The synthesized cDNA was 
stored at -20 °C for further experiments. 
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2.2.9 Method of qPCR 
 
Real-time PCR was performed in duplicate on Applied Biosystems, Foster City, CA, 
USA. Using TaqMan™ Fast Advanced Master Mix Catalog number:  4444556.  In 
each PCR tube, 10 μl of Master Mix was added to 1 μl of the probe, 6 μl of 
DNAse/RNAse free water and 3 μl of the diluted cDNA template (dilution of cDNA 
was 1:50 of dH2O). The mRNA levels of the murine liver tissue were normalised to 
the expression of housekeeping gene 36B4, using TaqMan Fam labelled gene 
expression 36B4 probe (Mm99999915_g1), catalogue number: 4331182. Expression 
was measured using CT values, normalized to that of 36B4 (ΔCT = CT (36B4) - CT 
(target) and then expressed as 2-ΔCT.  
 
 2.2.10 Method of mice ileal fgf-15 measurement 
 
Mice ileal fgf15 was assessed using the Mouse Fgf15 ELISA kit (Competitive EIA, 
LifeSpan BioSciences, Inc.) as per the manufacturer’s protocol. Briefly, a series of 
concentrations of standard solution is prepared with sample diluent solution. To each 
well, 50uL of working standard solution, sample or blank is added, followed by 50uL 
of detection reagent A working solution. The plate is then covered and incubated at 
37oC for 1 hour. The solution is aspirated and washed with the wash buffer 3 times 
before drying by gently tapping against clean absorbent paper. Then, 100uL detection 
reagent B working solution is added to each well and the plate is covered, mixed and 
incubated for 30 minutes at 37oC. The liquid is then aspirated and washed 5 times. 
After this, 90uL of TMB substrate solution is added to each well and the plate is 
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covered and incubated for 10-20 minutes at 37oC, protected from light. This is 
periodically monitored until optimal colour development has been achieved, after 
which 50uL stop solution is added to each well and the optical density value for each 
well is immediately determined using a microplate reader set to 450nm. 
 2.2.11 Microbiota analysis 
 
A single stool sample was collected from patients with biopsy-proven lean and non-
lean NAFLD, as well as lean healthy controls. Genomic DNA isolation from these 
materials were performed using the QIAGEN DNeasy Powerlyzer Powersoil kit 
(QIAGEN, Germany) according to the manufacturer’s instructions. The DNA extracts 
were used for sequencing of the V4 hypervariable region of the 16S ribosomal RNA 
(rRNA) gene as previously described(Choo et al. 2015). Briefly, amplicons were 
generated and indexed using the Illumina Miseq 16S Metagenomic Sequencing 
Library Preparation protocol 
(http://support.illumina.com/downloads/16s_metagenomic_sequencing_library_prepar
ation.html) with modifications. PCR amplification was performed using the following 
program: 95°C for 3 min, followed by 25 cycles of 95°C for 30s, 50°C for 30s and 
72°C for 30s, and a final extension step of 72°C for 30s. Dual-indexing of the 
amplicons was performed using 8 cycles of the same program. 
 
Paired-end 16S rRNA sequencing (2 x 300 bp sequence reads) was performed on an 
Illumina Miseq platform at the David R Gunn Genomics Facility (South Australian 
Health and Medical Research Institute). Bioinformatics processing of the 16S rRNA 
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sequence reads were performed using the Quantitative Insights into Microbial Ecology 
(QIIME) software (version 2-2018.2). Denoising was performed using the DADA2 
pipeline, and chimera filtering and operational taxonomic unit (OTU) assignment was 
performed against the SILVA 16S rRNA reference database (release v132) clustered 
at 97% similarity. A minimum subsampling depth of 8,335 reads and 10,698 reads was 
selected for microbiota composition analysis of the human stool and mice caecum 
samples, respectively. Taxa present in ≥3 samples and in > 5 sequence reads were used 
to analyse genera that are differentially abundant between groups. The Benjamini-
Hochberg method was used to control the false discovery rate for multiple testing 
correction. Stool processing and sequencing were performed at the South Australian 
Healthy and Medical Research Institute, Australia, in collaboration with Dr Geraint 
Rogers and Dr Jocelyn Choo.  
 2.2.12 Inflammatory cytokines measurement 
 
Inflammatory cytokines were measured on human serum samples using a human 
routine 16-plex cytokine panel kit, performed by Crux Biolab, Victoria, Australia. 
 2.2.13 Statistical analysis 
 
Data was analysed using SPSS version 24.0 (IBM, Armonk, NY). Values are 
expressed as mean ± standard deviation, median and interquartile range or frequency 
(percentage) as appropriate. P-values for comparisons of distributions between groups 
were assessed using Fisher’s exact test. The Mann-Whitney non-parametric test was 
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used to obtain significance between two means of continuous variables. The strength 
of associations between continuous variables was reported using Spearman’s rank 
correlations. Univariable analysis of variance (ANOVA) was used to examine factors 
associated with increasing total secondary bile acid levels as continuous variables. 
Multiple regression analysis was then undertaken to determine which factors 
significant on ANOVA remained independent predictors for total secondary bile acid 
levels when adjusted for other clinically relevant variables including age, gender, 
BMI, hypertension, diabetes, dyslipidaemia, total cholesterol, HOMA and histological 
profile (fibrosis, steatosis, ballooning, portal inflammation, lobular inflammation and 
NAS).  
 
Hepatic steatosis was graded from 0 to 3 and was dichotomized into mild steatosis 
(NASH CRN grades 0-2) and more severe steatosis (grade 3) for the purposes of 
statistical analysis. Hepatocyte ballooning was dichotomized into no ballooning and 
any ballooning for analysis purposes. Lobular and portal inflammation was 
dichotomized to mild (grade 0-1) and severe (grade 2 or more) (Brunt et al. 2011). 
Fibrosis stage was dichotomized to mild fibrosis (F0-1) and significant fibrosis (F2-4). 
This was based on a recent systematic review, which showed that the risk of liver-
related mortality increases exponentially from stage 2 fibrosis onwards (Eslam et al. 
2016c). Statistical significance was considered as p<0.05 throughout.  
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3 COMPARISON OF LEAN NAFLD WITH LEAN AND NON-LEAN 
HEALTHY CONTROLS 
 
3.1  INTRODUCTION 
 
The diagnosis of NAFLD and its sequelae NASH require the presence of hepatic 
steatosis as well as hepatocyte damage evidenced by inflammation and/or fibrosis. 
Excess cholesterol intake seen in some patients with NAFLD results in free cholesterol 
accumulation in the hepatocyte mitochondrial membrane, which leads to increased 
susceptibility to hepatocyte death in response to other noxious stimuli by promoting 
glutathione loss from mitochondrial and making the hepatocytes sensitive to TNF-
induced cytotoxicity (Duwaerts and Maher 2014). In addition, factors such as the 
genetics and the gut microbiota add to the complexity of NAFLD and NASH 
pathogenesis. Changes in gut microbiota profile in response to high energy feeding has 
been linked to enhanced endotoxin absorption from the gut, or “metabolic 
endotoxemia”, as well as promoting the production of pro-inflammatory cytokines and 
ethanol which eventually leads to hepatotoxicity (Cani et al. 2008; Duwaerts and 
Maher 2014). 
 
While many studies have shown that increasing body weight is associated with 
increased mortality, recent evidence has suggested that not all obese or overweight 
people carry the same metabolic risk and mortality (Kramer et al. 2013; Stefan et al. 
2017). Studies in the literature have started to delineate between obese people who are 
at risk of cardio-metabolic disease (or the “metabolically unhealthy obesity”) and 
obese people who are healthy, the so-called “metabolically healthy obesity”. Similarly, 
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metabolically unhealthy normal weight individuals carry risk for cardiovascular events 
and/or increased mortality (Eckel et al. 2015; Stefan et al. 2017). A large meta-
analysis recently showed that the risk for cardiovascular events and/or all-cause 
mortality was higher among metabolically unhealthy normal weight individuals 
compared to the metabolically healthy normal weight people (RR 3.14, 95% CI 2.36 – 
3.93) (Kramer et al. 2013).  
 
A recent large study involving 981 subjects with BMI in the normal range, overweight 
and obese, classified as metabolically healthy or unhealthy (metabolic health defined 
as having less than 2 parameters of metabolic syndrome) showed that within normal 
weight individuals, metabolically unhealthy individuals had significantly higher liver 
fat content and prevalence of NAFLD, significantly higher visceral fat mass and 
carotid-intima media thickness and a significantly lower percentage of subcutaneous 
leg fat mass and lower insulin sensitivity and secretion (Stefan et al. 2017). Factors 
that have been correlated with a metabolically unhealthy phenotype in normal weight 
individuals include older age and lower physical activity, after adjusting for male sex 
and waist circumference in a large population study (Wildman et al. 2008). 
 
Therefore, we aimed to test this finding in our cohort of patients using a cohort of 
patients with lean NAFLD (n=99) and comparing them to lean healthy controls (n=30) 
as well as non-lean healthy controls (n=46).  
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3.2  METHODS 
 
We compared a cohort of lean healthy controls (n=30) and non-lean healthy controls 
(n=46) with biopsy-proven lean NAFLD (n=99). Inclusion and exclusion criteria for 
these patients were outlined in section 2.1.2.2 and 2.1.2.3. Clinical and laboratory 
assessments of the participants were described in section 2.1.2.1. All lean NAFLD 
patients had a liver biopsy performed and histopathology was assessed as per section 
2.2.1. 
Methods of bile acid extraction and quantification, as well as serum FGF-19 and C4 
measurements were also described in the methods sections 2.2.3 to 2.2.5. Stools of a 
subset of patients were sent for microbiota analysis at the South Australian Health and 
Medical Research Institute (SAHMRI) as per section 2.2.11. In addition, serum 
inflammatory cytokine levels were measured at the Crux Biolab, Victoria as per 
section 2.2.12. 
 
Data was analysed using SPSS version 24.0 (IBM, Armonk, NY). Further details of 
statistical analysis were provided in section 2.2.13. 
 
3.3 RESULTS 
 3.3.1 Patient characteristics 
 
The baseline characteristics of lean and non-lean healthy controls as well as lean 
NAFLD patients are outlined in Table 5. All the patients in the lean and non-lean 
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healthy controls as well as lean NAFLD groups were matched by age and gender. 
There was no significant difference in the levels of serum fasting blood sugar level, 
total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides between the 
three groups.  
Metabolic health was defined as the absence of insulin resistance with no evidence of 
subclinical inflammation as determined by high sensitivity C-reactive protein (CRP), 
together with none or only one component of the metabolic syndrome according to the 
Adult Treatment Panel III criteria (hypertension, elevated fasting BSL, dyslipidaemia, 
elevated plasma triglyceridaemia or low plasma HDL cholesterol) (Lorenzo et al. 
2007; Wildman et al. 2008). With this definition, metabolically healthy patients had a 
significantly lower prevalence of hypertension compared to metabolically unhealthy 
normal weight patient, regardless of their BMI. 
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Table 5. Characteristics of lean and non-lean healthy controls 
and lean NAFLD patients 
#p-value was calculated using one-way Anova test. Abbreviations: MHNW: Metabolically 
healthy normal weight; MHO: Metabolically healthy obese; MUNW: Metabolically unhealthy 
normal weight. Metabolic health was defined as the absence of insulin resistance/diabetes with 
none or only one of the metabolic syndrome components. 
 
 3.3.2 Metabolic health status has more impact on bile acid levels 
than BMI alone 
 
To investigate the effect of metabolic health on bile acid metabolism, we first 
compared the total bile acid levels between lean and non-lean healthy controls as well 
as lean NAFLD patients. Interestingly, total bile acid level was not significantly 
different between the lean and non-lean healthy controls, however, the total bile acid 
level was significantly higher in patients with lean NAFLD suggesting the greater 
impact of metabolic health status on the bile acid level, beyond their BMI alone 
(Figure 3).  
  
Lean control 
(MHNW)    
(n = 30) 
Non-lean 
control (MHO)    
(n=46) 
Lean NAFLD 
(MUNW)      
(n = 99) 
p-value# 
Age (years) 46.7 ± 12 48.6 ± 11.2 46 ± 11.7 0.530 
Male (%) 22 (73.3) 35 (76.1) 69 (69.7) 0.502 
BMI (kg/m2) 22.8 ± 1.9 28.5 ± 3.2 23.2 ± 1.5 <0.001 
ALT (IU/ml) 27.1 ± 10.3 26.3 ± 8.7 57.9 ± 35.6 <0.001 
Fasting BSL (mmol/L) 4.9 ± 0.5 5.1 ± 0.3 5.3 ± 1.8 0.244 
Total Cholesterol (mmol/L) 5.0 ± 1.1 5.3 ± 1.1 5.1 ± 1.2 0.375 
HDL Cholesterol (mmol/L) 1.4 ± 0.4 1.5 ± 0.4 1.5 ± 0.6 0.943 
LDL Cholesterol (mmol/L) 3.0 ± 0.8 3.2 ± 0.9 3.6 ± 1.6 0.084 
Triglycerides (mmol/L) 1.3 ± 1.0 1.5 ± 0.8 1.6 ± 1.4 0.353 
Diabetes (%) 0 0 11 (11.1)  
Hypertension (%) 1 (3.3) 7 (15.2) 25 (25.3)  
Dyslipidaemia (%) 9 (30.0) 25 (54.3) 43 (43.4)  
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Figure 3. Total bile acids, total primary bile acids and total 
secondary bile acid levels between lean and non-lean healthy 
controls as well as lean NAFLD patients.      
The x-axis showed lean healthy controls (n=30), non-lean healthy controls (n=46), and 
lean NAFLD (n=99) patients and the y-axis showed mean concentration of bile acid 
levels in µmol/L. Results are expressed as mean ± SEM and P value was calculated 
using the Mann-Whitney non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
 
 3.3.3 Lean NAFLD patients had distinct bile acid profile  
 
The composition of the BA pool also differed between the groups. Lithocolic acid 
(LC) is abundant in the lean control group but not in the non-lean control and lean 
NAFLD groups (Figure 4). In addition, the proportion of conjugated primary bile 
acids, for example, glycocholic acid (GCA) (1.2275 ± 3.53182 umol/L in lean NAFLD 
vs 0.3403 ± 0.47052 umol/L in lean healthy controls and 0.2627 ± 0.28027 umol/L in 
non-lean healthy controls, p = 0.092), taurochenodeoxycholic acid (TCDCA) (0.2538 
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± 0.70753 umol/L vs 0.0746 ± 0.09019 umol/L and 0.0625 ± 0.06001 umol/L, p = 
0.004) and taurocholic acid (TCA) (0.2919 ± 1.04185 umol/L vs 0.0533 ± 0.8936 
umol/L and 0.0327 ± 0.03954 umol/L, p = 0.069) were higher in the lean NAFLD 
group compared to the two healthy control groups.  
 
Figure 4. Bile acid distribution in lean healthy controls and lean 
NAFLD patients.  
Bile acid composition as a percentage according to hepatic fibrosis. The x-axis shows 
lean healthy controls (n = 30) and lean NAFLD patients (n = 99), and the y-axis shows 
the percentage composition of each individual bile acid in %. 
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 3.3.4 Lean NAFLD patients had elevated individual serum bile 
acid levels  
 
Having demonstrated the importance of metabolic health on bile acid levels above and 
beyond the BMI, we next compared the bile acid profile and their regulation between 
lean NAFLD and lean healthy controls. The levels of total bile acids (5.56 ± 7.47 uM 
vs 2.50 ± 2.11 uM, p=0.002) as well as total primary BA (3.79 ± 6.42 uM vs 1.58 ± 
1.49 uM, p=0.018) and total secondary BA (1.73 ± 1.76 uM vs 0.91 ± 0.76 uM, 
p=0.003) were significantly higher in lean NAFLD patients compared to lean healthy 
controls (Figure 5A).   
 
In terms of primary bile acids, the concentration of both the cholic acid (CA) and 
chenodeoxycholic acid (CDCA) were higher in lean NAFLD compared to lean healthy 
controls although it was only significant for CDCA levels (0.47 ± 0.63 uM vs 0.21 ± 
0.27 uM, p=0.003, Figure 5B-C). 
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Figure 5. A) Bile acid levels in lean healthy controls and lean 
NAFLD B) Cholic acid (CA) and C) Chenodeoxycholic acid (CDCA) 
levels between lean healthy controls and lean NAFLD patients.  
The x axis shows lean healthy controls (n = 30, blue bar) and lean NAFLD patients (n = 
99, red bar) and the y axis shows the mean concentration of bile acid levels in 
µmol/L. Results are expressed as mean ± SEM and P value was calculated using the 
Mann-Whitney non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
A. 
B. 
C. 
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Similarly, the secondary bile acid deoxycholic acid was significantly higher in lean 
NAFLD patients compared to lean healthy controls (0.60 ± 0.57 uM vs 0.38 ± 0.39 
uM, p=0.019, Figure 6A) with higher secondary to primary bile acid ratio in the lean 
healthy controls (Figure 6B). 
 
Figure 6. A) Deoxycholic acid (DCA) levels and B) 
secondary/primary bile acid ratio between lean healthy controls 
and lean NAFLD patients.  
The x axis shows lean healthy controls (n = 30, blue bar) and lean NAFLD patients (n = 
99, red bar) and the y axis shows the mean concentration of bile acid levels in µmol/L 
in A, and secondary to primary bile acid ratio in B. Results are expressed as mean ± 
SEM and P value was calculated using the Mann-Whitney non-parametric t-test. 
P < 0.05, ** P<0.01, *** P<0.001. 
B. 
A. 
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3.3.5 Lean NAFLD patients had comparable FGF-19 levels to lean 
healthy controls in the early, but not in later stages of the 
disease 
 
There was no significant difference in levels of FGF-19 between lean healthy controls 
and lean NAFLD patients with none/mild fibrosis (F0-1). However, in lean NAFLD 
patients with moderate/severe fibrosis (F2-4), the level of FGF-19 was significantly 
lower compared to that in lean healthy controls (Figure 7). 
 
Figure 7. FGF-19 levels in lean healthy controls and lean NAFLD 
patients stratified by fibrosis stage.  
Mean concentration of FGF19 levels according to BMI and hepatic fibrosis. The x axis 
shows lean healthy controls (n = 30, green bar) and lean NAFLD patients with 
absent/mild (F0–F1, blue bar, n = 75) and moderate/severe (F2-4, red bar, n = 24) 
hepatic fibrosis; the y axis shows the mean concentration of FGF19 in pg/mL. Results 
are expressed as mean ± SEM and P value was calculated using the Mann-Whitney 
non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
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3.3.6 C4 levels in lean NAFLD compared to lean healthy controls 
 
When C4 level (a serum marker for BA synthesis) was measured, lean NAFLD 
patients had significantly higher levels of C4 compared to lean healthy controls. This 
was more so for lean NAFLD patients with more advanced fibrosis compared to early 
fibrosis (Figure 8). 
 
 
 
Figure 8. C4 levels between lean healthy controls and lean 
NAFLD patients 
Mean concentration of C4 levels according to BMI and hepatic fibrosis. The x axis 
shows lean healthy controls (n = 30, green bar) and lean NAFLD patients with 
absent/mild (F0–F1, blue bar, n = 75) and moderate/severe (F2-4, red bar, n = 24) 
hepatic fibrosis; the y axis shows the mean concentration of C4 in µmol/L. Results are 
expressed as mean ± SEM and P value was calculated using the Mann-Whitney non-
parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
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3.3.7 Microbiota profile in lean NAFLD patient is distinct from 
lean healthy controls 
 
A selection of patients from the lean healthy controls and lean NAFLD groups were 
used for the comparison of their microbiota profile. The patient characteristics are 
shown Table 6. Analysis of microbiota demonstrated a distinct separation in profiles 
between lean healthy controls and lean NAFLD (PERMANOVA P = 0.069, Pseudo-F 
= 2.019) (Figures 9A-C). More specifically, in the lean NAFLD group there was an 
increased abundance of the species Dorea and a reduction in the relative abundance of 
a number species, including Marvinbryantia and the Christensellenaceae R7 group. 
 
Table 6. Characteristics of lean healthy controls and lean NAFLD 
patients used in microbiota analysis 
  Lean control (n = 9) Lean NAFLD (n = 5) p-value 
Age (years) 56.1 ± 8.5 49 ± 8.5 0.259 
Male (%) 3 (33.3) 2 (40) 1.0 
BMI (kg/m2) 22.7 ± 1.9 24.0 ± 1.5 0.274 
ALT (IU/ml) 25.3 ± 9.6 97.5 ± 64.1 0.0051 
Total Cholesterol (mmol/L) 4.9 ± 1.3 5.2 ± 0.6 0.218 
Fasting BSL (mmol/L) 4.7 ± 0.3 7.1 ± 4.8 0.645 
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Figure 9. Microbiota profile of lean healthy controls and lean 
NAFLD patients.  
A) Non-metric Multi-dimensional scaling (NMDS) plot of distribution of gut microbiota in lean 
healthy controls (n = 9) and lean NAFLD patients (n = 5) showing distinct separation between 
the two groups. Circles represent 95% confidence limit of the standard error of samples in 
each group. B) Operational taxonomic unit (OUT) table between lean healthy controls (n = 9) 
and lean NAFLD patients (n = 5). C) Taxa differences between lean healthy controls (n = 9) 
and lean NAFLD patients (n = 5). 
B. 
A. 
C. 
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3.3.8 Lean NAFLD patients had higher inflammatory cytokine 
profile 
 
We next compared the inflammatory cytokine profiles from serum of lean healthy 
controls and lean NAFLD patients. Interestingly, patients with lean NAFLD had 
higher levels, although insignificant, of several inflammatory cytokines, including IL-
1 beta (p = 0.6905), IL-4 (p = 0.1646) and TNF-alpha (p = 0.1096) (Figures 10A-C).  
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Figure 10. Inflammatory cytokines level between lean healthy 
control and lean NAFLD 
The x axis shows lean healthy controls (n = 30) and lean NAFLD (n = 99); the y axis 
shows the mean concentration of inflammatory cytokines in pg/mL. Results are 
expressed as mean ± SEM and P value was calculated using the Mann-Whitney non-
parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
B. 
A. 
C. 
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3.4 DISCUSSION 
 
In this chapter, we first compared the characteristics of patients with lean NAFLD 
with groups of lean healthy controls as well as non-lean healthy controls. We were 
first interested to see the effect of metabolic health on the baseline metabolic profile of 
patients as well as on the bile acid profile. Lean NAFLD patients and metabolically 
unhealthy patients had a higher prevalence of hypertension compared to metabolically 
healthy patients regardless of their BMI. When we compared their bile acid profiles 
(including comparing it to the non-lean NAFLD patients), we found that patients who 
were metabolically unhealthy had significantly higher levels of bile acid levels 
compared to metabolically healthy patients, regardless of their BMI. 
 
We then focused on the comparison of lean healthy controls (to represent 
metabolically healthy patients) with lean NAFLD (to represent metabolically 
unhealthy patients). Here we found that patients with lean NAFLD had significantly 
higher total BA, total primary BA and total secondary BA compared to lean healthy 
controls with levels higher for certain individual BA like chenodeoxycholic acid 
(CDCA) and deoxycholic acid (DCA), both of which are potent FXR agonists.  
 
Next we compared the metabolic adaptation capacity between the two groups by 
measuring FGF-19 levels in the serum as markers of FXR activity. Although overall 
there was no significant difference in FGF-19 levels between lean healthy and lean 
NAFLD patients, when we stratified the lean NAFLD patients according to their 
fibrosis severity we found a striking difference in metabolic adaptation. Patients with 
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early stages of lean NAFLD (F0-F1) had similar levels of FGF-19 compared to lean 
healthy controls but this level significantly dropped in the later stages of the disease 
(F2-F4) suggesting a loss of metabolic adaptation as the disease progresses in the lean 
NAFLD patients. Exactly what triggers the switch or loss of metabolic adaptation is 
not clear and is beyond the scope of our study. It would be interesting for future 
studies to explore this further through longitudinal follow up of patients.  
 
The serum C4 level, which is a marker for bile acid synthesis (Arab et al. 2017) also 
reflected the FGF-19 levels with the level being lowest in the lean healthy controls, 
and highest in lean NAFLD with advanced fibrosis. Interestingly, however, unlike the 
FGF-19 levels, which were not significantly different between the lean healthy 
controls and lean NAFLD with early fibrosis, we saw significantly higher C4 levels in 
lean NAFLD with early fibrosis compared to lean healthy controls. This may reflect 
the metabolic adaptation that lean NAFLD possesses early on in the disease course, 
where the increased dietary intake of cholesterol is compensated by increased bile acid 
production to maintain serum cholesterol level and body weight. This may also 
explain the lower secondary to primary bile acid ratios seen in lean NAFLD patients 
compared to lean healthy controls. 
 
Lean NAFLD had a distinct separation in microbiota profile compared to the 
healthy controls with an increased abundance of Dorea that has been implicated in 
the pathogenesis and progression of NASH (Del Chierico et al. 2017b; Del Chierico 
et al. 2017a), and a decrease in several species protective for NAFLD such as 
Marvinbryantia and Christensellenaceae R7 group. Both are known to play a role in 
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the modulation and production of beneficial short chain fatty acids and in providing a 
desirable intestinal environment for the growth of probiotic bacteria (Ma et al. 2017; 
Zhou et al. 2017).  
 
Certain gut microbiota, especially those belonging to the Firmicutes phyla such as the 
Ruminococcus, Marvinbryantia and Christensellenaceae are known butyrate 
producers. Butyrate is a beneficial short chain fatty acids (SCFA) and are products of 
dietary fibre fermentation in the gut (Zhou and Fan 2019). Apart from providing 
energy for the intestinal epithelium, SCFAs also play significant roles in regulation of 
immunity, lipid and glucose metabolism as well as maintenance of gut microbiota 
homeostasis (Z. H. Zhao et al. 2019). Studies have shown that supplementation with 
butyrate-producing probiotics corrected high fat diet (HFD) induced steatohepatitis in 
mice through the production of butyrate, as well as improving the gastrointestinal 
barrier, thereby inhibiting the delivery of gut derived endotoxin to the liver (Zhou et 
al. 2017). The trend towards higher inflammatory cytokines seen in lean NAFLD 
compared to lean healthy controls further supports a gut-derived pathogenesis of lean 
NAFLD.  
 
3.5 CONCLUSION 
 
In this chapter we have demonstrated the importance of metabolic health on baseline 
metabolic risk profiles as well as bile acid levels. In addition, we have shown that lean 
NAFLD patients had altered gut microbiota, which increases their risk for NAFLD 
development and progression, as well as increases in their pro-inflammatory milieu 
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compared to lean healthy controls. Lean NAFLD however, demonstrated good 
metabolic adaptation, especially early in the disease process, with FGF19 levels 
comparable to those seen in the lean healthy controls.  
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4 COMPARISON OF METABOLIC ADAPTATION IN LEAN NAFLD 
WITH NON-LEAN NAFLD PATIENTS 
 
4.1 INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) affects about 20-30% of the world’s 
population and is a leading cause for end-stage liver disease, cancer and 
transplantation (Z. Younossi et al. 2018a). Despite this, the existence and clinical 
course of the entity known as “lean NAFLD” or “NAFLD in lean patients” has been 
the subject of intense debate and controversy. To many, lean NAFLD refers to 
individuals manifesting the disease in the context of a normal body mass index (BMI), 
but having excess visceral adiposity and insulin resistance, as well as metabolic 
dysfunction that is typically observed in people with obesity (Ruderman et al. 1998), 
the so called metabolically obese normal-weight (MONW) individual. The prevalence 
of lean NAFLD varies widely according to the criteria used for its definition but 
ranges from 5 to 45% (Ding et al. 2016). By this interpretation, lean NAFLD is similar 
if not identical to NAFLD associated with overweight and obesity, with insulin 
resistance at its core.  
 
Accumulating evidence however suggests that lean NAFLD might be a distinct patho-
physiological entity with about half (47-65%) having NASH (Z. M. Younossi et al. 
2016a). While “lean NAFLD” was first described in Asia, it has since been recognised 
globally (Z. Younossi et al. 2018a). Most aspects of lean NAFLD including its 
operational classification have not been systematically characterised. The most 
frequently used definition is that of hepatic steatosis with a BMI < 25 kg/m2 (or less 
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than 23 kg/m2 in Asians) in the absence of significant alcohol intake (Das and 
Chowdhury 2013). The natural history of lean NAFLD is even less well characterised; 
some data suggests that they have worse mortality and accelerated disease progression, 
despite a more favourable metabolic risk profile (A. C. Dela Cruz et al. 2014; 
Hagstrom et al. 2018). Lastly, the pathogenesis and mechanisms for their favourable 
metabolic profile compared to obese NAFLD is puzzling and poorly understood, while 
therapeutic options for lean NAFLD remain undefined. 
 
We hypothesized that the pathogenesis of lean and obese NAFLD and their distinct 
metabolic and histological profiles is caused by more than just differences in body 
weight and body mass index. We considered that the clinical phenotype of lean 
NAFLD might reflect differences in the integration of signals from the diet and the 
systemic metabolic milieu, as also the enterohepatic axis comprising both bile acids 
and gut microbiota. We tested this hypothesis in a large well-phenotyped biopsy 
proven cohort of 538 Caucasian patients with NAFLD. 
 
4.2 METHODS 
 
The cohort comprised five hundred and thirty-eight consecutive Caucasian patients 
with histologically characterized NAFLD. The inclusion criteria and clinical and 
laboratory assessments and histopathology are described in detail in methods chapter. 
Ethics approval was obtained from the Human Ethics committee of the Western 
Sydney Local Health District and the University of Sydney. All other sites had ethics 
approval from their respective ethics committees. 
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Methods of genotyping, high throughput bile acid profiling, quantification of C4, 
FGF19, and microbiome analysis are provided in the methods chapter. In addition, 
serum phosphatidylethanol level was measured in all patients to rule out significant 
alcohol intake in the past few weeks prior to recruitment. Details on the method of 
serum phosphatiylethanol level measurement is also described in chapter 2, methods. 
 
Data were analysed using SPSS version 24.0 (IBM, Armonk, NY). Values are 
expressed as mean ± standard deviation, median and interquartile range or frequency 
(percentage) as appropriate. Statistical significance was considered as p<0.05 
throughout; details are provided in chapter 2, methods.  
 
4.3 RESULTS 
 
 4.3.1 Clinical, histological and genetic characteristics of patients 
with lean NAFLD 
 
A total of 538 patients with biopsy proven NAFLD were recruited for the study. 
Ninety-nine patients (18%) were lean. The clinical and biochemical characteristics of 
lean NAFLD compared to their counterpart non-lean patients are presented in Table 7. 
Both groups had similar non-significant phosphatidylethanol level in the blood 
therefore ruling out significant alcohol intake (values above 253 ng/mL are regarded 
as significant alcohol consumption in the past weeks (Kechagias et al. 2015)). In 
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addition to lower BMI, lean patients had lower waist hip ratio (WHR) and a better 
metabolic profile, including a significantly lower frequency of diabetes, a higher 
serum HDL, and lower serum triglycerides, fasting blood glucose and HOMA-IR 
values, compared to their non-lean counterparts. Histologically, lean patients had 
higher prevalence of none or mild fibrosis and lower NAS scores (p<0.001 for both), 
as well as lower serum ALT (Figure 11). In total, lean patients have favourable 
metabolic and histological features compared to non-lean NAFLD.  
Lean NAFLD patients had a significantly higher prevalence of carriage of the TM6SF2 
rs58542926 (T) allele compared to non-lean patients, but a similar prevalence of the 
PNPLA3 GG polymorphism (Table 7). To adjust for the effect of confounding factors, 
the TM6SF2 rs58542926 (T) allele still associated with lean NAFLD in a multivariable 
model adjusting for age, gender, ALT, diabetes, total cholesterol level, fibrosis, 
steatosis and PNPLA3 genotype (OR 2.567, 95% confidence interval 1.426-4.619, p = 
0.002). 
 
Figure 11. Fibrosis grade distribution 
The distribution of fibrosis grades amongst patients with lean NAFLD (n=99) and non-
lean NAFLD (n=439) 
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Table 7. Clinical and histological characteristics of lean and non-
lean NAFLD patients 
  Lean NAFLD (n = 99) Non-lean NAFLD (n = 439) p-value 
Age (years) 46 ± 11.7 47 ± 13.0 0.445 
Male (%) 69 (69.7) 290 (64.9) 0.413 
BMI (kg/m2) 23.2 ± 1.5 30.8 ± 4.7 <0.001 
PNPLA3 I148M (no, %) 
(CC/CG/GG) 32(32.3)/39(39.4)/16(16.2)  145(32.4)/172(38.5)/67(14.9)  0.973 
TM6SF2 E167K (no, %) 
(CC/CT/TT) 59(59.6)/22(22.2)/3(3.0)  321(71.8)/50(11.8)/6(1.3)  0.005 
ALT (IU/ml) 57.9 ± 35.6 72.3 ± 46.8 <0.001 
Waist/ Hip ratio (WHR)* 
    Normal WHR  
    Elevated WHR     
0.919 ± 0.062 
25 (29.2) 
29 (29.3) 
0.971 ± 0.079 
46 (10.3) 
189 (42.3) 
<0.001 
 
 
Phosphatidylethanol level 
(ng/mL) 66.35 ± 48.59 66.45 ± 52.72 0.8829 
Diabetes (%) 11 (11.1) 128 (28.6) <0.001 
Hypertension (%) 25 (25.3) 158 (35.3) 0.060 
Dyslipidaemia (%) 43 (43.4) 242 (54.1) 0.059 
Total Cholesterol 
(mmol/L) 5.1 ± 1.2 5.2 ± 1.2 0.472 
HDL-C (mmol/L) 1.5 ± 0.6 1.2 ± 0.3 <0.001 
LDL-C (mmol/L) 3.6 ± 1.6 3.5 ± 1.6 0.667 
Triglyceride (mmol/L) 1.6 ± 1.4 1.9 ± 1.2 0.083 
Fasting BSL (mmol/L) 5.3 ± 1.8 5.9 ± 1.8 0.006 
HOMA-IR 2.8 ± 1.9 5.4 ± 5.9 <0.001 
Fibrosis (%) 
   F0-1 (%) 
   F2-4 (%) 
75 (75.8) 
24 (24.2) 
239 (54.6) 
200 (45.4) 
<0.001 
 
Ballooning (%) 
   No ballooning (%) 
   Any ballooning (%) 
37 (37.4) 
62 (62.6) 
131 (30.4) 
308 (69.6) 
0.1510 
 
Steatosis (%) 
   Grade 1-2 (%) 
   Grade 3 (%) 
85 (85.9) 
14 (14.1) 
351 (81.2) 
88 (18.8) 
0.2530 
 
Lobular inflammation  
   Grade 0-1 (%) 
   Grade 2 or more (%) 
88 (88.9) 
11 (11.1) 
352 (80.5) 
87 (19.5) 
0.0782 
 
NAS score  3 ± 2 4 ± 2 0.001 
Values are mean±SD, or number (%), p-value was calculated using Fisher’s exact test and 
student’s t-test. *WHR based on 54 lean patients and 235 non-lean patients. Normal WHR 
defined as less than 0.90 for males and less than 0.85 for females. DNA was available for 471 
patients (86%). 
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4.3.2 Serum bile acid profile is associated with NAFLD severity, 
but not steatosis 
 
Although there is increasing evidence to suggest a critical role for BAs in metabolic 
diseases including NAFLD, their correlation with disease severity is conflicting, likely 
due to the limited sample sizes and various methodologies adapted in previous studies. 
We explored the association between the BA profile and liver histology. 
 
No differences in the total BA, total primary or total secondary BA levels were noted 
between patients with mild steatosis (S1-S2) compared to those with severe steatosis 
(S3) (Figure 12). Next, the association with steatohepatitis activity including the 
severity of inflammation and hepatocyte ballooning was tested. In this analysis, 
significantly higher total BAs (p = 0.006), primary BAs (p = 0.031) and secondary 
BAs (p < 0.001) were found in patients with hepatocyte ballooning, compared to those 
without ballooning (Figure 13).  
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Figure 12. Steatosis grade and bile acid concentration 
Mean concentration of total bile acids, total primary bile acids and total secondary 
bile acids according to hepatic steatosis. The x axis shows hepatic steatosis 
dichotomized as mild (grade 1-2, n = 436) or moderate/severe (grade 3, n = 102), and 
the y axis shows the mean concentration of bile acid levels in µmol/L. Results are 
expressed as mean ± SEM and P value was calculated using the Mann-Whitney non-
parametric t-test. P < 0.05, ** P<0.01, *** P<0.001.  
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Figure 13. Ballooning grade and bile acid concentration 
Mean concentration of total bile acids, total primary bile acids and total secondary 
bile acids according to hepatocyte ballooning. The x axis shows hepatic ballooning 
dichotomized as no ballooning (n = 168) or any ballooning (n = 370), and the y axis 
shows the mean concentration of bile acid levels in µmol/L. Results are expressed as 
mean ± SEM and P value was calculated using the Mann-Whitney non-parametric t-
test. *P < 0.05, ** P<0.01, *** P<0.001.  
 
 
Next, we investigated the relationship between BA and lobular and portal 
inflammation. When comparing degrees of inflammation, higher grades of lobular 
inflammation were associated with higher total (p = 0.027) and secondary BAs 
(1.4680 ± 1.8109 vs 1.4563 ± 1.0038, p = 0.021), while there was no significant 
difference in primary BA levels (p = 0.073). Similarly, there was no significant 
difference in the total BA, primary and secondary BA levels with different grades of 
portal inflammation (Figures 14A and B). 
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Figure 14. Bile acid levels and their associations with 
inflammation.  
A. Mean serum bile acid levels in different lobular inflammation grades, dichotomized 
as lobular inflammation grade 0-1 and grade 2 or more. The x axis shows lobular 
inflammation dichotomized as absent/mild (grade 0-1, n = 440) or moderate/severe 
(grade 2 or more, n = 98), and the y axis shows the mean concentration of bile acid 
levels in µmol/L. B. Mean serum bile acid levels in different portal inflammation 
grades dichotomized as grade 0-1 and grade 2 or more. The x axis shows portal 
inflammation dichotomized as absent/mild (grade 0-1, n = 440) or moderate/severe 
(grade 2 or more, n = 98), and the y axis shows the mean concentration of bile acid 
levels in µmol/L. Results are expressed as mean ± SEM and P value was calculated 
using the Mann-Whitney non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001.  
A. 
B. 
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Higher levels of total BAs (p = 0.001), primary BAs (p = 0.001) and secondary BAs (p 
= 0.002) were seen in patients with higher NAS score, defined as > 3 compared to 
patients with lower scores (Figure 15). Similarly, patients with NASH had higher 
levels of total, primary and secondary BAs, compared to patients with steatosis, but 
only the secondary BA levels were significantly different between the two groups (p = 
0.047).  
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Figure 15. Bile acid distribution with respect to NAFLD activity 
scores (NAS). 
Mean concentration of total bile acids, total primary bile acids, and total secondary 
bile acids according to NAS. The x-axis shows NAS dichotomized as absent/mild (score 
0-3, n = 251) or moderate/severe (grade 3 or more, n = 287), and the y-axis shows the 
mean concentration of bile acid levels in µmol/L. Results are expressed as mean ± 
SEM and P value was calculated using the Mann-Whitney non-parametric t-test. 
P < 0.05, ** P<0.01, *** P<0.001.  
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Figure 16. Bile acid distribution with respect to fibrosis grade 
A) Bile acid composition as a percentage according to hepatic fibrosis. The x-axis 
shows patients with absent/mild (F0-F1, left, n = 314) and moderate/severe fibrosis 
(F2-F4, right, n = 224), and the y-axis shows the percentage composition of each 
individual bile acid in %. B) Mean concentration of total bile acids, total primary bile 
acids and total secondary bile acids according to hepatic fibrosis. The x-axis shows 
hepatic fibrosis dichotomized as absent/mild (F0–F1, n = 314) or moderate/severe 
(F2–F4, n = 224) and the y-axis shows the mean concentration of bile acid levels in 
µmol/L. Results are expressed as mean ± SEM and P value was calculated using the 
Mann-Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
A. 
B. 
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Lastly, the association of BAs with NAFLD fibrosis stage was tested. The distribution 
of all individual BAs between patients with none/mild fibrosis and those with 
significant fibrosis is depicted in Figure 16A. Patients with significant fibrosis (≥F2) 
had higher total (p = 0.017), primary (p = 0.018) and secondary BA levels (p = 0.045) 
compared to those with none/mild fibrosis (F0-1) (Figure 16B).  This is consistent 
with previous studies (Puri et al. 2017). 
 
At the level of individual BAs, the level of cholic acid was significantly higher in 
patients with significant fibrosis compared to those with none/mild fibrosis (p = 0.026) 
(Figure 15A). Similarly, the levels of glycine and taurine conjugated BAs were 
significantly higher in patients with significant fibrosis compared to those with 
none/mild fibrosis (p = 0.002 and p < 0.001 respectively) (Figures 17B-C).  
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Figure 17. Individual bile acid between fibrosis grades 
A) Mean concentration of cholic acid (CA) according to hepatic fibrosis. The x-axis 
shows hepatic fibrosis dichotomized as absent/mild (F0–F1, n = 314) or 
moderate/severe (F2–F4, n = 224), and the y-axis shows the mean concentration of 
bile acid levels in µmol/L. B) Mean concentration of glycine conjugated bile acids 
according to hepatic fibrosis. The x-axis shows hepatic fibrosis dichotomized as 
absent/mild (F0–F1, n = 314) or moderate/severe (F2–F4, n = 224), and the y-axis 
shows the mean concentration of bile acid levels in µmol/L. C) Mean concentration of 
taurine conjugated bile acids according to hepatic fibrosis. The x-axis shows hepatic 
fibrosis dichotomized as absent/mild (F0–F1, n = 314) or moderate/severe (F2–F4, n = 
224), and the y-axis shows the mean concentration of bile acid levels in µmol/L. 
Results are expressed as mean ± SEM and P value was calculated using the Mann-
Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
B. 
C. 
A. 
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4.3.3 Lean NAFLD patients have higher serum bile acid levels  
 
Next we explored the bile acid profile between patients with lean and non-lean 
NAFLD. Interestingly, patients with lean NAFLD had higher total, primary and 
secondary BA levels compared to those with non-lean NAFLD, though this was only 
significant for the secondary bile acids (p=0.010) (Figure 18B). The composition of 
individual BAs also differed between lean and non-lean NAFLD patients, wherein 
lean patients had lower Deoxycholic acid (DCA), Glycochenodeoxycholic acid 
(GCDCA) and chenodeoxycholic acid (CDCA), but more glycocholic acid (GCA) 
compared to the non-lean patients (Figure 18A). Lean NAFLD patients also had non-
significantly higher total conjugated and total unconjugated BAs compared to non-lean 
NAFLD patients.  
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Figure 18. Bile acid distribution in lean and non-lean NAFLD 
patients. 
A) Bile acid composition in percentage between lean and non-lean NAFLD patients. 
The x-axis shows lean (n = 99) and non-lean NAFLD patients (n = 439), and the y-axis 
shows the percentage composition of each individual bile acid in %. B) Mean 
concentration of total bile acids, total primary bile acids and total secondary bile 
acids in lean and non-lean NAFLD patients. The x-axis shows lean (n = 99) and non-
lean NAFLD patients (n = 439) and the y-axis shows the mean concentration of bile 
acid levels in µmol/L. Results are expressed as mean ± SEM and P value was 
calculated using the Mann-Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** 
P<0.001.  
 
A. 
B. 
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Given the strong correlation between BA profiles and fibrosis, we examined the 
relationship between bile acids and lean NAFLD stratified by fibrosis stage. When 
stratified in this way, in those with mild fibrosis (F0-1), higher total secondary BA 
levels were observed in lean compared to non-lean NAFLD patients (p = 0.004). No 
significant difference between lean and non-lean patients was observed in those with 
more severe fibrosis (Figures 19A and B). The predominant secondary BAs 
contributing to this difference were deoxycholate (DCA) and ursodeoxycholic acid 
(UDCA) (p<0.05 for both) (Figures 20A and B). Glycocholic acid (GCA) was also 
higher in lean NAFLD patients; however, this difference was not significant (Figure 
21A). The secondary to primary BA ratio was significantly higher in patients with lean 
compared to non-lean NAFLD (p = 0.018) (Figure 21B). 
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Figure 19. Bile acid levels between lean and non-lean stratified 
by fibrosis degrees 
A) Mean concentration of total bile acids, total primary bile acids and total secondary 
bile acids in lean and non-lean patients with absent/mild fibrosis. The x-axis shows 
lean (n = 75) and non-lean (n = 239) patients with absent/mild (F0–F1) hepatic 
fibrosis and the y-axis shows the mean concentration of bile acid levels in µmol/L. B) 
Mean concentration of total bile acids, total primary bile acids and total secondary 
bile acids in lean and non-lean patients with moderate/severe fibrosis. The-x axis 
shows lean (n = 24) and non-lean (n = 200) patients with moderate/severe (F2–F4) 
hepatic fibrosis and the y-axis shows the mean concentration of bile acid levels in 
µmol/L. Results are expressed as mean ± SEM and P value was calculated using the 
Mann-Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
 
A. 
B. 
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Figure 20. Individual bile acids between lean and non-lean 
A) Mean concentration of deoxycholic acid (DCA). The x-axis shows lean (n = 99) and 
non-lean patients (n = 439), and the y-axis shows the mean concentration of bile acid 
levels in µmol/L. B) Mean concentration of Ursodeoxycholic acid (UDCA). The x-axis 
shows lean (n = 99) and non-lean NAFLD patients (n = 439), and the y-axis shows the 
mean concentration of bile acid levels in µmol/L. Results are expressed as 
mean ± SEM and P value was calculated using the Mann-Whitney non-parametric t-
test. *P < 0.05, ** P<0.01, *** P<0.001.  
A. 
B. 
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Figure 21. GCA levels and secondary/primary BA ratio in lean 
and non-lean NAFLD 
A) Mean concentration of glycocholic acid (GCA). The x-axis shows lean (n = 99) and 
non-lean patients (n = 439), and the y-axis shows the mean concentration of bile acid 
levels in µmol/L. B) Secondary to primary BA ratio in lean and non-lean NAFLD 
patients. The x-axis shows lean (n = 99) and non-lean NAFLD patients (n = 439), and 
the y-axis shos secondary to primary BA ratio. Results are expressed as mean ± SEM 
and P value was calculated using the Mann-Whitney non-parametric t-test. *P < 0.05, 
** P<0.01, *** P<0.001.  
 
A. 
B. 
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In a subsequent analysis we determined the relevant clinical factors associated with 
secondary BA levels. Consistently, on univariable analysis, BMI, fibrosis and 
ballooning were associated with secondary bile acid levels. On multivariable analysis, 
only BMI and fibrosis stage remained independently, negatively and positively 
associated with secondary BA levels, respectively (Table 8).  
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Table 8. Univariable and multivariable analysis of total 
secondary bile acids with relevant clinical factors 
Clinical 
factors 
Univariable analysis Multivariable analysis 
β 95% CI p-
value 
β 95% CI p-
value 
Age 0.072 -0.001 0.022 0.082     
Gender -0.021 -0.385 0.222 0.599     
BMI -0.09 -0.059 -0.003 0.029 -0.125 -0.077 -0.014 0.005 
Diabetes -0.046 -0.536 0.148 0.266     
Hypertension 0.016 -0.248 0.369 0.7     
Dyslipidaemia -0.036 -0.413 0.16 0.386     
Total 
cholesterol 
-0.046 -0.191 0.053 0.266     
HOMA-IR 0.027 -0.025 0.042 0.625     
Fibrosis 0.141 0.082 0.333 0.001 0.128 0.052 0.326 0.007 
Steatosis -0.055 -0.331 0.074 0.214     
Ballooning 0.135 0.114 0.513 0.002 0.094 0.009 0.429 0.051 
Lobular 
inflammation 
-0.037 -0.36 0.142 0.396     
Portal 
Inflammation 
-0.03 -0.442 0.248 0.58     
NAS 0.007 -0.09 0.107 0.869     
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4.3.4 Lean NAFLD patients have higher serum FGF19 levels 
 
FXR dysregulation has been implicated in the pathogenesis of NAFLD so we were 
interested to determine if differential effects are observed in lean versus non-lean 
NAFLD (Jiao et al. 2017; Puri et al. 2017). To examine for this, serum FGF19 a 
surrogate marker of FXR activity was measured. In this analysis, reduced levels of 
FGF19 were observed with the advancement of fibrosis stage (p = 0.030) (Figure 22). 
Patients with lean NAFLD had significantly higher FGF19 levels compared to non-
lean NAFLD patients (p = 0.028) (Figure 23A). Interestingly, when stratified 
according to fibrosis severity, the differences were more profound in those with mild 
fibrosis (F0-F1) (p = 0.005), with the reverse being true as fibrosis severity increased; 
this was however not significant (Figure 23B-C). 
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Figure 22. FGF-19 in early and late fibrosis 
 
Mean concentration of FGF19 according to hepatic fibrosis. The x-axis shows hepatic 
fibrosis dichotomized as absent/mild (F0–F1, n = 314) or moderate/severe (F2–F4, n = 
224), and the y-axis shows the mean concentration of FGF19 in pg/mL. Results are 
expressed as mean ± SEM and P value was calculated using the Mann-Whitney non-
parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
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Figure 23. FGF-19 in lean and non-lean, and stratified by fibrosis 
degree 
A) Mean concentration of FGF19 in lean and non-lean NAFLD patients. The x-axis 
shows lean (n = 99) and non-lean (n = 439) NAFLD patients, and the y-axis shows the 
mean concentrations of FGF-19 levels in pg/mL. B) Mean concentration of FGF19 
levels in lean and non-lean patients according to BMI and hepatic fibrosis. The x-axis 
shows lean and non-lean NAFLD patients with absent/mild fibrosis (F0–F1, n = 75 for 
lean and n = 239 for non-lean NAFLD) and and the y-axis shows the mean 
concentrations of FGF-19 levels in pg/mL. C) Mean concentration of FGF19 levels in 
lean and non-lean patients according to BMI and hepatic fibrosis. The x-axis shows 
lean and non-lean NAFLD patients with moderate/severe fibrosis (F2-4, n = 24 for 
lean and n = 200 for non-lean); and the y-axis shows the mean concentrations of FGF-
19 levels in pg/mL. Results are expressed as mean ± SEM and P value was calculated 
using the Mann-Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
A. 
C. 
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4.3.5 Lean NAFLD patients have lower C4 levels 
 
To investigate differences in bile acid metabolism between lean and non-lean NAFLD, 
C4 levels, a bile acid synthesis intermediate was measured as a marker of de novo BA 
synthesis. In this analysis, no difference in levels of C4 was observed according to 
fibrosis stage (Figure 24A). However, as expected, patients with lean NAFLD had 
significantly lower C4 levels compared to their non-lean counterparts (p = 0.016) 
(Figure 24B). This difference was more predominant in those with mild fibrosis (F0-
F1) (p = 0.010), but not in those with moderate/severe fibrosis (F2-F4) (Figure 24C-
D).  
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Figure 24. C4 levels between lean and non-lean 
A) Mean concentration of C4 according to hepatic fibrosis. The x-axis shows hepatic 
fibrosis dichotomized as absent/mild (F0–F1, n = 314) or moderate/severe (F2–F4, n = 
224), and the y-axis shows the mean concentration of C4 in umol/mL. B) Mean 
concentration of C4 in lean and non-lean NAFLD patients. The x-axis shows lean (n = 
99) and non-lean (n = 439) NAFLD patients, and the y-axis shows the mean 
concentrations of C4 in umol/mL. C) Mean concentration of C4 levels according to 
BMI and hepatic fibrosis. The x-axis shows lean and non-lean NAFLD patients with 
absent/mild fibrosis (F0–F1, n = 75 for lean and n = 239 for non-lean NAFLD) and the 
y-axis shows the mean concentration of C4 in umol/mL D) Mean concentration of C4 
levels according to BMI and hepatic fibrosis. The x-axis shows lean and non-lean 
NAFLD patients with moderate/severe fibrosis (F2-4, right panel, n = 24 for lean and n 
= 200 for non-lean); and the y-axis shows the mean concentration of C4 in umol/mL. 
Results are expressed as mean ± SEM and P value was calculated using the Mann-
Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
F0-F1 F2-F4
0.00
0.02
0.04
0.06
C
4 
(u
M
)
C. D. 
A. B. 
  105 
4.3.6 Lean NAFLD patients have a distinct microbiota profile  
 
The composition of the gut microbiome and their interaction with BAs affects FXR-
mediated signalling in both the liver and intestine and is implicated in NAFLD 
pathogenesis (Jiao et al. 2017; Ramirez-Perez et al. 2017). Hence, we determined gut 
microbiome composition in a small exploratory subset of patients with available stool 
samples by 16S rRNA amplicon sequencing. At the phylum level, no differences in 
taxonomic composition of the gut microbiome were observed according to lean versus 
obese BMI status. At the genus level, Erysipelotrichaceae UCG-003, as well as several 
bacterial genera within the Clostridiales order including Ruminococcus, Clostridium 
sensu stricto 1, Romboutsia and Ruminococcaceae UCG-008 were enriched in lean 
patients, while Ruminiclostridium and Streptococcus were enriched in obese NAFLD 
patients (Mann-Whitney test, p<0.05) (Figures 25 and 26A-F). These changes 
remained significant for Ruminococcaceae UCG-008 when corrected for multiple 
comparison testing (FDR p= 0.010). 
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Figure 25. Microbiota profile between lean and non-lean 
Microbiota abundance differences between the lean and non-lean NAFLD patients. 
The colour denoting each taxa represents the group in which the taxa was identified 
to be significantly increased compared to the comparison group (p < 0.05). 
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Figure 26. Individual taxa differences between lean and non-lean 
Abundance of bacterial genera and species that differ between patients with lean 
(n=5) and obese NAFLD (n=24). A) Romboutsia, B) Ruminococcus, C) 
Erysipelotrichaceae, D) Ruminoclostridium. Results are expressed as mean ± SEM and 
P value was calculated using the Mann-Whitney non-parametric t-test. *P < 0.05, ** 
P<0.01, *** P<0.001.  
 
 
A. B. 
C. 
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4.4 DISCUSSION 
 
Lean NAFLD constitutes a significant proportion of NAFLD patients though its 
pathogenesis is not well understood. Herein we provide a testable hypothesis for the 
pathophysiological distinction between lean and non-lean NAFLD that can be 
examined in other cohorts. Using biopsy proven Caucasian patients in whom the lean 
NAFLD entity is less frequent than in cohorts from Asia, we demonstrate that lean 
patients have distinct metabolic, genetic, histologic and bile acid profiles, C4 levels, as 
well as differences in FXR activity and gut microbiota compared to their non-lean 
counterparts.  
 
Consistent with other reports (Z. Younossi et al. 2018a), around 1 in 5 Caucasian 
patients with NAFLD are lean and have a favourable metabolic and pathological 
profile, with less insulin resistance and dyslipidaemia, and milder liver histology. A 
reciprocal and intimate interaction between bile acids and gut microbiota is 
associated with, and thought to regulate, metabolic and hepatic traits (Arab et al. 2017; 
Schnabl and Brenner 2014). Although myriad factors could explain the differences we 
observed, our results in toto suggest that the balance and interaction between the 
systemic metabolic milieu and changes in the intestinal microbiome and bile acid 
physiology govern the expression of hepatic disease and the onset and progression 
of NAFLD in patients with a normal BMI.  
 
To elaborate, increased bile acid levels as we observed in lean NAFLD, are reported 
to mediate resistance to diet-induced obesity, a phenomenon called “obesity-
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resistance” (Watanabe et al. 2006; Watanabe et al. 2011). Obesity-resistant rodents 
can burn more dietary fat by increasing energy expenditure. Of relevance, bile acids 
(including major bile acid species such as CA, TCA, DCA and CDCA) increase 
energy expenditure (Watanabe et al. 2006) and CDCA increases human brown 
adipose tissue activity (E. P. M. Broeders et al. 2015). FGF19 which was also 
increased in lean NAFLD, is reported to be a key regulator of energy expenditure 
and improves glucose and lipid homeostasis (Fu et al. 2004), while gut-restricted 
FXR agonism promotes metabolic improvements and enhances thermogenesis and 
browning of white adipose tissue (WAT) in mice (Fang et al. 2015). At microbiota 
level, patients with lean NAFLD had distinct gut microbiota compared to those who 
were non-lean. Lean NAFLD had an increased abundance of members belonging to 
the Clostridium genus, and as well Ruminococcaceae that are involved in the 
formation of bile acids (Kakiyama et al. 2013; Wahlstrom et al. 2016b). Thus, we 
surmise that patients with lean NAFLD have an obesity-resistant phenotype in part 
mediated by greater levels of bile acids, FGF19 and microbiota changes. 
 
The milder disease and favourable metabolic profile of patients with lean NAFLD 
could be explained by the current findings. There is strong evidence that activation 
of bile acid signalling induces improvements in metabolic (glucose and lipid) 
phenotype in murine models, mediated through the actions of FXR activity and 
Takeda G protein-coupled receptor 5 (TGR5) (Pathak et al. 2018; Pierre et al. 
2016). Activation of the FXR in hepatic stellate cells has also been shown in murine 
models to protect against liver fibrosis formation (Schumacher et al. 2020). 
Furthermore, in both humans and murine models, elevated bile acids play a role in 
the metabolic improvements after bariatric surgery, including in type 2 diabetes, 
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dyslipidemia and NASH, even before significant weight loss (A. P. Chambers et al. 
2011; Kohli et al. 2015; Patti et al. 2009). Thus, we suggest that lean patients can 
adapt metabolically and excrete greater amounts of bile acids while their obese 
counterparts are those less able to excrete adequate amounts of bile acids to rid 
themselves of excess cholesterol, even if they are able to maintain a plasma 
cholesterol level comparable to that of lean patients. Consistently, in humans, lean 
and obese patients have differential defence mechanisms to maintain stable serum 
cholesterol levels, wherein dietary cholesterol appears to preferentially induce bile 
acid synthesis in lean compared to obese patients (Klass et al. 2006).  
Notably, we did not observe any association between bile acid levels and hepatic 
steatosis, indicating a potential lack of a protective effect of bile acids on the 
development of steatosis, as opposed to changes in peripheral tissues. Alternatively, 
changes in microbiota might explain the development of steatosis (Chu et al. 2018). 
Similarly, compared to non-lean NAFLD they had an increased relative abundance 
of several phylotypes within the Erysipelotrichaceae family in both patient and 
murine models that have been repeatedly linked to host lipid and cholesterol 
phenotypes in different species (humans, mice, and hamsters) and positively 
associates with changes in liver fat in humans (Martinez et al. 2013). Use of plant 
sterol esters (PSE) to reduce cholesterol in hamsters likewise reduced 
Erysipelotrichaceae abundance (Martinez et al. 2013). Ruminococcaceae UCG-008, 
Clostridium sensu stricto 1 and Romboutsia, which were also enriched in lean 
NAFLD are reported to be strongly correlate with hepatic triglycerides (L. Zhao et 
al. 2018). 
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At a genetic level, we demonstrated that while there was no significant difference in 
the proportions of patients with PNPLA3 rs738409 GG genotype, a significantly 
greater proportion of patients with lean NAFLD carried the TM6SF2 rs58542926 (T) 
allele than non-lean NAFLD patients. Interestingly, TM6SF2 is implicated in 
cholestrol synthesis (Fan et al. 2016) and TM6SF2, but not PNPLA3 genotypes 
correlate with endotoxemia (Pang et al. 2017). Hence, the lean NAFLD phenotype 
might be consistent with “obesity-resistance”, where individuals are still prone to 
develop steatosis in response to an obesogenic environment (and perhaps a diet 
enriched in cholesterol), likely by genetic and gut-driven mechanisms. 
 
We observed that differences between lean and non-lean patients were more 
profound in those with early stages of liver fibrosis. This suggests that with disease 
progression, homeostatic responses might possibly no longer be able to limit 
inflammation and fibrosis, leading ultimately to long-term adverse outcomes, 
despite a favourable baseline metabolic and histological profile (A. C. Dela Cruz et 
al. 2014; Hagstrom et al. 2018). This hypothesis is supported by the higher serum 
bile acid levels and lower FGF19 levels in patients with significant fibrosis. 
Longitudinal studies would be needed to confirm the findings. 
 
The strengths of our report include the study of a large, well-defined, biopsy-proven 
Caucasian cohort, and as detailed an investigation as is possible, from cross-
sectional data. However, our study also has limitations. First, patients were seen in 
tertiary referral centres, and may suffer from selection bias. In addition, dietary 
histories were not available given the accumulation of cohorts over several years, 
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while the cross-sectional design did not allow for interventions or longitudinal 
outcomes and thus, a causal relationship cannot be demonstrated. Lastly, our study 
is limited by the small sample size with regards to microbiome analysis. It would 
also be interesting in future studies to measure differences in faecal bile acids. 
 
4.5 CONCLUSION 
 
In conclusion, in contrast to non-lean NAFLD, lean patients are likely to have a 
distinct pathophysiology. We suggest that the onset of disease occurs at a lower 
BMI set point (with lower measures of insulin resistance and dyslipidaemia) and is 
shaped by the genetics background and early alterations in bile acid and gut 
microbiota profile. These changes might reflect altered dietary composition (perhaps 
with an excess of dietary cholesterol, as previously reported in patients with lean 
NAFLD (Enjoji et al. 2012; Musso et al. 2003; Yasutake et al. 2009b)), altered 
cholesterol metabolism, limitations in adipocyte numbers in childhood, or 
differences in mucosal immunology. Secondary or concomitant alterations in gut 
microbiota composition also drives the phenotype to a greater extent than in patients 
with non-lean NAFLD. This hypothesis does not negate the possibility that there are 
overweight/obese NAFLD patients with a similar pattern of compensatory 
mechanisms but suggests that lean patients have a preponderance of a gut-mediated 
phenotype. Further studies are needed to investigate the contribution of early-stage 
adaptive mechanisms on the long-term hepatic and extrahepatic outcomes of this 
disease. Our hypothesis would suggest that these individuals will have more severe 
and progressive liver disease as it has been suggested before (A. C. Dela Cruz et al. 
2014; Hagstrom et al. 2018), but this hypothesis needs further confirmation.  
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5  CHARACTERISATION OF METABOLIC ADAPTATION IN MICE 
MODELS OF LEAN AND NON-LEAN NAFLD  
 
5.1 INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is a heterogeneous disease with a spectrum 
ranging from simple steatosis to the more severe form, non-alcoholic steatohepatitis 
(NASH) with its associated morbidity and mortality. Various modifiable factors such 
as diet, microbiota and lifestyle, as well as non-modifiable factors such as genetics and 
epigenetics influence NAFLD pathogenesis.  
 
Given the complexity of NAFLD pathogenesis, animal models have become an 
integral part of elucidating the pathophysiology and the effects of treatment for 
NAFLD. Generally, the C57BL/6 strain in mice and Wistar and Sprague Dawley rat 
strains are preferred for NAFLD models due to the intrinsic predilection to develop 
obesity, type 2 diabetes mellitus and NAFLD (Van Herck et al. 2017).  
 
NAFLD and its metabolic syndrome components can be induced in animal models 
using nutritional, chemical or genetic models, or a combination of these. The ideal 
animal model of NAFLD should reflect the pathophysiology of human 
NAFLD/NASH with the hepatic as well as metabolic manifestations. Although many 
of the genetic models of NASH induce steatohepatitis, they do not occur very quickly 
as in the dietary models, in addition to them being more costly. Furthermore, many 
genetic models of NASH require a secondary stimulus such as dietary or endotoxin to 
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promote progression from steatosis to steatohepatitis. Lastly, the implicated mutations 
used in the genetic models of NASH are often not prevalent in human patients, making 
the models less applicable (Jacobs et al. 2016). Chemically induced animal models 
like the genetic models also often require a combination of dietary interventions to 
achieve the desired outcomes. Hence these models are more useful for investigation of 
a more advanced NAFLD phenotype such as advanced fibrosis, cirrhosis and HCC 
(Jacobs et al. 2016). Therefore, dietary animal models of NAFLD are more commonly 
utilised. 
 
One of the diets commonly used in NAFLD animal models is the atherogenic (Ath) 
diet. This diet contains a relatively high dose of cholesterol and cholic acid. The 
atherogenic diet induces steatosis and inflammation typically after 6 weeks, with 
hepatocellular ballooning and fibrosis. In addition, these animals display increased 
levels of ALT and total cholesterol, with minimal weight gain. The addition of a high-
fat component to the Ath diet can increase hepatic insulin resistance and further 
accelerate disease progression (Van Herck et al. 2017). 
 
The excessive intake of fructose, a monosaccharide primarily metabolized in the liver 
has been associated with the development and progression of NAFLD by promoting 
fat deposition, inflammation, oxidative stress, insulin resistance and fibrosis 
(Stephenson et al. 2018). Fructose-supplemented drinking water in both rats and mice 
induces simple steatosis after 8 weeks with significant increases in body weight, 
plasma triglycerides and glucose levels. In addition, there is intestinal bacterial 
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overgrowth observed, followed by increased endotoxin levels in the portal blood and 
activation of Kupffer cells (Van Herck et al. 2017). 
 
In our study, we were interested to see if the findings found in lean and non-lean 
NAFLD patients could be replicated in mice models. For this, we used C57BL/6 mice 
fed either an atherogenic (Ath) diet to replicate lean NAFLD given its ability to induce 
steatosis and inflammation without inducing weight gain, or a high sucrose (HS) diet 
to replicate our non-lean NAFLD models given its ability to promote NAFLD 
development and progression with insulin resistance and the associated significant 
weight gain. 
 
5.2 METHODS 
 
Five to six male C57BL/6 mice were fed either a high sucrose diet (HS) diet or 
cholesterol rich diet (ChR) to recapitulate human non-lean and lean NAFLD features, 
respectively. Details of the source of mice, dietary composition for the two groups as 
well as methods for RNA extraction from mice tissues, cDNA synthesis and qPCR are 
described in chapter 2. Bile acid profile measurement, serum fgf15 level and gut 
microbiota profile methods are  described in chapter 2. 
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5.3 RESULTS 5.3.1 High sucrose, but not the cholesterol rich diet results in 
weight gain and increased steatosis 
 
Mice fed the high sucrose (HS) diet gained an average 30-40% of weight compared to 
their baseline weight. This is in contrast to mice fed the ChR diet where they remained 
lean (Figure 27A and B) 
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Figure 27. Body weight and liver/body weight ratio in mice fed 
cholesterol rich (ChR) and high sucrose (HS) diet 
A. Changes in body weight over time. The x-axis shows the number of weeks and the 
y-axis shows the % change in body weight from baseline. B. Liver/body weight ratio in 
ChR diet mice and HS diet mice. The x-axis shows the ChR and HS fed mice and the y-
axis shows the ratio of the liver to total body weight. Results are expressed as 
mean ± SEM and P value was calculated using the Mann-Whitney non-parametric t-
test. *P < 0.05, ** P<0.01, *** P<0.001.  
 
 
A.
 
B. 
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Additionally, mice fed the HS diet had higher fasting serum glucose level with worse 
glucose tolerance test compared to mice fed the ChR diet (Figure 28A and B). In both 
groups, a glucose loading dose was administered and blood sugar level was measured 
every 20 minutes. There was a peak of blood glucose concentration seen in both 
groups after a glucose loading, followed by more rapid resolution of the glucose peak 
in the ChR mice group, indicating better glucose tolerance. 
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Figure 28. A. Fasting blood glucose levels and B. glucose 
tolerance test between mice fed cholesterol rich (ChR) and high 
sucrose (HS) diet.  
The x-axis shows the ChR (n=5) and HS (n=6) groups in A, and time after blood 
glucose loading in minutes in B and the y-axis shows blood glucose levels in mg/dL. 
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All mice in both groups developed NAFLD at the end of the study. As shown in the 
representative histology images in Figure 29, mice fed the HS diet developed 
increased steatosis; mice fed the ChR diet developed steatosis with increased 
inflammatory infiltrates.  
 
 
Figure 29. Histology images of mice fed cholesterol rich (ChR) 
and high sucrose (HS) diet.  
Hematoxylin and Eosin (H&E) images of liver biopsies taken from ChR (n=5) and HS 
(n=6) mice 
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5.3.2 Lean NAFLD mice models have higher bile acid levels with 
distinct profile 
 
Like our human results, our lean NAFLD mice models had higher total (p = 0.01), 
primary (p = 0.02) and secondary bile acids (p = 0.06) compared to the non-lean 
NAFLD mice models, although this was only significant for total and primary BA 
levels  (Figure 30).  
 
Figure 30. Total bile acids, total primary bile acids and total 
secondary bile acids level in mice fed cholesterol rich (ChR) and 
high sucrose (HS) diet.  
The x-axis shows total BA, total primary BA and total secondary BA in ChR (blue, n=5) 
and HS (red, n=6) diet fed mice. The y-axis shows mean BA concentration in uMol/L. 
Results are expressed as mean ± SEM and P value was calculated using the Mann-
Whitney non-parametric t-test. *P < 0.05, ** P<0.01, *** P<0.001.  
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In terms of BA distribution profile, the primary BAs cholic acid (CA) and its 
conjugate taurocholic acid (TCA), as well as taurodeoxycholic acid (TDCA) were 
present in higher proportion in the ChR group compared to the HS group (Figure 31). 
On the other hand, muricholic acid (MCA), deoxycholic acid (DCA) and lithocholic 
acid (LC) were present in a higher proportion in the HS compared to the ChR group 
(Figure 31). 
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Figure 31. Bile acid distribution between mice fed cholesterol 
rich (ChR) and high sucrose (HS) diet.  
The x-axis shows the cholesterol rich (ChR, n=5) and high sucrose (HS, n=6) fed mice 
groups. The y-axis shows proportion of each BA in %. 
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5.3.3 Lean NAFLD mice model has a distinct gut microbiota 
profile 
 
Analysis of the microbiota demonstrated a distinct and separate microbiota profile 
between lean NAFLD and non-lean NAFLD mice models, with changes in 
composition (PERMANOVA P= 0.009, pseudo-F= 18.58, 126 permutations, Figure 
32A) as reflected broadly by significant changes in the relative abundances of the two 
major phyla, Firmicutes and Bacteroidetes, as well as in Actinobacteria, Cyanobacteria 
and Proteobacteria. Mice fed the ChR diet were observed to have an increased relative 
abundance of Bacteroidetes and a decrease in Firmicutes compared to those fed high 
sucrose (Figure 32B). As we observed in humans, similar trends were noted for the 
abundance of members of the Ruminococcaceae bacterial family in the high 
cholesterol diet fed (lean NAFLD) mice. These changes were also observed for 
several phylotypes within the Erysipelotrichaceae (Figures 32C and D). 
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Figure 32. Gut microbiota profile in mice fed cholesterol rich 
(ChR) diet and mice fed high sucrose (HS) diet.  
A. Microbiota composition between the two groups showing distinct separation of 
profiles. B. Comparison of the abundance of the phyla Firmicutes and Bacteroidetes 
between the two groups. C. Microbiota abundance differences between the two 
groups. The colour denoting each taxa represents the group in which the taxa was 
identified to be significantly increased compared to the comparison group (p < 0.05). 
D. Microbiota composition between the two groups. Each colour denotes each taxa 
and the y-axis represents the % abundance. 
 
C. 
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5.3.4 The increased bile acids in lean NAFLD mice model is due 
to increased bile acid synthesis 
 
To investigate if the increased levels of BA seen in the lean NAFLD mice model is 
due to increased BA production or increased BA reuptake from the enterohepatic 
circulation, we performed qPCR on mice liver and ileal tissues to quantify the mRNA 
levels of several BA synthetic enzymes as well as BA transporters.  
 
Our results showed that in the lean NAFLD model, BA synthetic enzyme mRNAs in 
the liver were significantly higher compared to those in the non-lean NAFLD mice 
model. This was true for both the BA synthetic enzymes involved in the classical 
pathway (p = 0.0016 for CYP7A1 (Figure 33A and C) and p = 0.001 for CYP8B1) as 
well as alternative pathway (p = 0.0031 for CYP27A1) (Figure 33B).  
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Figure 33. Liver bile acid synthetic enzyme mRNA levels in mice 
fed a cholesterol rich (ChR) or a high sucrose (HS) diets.  
A. Cytochrome P450 7A1 (CYP7A1, classical pathway). B. Cytochrome P450 27A1 
(CYP27A1, alternative pathway) and C. Cytochrome P450 8B1 (CYP8B1, classical 
pathway). The x-axis shows the two groups, cholesterol rich (ChR, n=5) versus high 
sucrose (HS, n=6) fed mice. The y-axis shows mRNA levels in folds, using 36B4 as 
housekeeping gene. Results are expressed as mean ± SEM and P value was calculated 
using the Mann-Whitney non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
 
 
C. 
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When we compared the BA transporter mRNA levels between lean and non-lean 
NAFLD models, although it appeared that there was increased expression of BA 
transporters OST beta and ASBT in the ileum of lean NAFLD models, this was not 
significant (p = 0.1049 for OST beta and p = 0.3450 for ASBT) (Figure 34A and B). 
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Figure 34. Ileal bile acid transporters organic solute transporter 
beta (OST beta) and apical sodium bile acid transporter (ASBT) 
in mice fed a cholesterol rich (ChR) or a high sucrose (HS) diet 
A. OST beta bile acid transporter and B. ASBT bile acid transporter. The x-axis shows 
the two groups, cholesterol rich (ChR, n=5) versus high sucrose (HS, n=6) fed mice. 
The y-axis showed mRNA levels in folds, using 36B4 as housekeeping gene. Results 
are expressed as mean ± SEM and P value was calculated using the Mann-Whitney 
non-parametric t-test. P < 0.05, ** P<0.01, *** P<0.001. 
A. 
B. 
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5.3.5 Lean NAFLD mice model have elevated FXR activity  
 
Analysis of ileal fibroblast growth factor 15 (fgf15), the mouse equivalent of human 
FGF-19 showed significantly higher levels in our lean NAFLD, compared to the 
non-lean NAFLD mice (Figure 35A).  The increased fgf15 levels activates the FGF 
receptor in the liver to stimulate hepatic FXR activity (Figure 35B). 
 
 
 
Figure 35. Serum fgf15 levels (A) and FXR mRNA levels (B) in 
mice fed a cholesterol rich (ChR) or a high sucrose (HS) diet.  
The x-axis shows the cholesterol rich (ChR, blue, n=5) and high sucrose (HS, red, n=6) 
diet fed mice. The y-axis showed the mean serum fgf15 levels in pg/ml in A, and 
mRNA levels in folds in B, using 36B4 as housekeeping gene. Results are expressed as 
mean ± SEM and P value was calculated using the Mann-Whitney non-parametric t-
test. P < 0.05, ** P<0.01, *** P<0.001. 
A. 
B. 
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5.4 DISCUSSION  
 
We used mice fed a cholesterol rich diet (ChR) to replicate human lean NAFLD and 
mice fed a high sucrose (HS) diet to replicate non-lean NAFLD patients. Mice fed the 
ChR diet like in human lean NAFLD maintained their weight throughout the period, as 
opposed to mice fed a HS diet. The latter gained significant amounts of weight during 
the experiment. Furthermore, mice in the ChR diet group had significantly better 
fasting glucose levels as well as a better response to the glucose tolerance test 
suggesting better insulin sensitivity. Histologically, both mice groups developed 
steatosis, however, the lean NAFLD mice demonstrated increased inflammatory 
infiltrates.  
 
Like in human NAFLD, the gut microbiota profile in the mice models showed similar 
patterns between the groups. There was increased Bacteroidetes and decreased 
Firmicutes in the lean NAFLD compared to the non-lean NAFLD mice. Previous 
studies have demonstrated possible roles of certain families of microbiota including in 
Bacteroidaceae and Erysipelotrichaceae with BA metabolism. Increased BA levels are 
associated with increased levels of these families (Zietak 2016). This may explain our 
finding of increased BA production through up-regulation of BA synthetic enzyme 
mRNA. Furthermore, certain taxa belonging to the family Erysipelotrichaceae and 
Coriobacteriaceae have been shown to be decreased in non-obese humans or those 
who have lost weight after gastric bypass compared to obese humans (Zhang et al. 
2009). This is similar to our mice where the levels of the taxa belonging to 
Erysipelotrichaceae was lower in the lean compared to the non-lean NAFLD mice.  
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We were able to demonstrate increased levels of bile acids in lean NAFLD mice which 
is similar to what was seen in human NAFLD patients. Further testing also suggested 
that the increased level of bile acid is due to increased bile acid production, as 
evidenced by the up regulation of BA synthetic enzymes involved in both the classical 
and alternative pathways.  
 
The increased levels of ileal bile acid transporter mRNAs for ASBT and OSTβ (which 
accounts for more than 95% of intestinal BA reabsorption from the distal ileum 
enterocytes (Chavez-Talavera et al. 2017)), despite not being significant, may reflect 
the better metabolic adaptation seen in lean NAFLD mice, as in our human lean 
patients. Bile acids stimulate secretion of several hormones including fgf15 (mouse 
equivalent of human FGF-19) from the enteroendocrine cells which has positive 
metabolic effects, including improved glucose tolerance. In addition, fgf15 is involved 
in metabolic adaptation through mediating bile acid synthesis in the liver, acting via 
the FXR pathway.  
 
Despite the many similarities and benefits of using mice models to study human 
disease in terms of their homogeneity and more standardized nutritional manipulation,  
there are also differences between mice and humans. Thus , results from mice models 
must be interpreted with caution. Mice for example have distinct bile acid homeostasis 
compared to humans. Whereas in humans the primary bile acid pool is made up of 
cholic acid (CA) and chenodeoxycholic acid (CDCA) and their conjugates, in mice the 
majority of the primary BA pool is comprised of T-βmuricholic acid (T-βMCA) and 
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T-αmuricholic acid (T-αMCA) which are formed through hydroxylation of CDCA and 
UDCA respectively, via the enzyme CYP2c70 (McGlone et al. 2019). This difference 
in BA pool composition also affects the physiology seen in the two species, as MCA 
are FXR antagonists, whereas CDCA is a potent FXR agonist (McGlone et al. 2019). 
In addition, there are also differences in the homeostasis of BA in humans and mice. 
In mice, bile acids are almost exclusively conjugated with taurine which has greater 
solubility, whereas in humans, the majority of bile acids are conjugated with glycine, 
with only a small proportion being conjugated to taurine (McGlone et al. 2019). 
 
5.5 CONCLUSION 
 
Lean NAFLD is a unique sub-group of NAFLD with unclear pathophysiology. In this 
study we demonstrated using mice models fed a cholesterol rich or a high sucrose diet, 
certain similarities to human NAFLD patients, namely in their histological and 
metabolic profile, as well as in bile acid homeostasis. We also demonstrated a distinct 
and improved metabolic adaptation in the lean mice similar to human patients with 
respect to increased FXR activity. Although the results suggests the potential to 
undertake interventional experiments on NAFLD pathophysiology, including lean 
NAFLD, mice models have key differences with respect to their bile acid physiology 
and results must therefore be interpreted with caution. 
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6 METABOLOMIC ANALYSIS OF LEAN NAFLD COMPARED TO 
NON-LEAN NAFLD AND LEAN HEALTHY CONTROLS 
 
6.1 INTRODUCTION 
 
The search for non-invasive biomarkers for the diagnosis and staging of NAFLD is an 
unmet need. Liver biopsy remains the gold standard for diagnosing and staging 
NAFLD, but it is invasive and subject to sampling error and inter-observer variability 
(Brunt et al. 2011). Although multiple non-invasive methods have been studied for use 
in quantification of hepatic steatosis and fibrosis including magnetic resonance 
imaging proton density fat fraction (MRI-PDFF) and magnetic resonance elastography 
(MRE), these modalities lack the ability to quantify hepatic inflammation, ballooning 
and injury, all essential for the diagnosis of NASH (Mayo et al. 2018).   
 
Current therapeutic options for NAFLD and NASH are limited to lifestyle intervention 
but the optimal dietary nutrient composition and exercise requirement are still 
debatable to achieve the greatest histologic benefit. Although several drugs have been 
considered useful for use in NAFLD, their benefit and long-term efficacy as well as 
safety are uncertain. Hence, metabolomics might provide an interesting tool to achieve 
early and better diagnosis, understand disease pathogenesis and suggest targets for 
development of new treatments (Gitto et al. 2018). 
 
Previous studies on metabolomic profiling in patients with NAFLD and NASH have 
shown modifications in the metabolites including lipids, amino acids, glucose and bile 
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acid pathways. The results however remain conflicting due to the vast range of sample 
sizes, differences in populations as well as methods of metabolomic profiling (Gitto et 
al. 2018).  
 
We identified the bile acid pathway to be significantly altered between different stages 
of NAFLD as well as between lean and non-lean NAFLD. Hence, in this chapter we 
aim to further explore this from a metabolomics perspective to determine if other 
metabolic pathways are different between the lean and non-lean NAFLD groups. 
 
6.2 METHODS 
 
We selected a sub-group of patients from our large cohort for metabolomics analysis 
keeping the ratio between the lean and non-lean NAFLD groups similar to that of our 
previous comparisons. A total of 181 patients were analysed (19 lean and 162 non-lean 
NAFLD). We performed untargeted metabolomics analysis using two different 
platforms, the AMIDE (negative ion mode) and the HILIC (positive ion mode) 
methods, which look into different metabolic pathways as described below. 
 6.2.1 AMIDE METHOD 
 
The AMIDE method measures polar compounds by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) using electrospray ionization (ESI) in the negative 
ion mode.  Positive mode can also be used. Analytes include amino acids, 
nucleotides, nucleosides, nucleotide triphosphates, high-energy intermediates, organic 
acids, TCA cycle intermediates, bile acids and vitamins. 
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Briefly, 80μL of amide IS-IS is added to 20μL of each serum sample and the mixture 
vortexed to promote protein precipitation. The sample mixtures are centrifuged at 
14000rpm for 20 minutes at 4oC. After that, 75μL of the supernatant is transferred 
into glass vials with inserts, taking care to avoid transferring protein pellet particles. 
The vial is capped and stored at -30oC until time of analysis. Further details on 
reagent preparation, mass spectrometer settings and list of metabolites are in the 
Appendix section. 
 6.2.2 HILIC METHOD 
 
The HILIC method measures polar compounds by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) using electrospray ionization (ESI) in the positive ion 
mode. Analytes include amino acids, nucleotides, neurotransmitters and selected 
medications and vitamins. 
 
Briefly, to 10μL of serum, 90 μL of HILIC IS-IS is added and the mixture vortexed to 
promote protein precipitation. The sample mixtures are then centrifuged at 14000 rpm 
for 20 minutes at 4oC. After that, 75μL of supernatant is transferred into glass vials 
with inserts, taking care to avoid transferring protein pellet particles. The vial is 
capped tightly and stored at -30oC until time of analysis. Further details on reagent 
preparation, mass spectrometer settings and list of metabolites are in the Appendix 
section. 
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6.2.3 STATISTICAL ANALYSIS 
 
Ions from both ESI- and ESI+ are merged and imported into the SIMCA-P program 
(version 14.1) for multivariate analysis. A principal components analysis (PCA) is first 
used as an unsupervised method for data visualization and outlier identification. 
Supervised regression modelling is then performed on the data set by use of partial 
least squares discriminant analysis (PLS-DA) or orthogonal partial least squares 
discriminant analysis (OPLS-DA) to identify the potential biomarkers. The biomarkers 
are filtered and confirmed by combining the results of the VIP values (VIP > 1.5) and 
t-test (p < 0.05). The quality of the fitting model can be explained by R2 and Q2 values. 
R2 displays the variance explained in the model and indicates the quality of the fit. Q2 
displays the variance in the data indicating the model’s predictability. Figure 36 
shows a flowchart of how metabolomics analysis was performed. 
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Figure 36. Flowchart of metabolomics analysis from sample 
preparation to identification 
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6.3 RESULTS 
 6.3.1 Patient demographics 
 
We analysed a total of 181 well-characterised, biopsied NAFLD patients (19 lean and 
162 non-lean). The baseline patient demographics are shown in Table 9. 
 
Patients in both lean and non-lean NAFLD groups were selected to match in terms of 
their age and gender. Apart from patients in the non-lean NAFLD patients having 
significantly more diabetes, there was no significant difference in the total cholesterol 
level as well as their histological profile between the two groups. 
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Table 9. Baseline characteristics of lean and non-lean NAFLD 
patients for metabolomics analysis 
  Lean NAFLD (n = 19) Non-lean NAFLD (n = 162) p-value 
Age (years) 50 ± 8.01 51 ± 13.6 0.7541 
Male (%) 10 (52.6) 81 (50) 1.000 
BMI (kg/m2) 23.0 ± 1.3 32.4 ± 5.8 <0.001 
ALT (IU/ml) 65.2 ± 36.0 74.0 ± 52.8 0.4808 
Diabetes (%) 2 (10.5) 39 (24.1) <0.001 
Hypertension (%) 7 (36.8) 58 (35.8) 1.000 
Dyslipidaemia (%) 9 (47.4) 90 (55.6) 0.6274 
Total Cholesterol (mmol/L) 5.3 ± 1.2 5.1 ± 1.2 0.4928 
Fibrosis (%) 
   F 0-1 (%) 
   F 2-4 (%) 
14 (73.7) 
5 (26.3) 
100 (61.7) 
62 (38.3) 0.4519  
Ballooning (%) 
   No ballooning (%) 
   Any ballooning (%) 
14 (73.7) 
5 (26.3) 
105 (64.8) 
57 (35.2) 0.6105  
Steatosis (%)** 
   Grade 1-2 (%) 
   Grade 3 (%) 
15 (78.9) 
4 (11.1) 
133 (82.1) 
29 (17.9) 0.7548  
Portal inflammation  
   No inflammation (%) 
   Inflammation (%) 
10 (52.6) 
9 (47.4) 
78 (48.1) 
84 (51.9) 0.8181  
Lobular inflammation  
   No inflammation (%) 
   Inflammation (%) 
8 (42.1) 
11 (57.9) 
77 (47.5) 
 85 (52.5) 0.8089  
NAS score  2 ± 2 3 ± 2 0.0407 
 
Values are mean±SD, or number (%), p-value was calculated using Fisher’s exact test and 
student’s t-test.  
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6.3.2 Principal component analysis demonstrates unclear 
groupings between the two groups 
 
After normalization is carried out, a line plot was used and all the peaks are merged 
and imported into the SIMCA-P software for multivariate statistical analysis. As 
shown in Figure 37, the line plot demonstrated relative system instability during 
sample analysis 
 
Figure 37. The line plot of samples 
Line plot of samples to evaluate the methodology. The x-axis indicates the number of 
samples and the y-axis indicates the 95% confidence interval. 
 
To investigate global metabolism variations, we first use PCA to analyse all 
observations acquired in both ion modes. PCA is a technique used to emphasize 
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variation and bring out strong patterns in a dataset. It is often used to make data easy 
to explore and visualize. It also acts as an unsupervised pattern recognition method for 
handling metabolomics data and can classify the metabolic phenotypes based on all 
imported samples. Due to the unsupervised pattern, the result can be unsatisfactory 
sometimes. As shown in the PCA plot (Figure 38), an overview of all samples in the 
data can be observed and exhibit an unclear grouping trend between the two groups. 
 
Figure 38. The scores scatter plot of the PCA model. 
The x-axis represents the first component and the y-axis represents the second 
component. The two groups are denoted as 1 (lean NAFLD) and 2 (non-lean NAFLD). 
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6.3.3 Metabolic changes in the two groups 
 
In order to eliminate any non-specific effects of the operative technique and confirm 
the biomarkers, partial least square discriminant analysis (PLS-DA) and orthogonal 
partial least square discriminant analysis (OPLS-DA) was performed to compare 
metabolic changes in the two groups, respectively. 
In PLS-DA score plot, as well as the OPLS-DA score plot, an unclear separation of the 
two groups is observed (Figures 39 and 40). 
 
Figure 39. The scores scatter plot of partial least squares 
discriminant analysis (PLS-DA) model between lean and non-
lean NAFLD. 
The groups are marked as 1 (lean NAFLD) and 2 (non-lean NAFLD) 
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Figure 40. The scores scatter plot of the orthogonal partial least 
squares discriminant analysis (OPLS-DA) model between lean 
and non-lean NAFLD 
The groups are marked as 1 (lean NAFLD) and 2 (non-lean NAFLD). 
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Interestingly, while there was no clear separation between the two groups when 
analysed based on lean and non-lean NAFLD groups overall, there was distinct 
separation in the OPLS-DA model between the extremes of lean NAFLD patients with 
advanced fibrosis and non-lean NAFLD patients with none/mild fibrosis (Figure 41).  
This could reflect differences in metabolism between advanced and none/mild fibrosis. 
 
Figure 41. Scores scatter plot of the orthogonal partial least 
squares discriminant analysis (OPLS-DA) between lean NAFLD 
with advanced fibrosis and non-lean NAFLD with none/mild 
fibrosis 
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6.3.4 Single variable analysis based on significant variable 
importance of projection (VIP) values 
 
Significantly changed metabolites between the groups were filtered out based on the 
variable importance of projection (VIP) values. Significant VIP values are considered 
to be VIP > 1.5. The PLS-DA loading plot is shown in Figure 42 with metabolites in 
red labelled as significant compounds (VIP > 1.5).  
 
Figure 42. The loading plot of the PLS-DA model, with 
metabolites in red labelled as significant compounds (VIP>1.5).  
Var_60 is Cystamine and Var_19 is Pyruvate.  
 
 
 
Univariate analysis was then performed on a volcano plot, shown in Figure 43, 
including fold change analysis and t-test. As shown, the result from the univariate 
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analysis did not show any significance, likely due to the small number of samples and 
the instability of sample analysis. 
 
Figure 43. Volcano plot of data. 
Univariate analysis of metabolites with values of Y > 1.30 and X > 1 considered to be a 
significant increase; values of Y > 1.30 and X < 1 considered to be a significant 
decrease. 
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6.3.5 Identification of potential biomarkers 
 
The chemical structures of important metabolites were then identified according to 
online databases such as the Human Metabolome Database (www.hmdb.ca), Metlin 
(www.metlin.scripps.edu) and massbank (www.massbank.jp) using the data of 
accurate masses and MS/MS fragments. When necessary, further confirmation was 
acquired through comparisons with authentic standards including retention times and 
MS/MS fragmentation patterns.  
 
6.3.6 Cluster analysis  
 
Mean values of metabolite contents are used to calculate the metabolite ratio. After log 
transformation of the data, median centred ratios are then normalized. Hierarchical 
clustering analysis (HCA) is performed using the complete linkage algorithm of the 
program Cluster 3.0 (Stanford University) and the results are visualized using 
Treeview (Stanford University). Metabolite ratios from two independent experiments 
of every significant metabolite are used for the HCA. Colour intensity correlates with 
degree of increase (red) and decrease (blue) relative to the mean metabolite ratio. The 
HCA of metabolomics data from the lean and non-lean NAFLD groups is shown in 
Figure 44. 
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Figure 44. Hierarchical cluster analysis of metabolomics data 
from significant metabolites 
Hierarchical cluster analysis (HCA) from metabolite ratios of every significant 
metabolite. Red denotes degree of increase and blue denotes degree of decrease 
relative to the mean metabolite ratio. 
 
After performing the HCA, the top 3 metabolites with the most significant fold change 
were identified. Table 10 shows the fold change for the top 3 metabolites and the t-test 
analysis between the two groups. 
 
Table 10. T-test analysis of the top 3 metabolites  
Metabolite  Mean metabolite ratio Fold change (FC) Log2FC p-value 
ATP 11.6739 0.655834 -0.6086 0.011797 
Fructose-6-phosphate 1.013142 0.795882 -0.32943 0.01206 
Cysteine 1.331316 0.944543 -0.08231 0.009122 
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6.3.7. Correlation network of metabolites 
 
To investigate the latent relationships of the metabolites, a correlation network 
diagram was constructed based on the KEGG databases and MBRole. All significant 
metabolites are imported to obtain the categorical annotations, including pathways, 
enzyme interactions and other biological annotations, using the limiting condition of p 
< 0.05 in the MBRole.  
A metabolic pathway map is then constructed based on relevant literature and the 
KEGG database. The correlation map is shown in Figure 45. 
 
 
Figure 45. Metabolic network of the significantly changed 
metabolites.  
Red represents increase and green represents decrease. 
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6.4 DISCUSSION 
 
In this chapter, we performed non-targeted metabolomics analysis comparing 
metabolites in lean and non-lean NAFLD patients. As previously outlined by us and 
other studies, lean NAFLD represents a distinct subgroup characterised by better 
metabolic adaptation mediated by the interplay of gut microbiota, bile acid 
metabolism, genetic background and lifestyle factors. We aimed to perform untargeted 
metabolomics analysis to determine if we were able to find signature metabolites 
which are characteristic of lean NAFLD. The metabolomics analysis demonstrated a 
few salient findings.  
 
Firstly, one of the top 3 metabolites that were identified to be different between the 
two groups was fructose-6-phosphate. Fructose-6-phosphate is a metabolite from 
glucose and fructose metabolism which has been implicated in human and animal 
studies to be involved in the pathogenesis of NAFLD and NASH through promotion 
of fat accumulation in the liver due to both increased lipogenesis and decreased fat 
oxidation (Jensen et al. 2018). This is partly mediated through the metabolism of 
fructose by fructokinase C with associated ATP consumption, which results in 
nucleotide turnover and uric acid generation. This promotes fat accumulation (Jensen 
et al. 2018). Interestingly, ATP was also identified as one of the significantly different 
metabolites between lean and non-lean NAFLD groups, further supporting this 
hypothesis. 
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Cysteine, a trans-sulphuration product from a sulphur containing amino acid 
homocysteine, was also identified to be significantly different between lean and non-
lean NAFLD patients. Disturbances in the metabolism of homocysteine and cysteine 
has been implicated in a number of conditions such as cardiovascular disease and 
type-2- diabetes, as well as in obese NAFLD through promotion of hepatic oxidative 
stress (Francque et al. 2016; Kalhan et al. 2011). Furthermore, a study on 
metabolomics profile in paediatric patients with NAFLD also found a positive 
correlation between plasma cysteine level and presence of hepatic fibrosis suggesting 
its potential role in disease progression (Pastore et al. 2014) 
 
The significantly altered ABC (ATP-binding cassette) transporters pathway between 
lean and non-lean NAFLD is also interesting. ABC transporters are a group of 
membrane transporters, which consist of a wide variety of proteins that hydrolyze 
ATP to actively transport xenobiotics, endobiotics and their conjugates across cellular 
membranes. These efflux transporters reside on the sinusoidal and canalicular 
membranes of hepatocytes and transport substrates into the blood and bile, 
respectively (Hardwick et al. 2011). Disruptions of these transporter functions have 
been implicated in multiple diseases including NAFLD. In one study of ABC 
transporter functions during progression of NAFLD to NASH, increased expression of 
multiple efflux transporters and altered cellular localization of ABC transporters, 
especially ABCC2 was found in NASH (Hardwick et al. 2011). 
 
Bile acid metabolism although not considered to be the top significantly altered 
pathway in our study remained significantly different between lean and non-lean 
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NAFLD groups (p = 0.0101). This is consistent with results from our previous 
chapters as well as multiple other studies in NAFLD. 
 
Metabolomic profiling between lean and non-lean NAFLD has previously been 
undertaken. In one study, the serum metabolome of 187 subjects from lean healthy, 
lean NAFLD and obese NAFLD was compared; this showed differences in 
phosphatidylcholine and lysine, and branched chain amino acids lysine, tyrosine and 
valine to be significantly different on multiple logistic regression analysis (Feldman et 
al. 2017b). Unfortunately, due to the instability of the sample analysis (owing to 
technical reasons which resulted in the run being interrupted several times) as well as 
the underpowered sample size, most of the results were insignificant. However, when 
samples were analysed based on the extremes of BMI in the two groups, the scatter 
plot demonstrated a much clearer separation between two groups, although this could 
be due to differences in metabolism between patients with advanced versus mild 
fibrosis and not necessarily BMI driven. Unfortunately, there were only a small 
number of patients with advanced fibrosis in the lean group making this analysis 
limited.  
 
Future directions would involve increasing the number of samples, especially those at 
extremes of BMI and fibrosis to hopefully distinguish the two groups better and 
potentially identify metabolites which are able to be used as potential biomarkers for 
diagnosis or prognostication purposes in patients with lean NAFLD.  
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6.5 CONCLUSION 
 
In conclusion, metabolomics analysis remains a useful tool for identification of 
biomarkers for many diseases including lean NAFLD. Our analysis, although mostly 
insignificant, suggested a few differences in metabolism between lean and non-lean 
patients, especially for those involved in fructose/glucose metabolism as well as in 
active transporters. Further studies are required to better characterise this important 
subgroup of NAFLD. 
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7 SUMMARY AND CONCLUSIONS 
 
7.1 SUMMARY OF FINDINGS 
 
This series of chapters are part of a project to investigate the underlying pathogenesis 
of lean NAFLD, a subgroup which is under-recognized with unclear mechanisms.  
 
We have introduced the concept of metabolic health and how it governs an 
individual’s risk for development of metabolic disease, including NAFLD. This is 
mediated through the regulation of adiposity, insulin resistance, inflammation and bile 
acid metabolism. In the first result chapter we investigated the role of metabolic health 
in bile acid metabolism in lean NAFLD compared to lean and non-lean healthy 
controls. We found that metabolic health status played a greater role in determining 
their bile acid levels. Subsequently, we investigated the difference in bile acid 
metabolism and regulatory pathways between lean NAFLD and lean healthy controls 
in more detail and found that in addition to lean patients demonstrating higher levels 
of bile acids, they also had a distinct gut microbiota profile. Taken together, this 
appears to have increased their inflammatory profile as shown by the trend to an 
increase in inflammatory cytokines compared to their lean healthy counterparts. 
 
In the next chapter we compared the characteristics of lean NAFLD patients with 
those who were non-lean. We discovered that bile acid levels tended to increase as 
fibrosis degree increased. Interestingly, the bile acid levels, especially secondary bile 
acid levels, were significantly higher in lean NAFLD patients compared to their non-
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lean counterparts. Lean patients also demonstrated a higher proportion of TM6SF2 risk 
allele carriage compared to the non-lean NAFLD patients, as well as a distinct 
microbiota profile. The enriched species have been described to be involved in bile 
acid synthesis and hepatic steatosis formation. However, on further investigation we 
discovered that although the bile acid levels were higher in lean NAFLD, these 
patients tended to have milder histology and fibrosis at baseline. This suggests a 
compensatory mechanism to counteract the increased bile acid levels. We looked into 
the bile acid regulatory mechanisms and discovered that there is increased level of 
FXR activity (measured through serum FGF-19 levels) in the lean NAFLD patients, 
especially in the early stages of the disease. This increase in FXR activity may act as a 
compensatory metabolic adaptation mechanism by decreasing bile acid formation (as 
shown by the reduced level of serum C4) as well as non-bile acid mediated pathway 
through its action on glucose and insulin sensitivity and reduction in liver fibrosis 
(Pathak et al. 2018; Schumacher et al. 2020). At least in the early stages of the disease 
this may explain the milder histology. The increased bile acid levels along with 
increased FXR activity and altered gut microbiota profile may also support the 
metabolic adaptation capacity that lean NAFLD patients possess in order to rid 
themselves of excess cholesterol and remain obesity-resistant. However, this 
adaptation capacity tends to be lost with disease progression as shown by the marked 
decrease in FXR activity, increased serum C4 levels and subsequently increased bile 
acid levels, resulting in rapid progression of liver disease. The proposed hypothesis is 
summarised in Figure 46. 
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Figure 46. Proposed model for the differential pathophysiology 
between lean and obese patients with NAFLD.  
Lean patients have better metabolic and liver histology profiles. Consistent with the 
notion that lean patients have appropriate metabolic adaptation to an obesogenic 
environment, they are obesity resistant. The compensatory mechanisms include 
increases in bile acids and FXR activity and distinct gut microbiota profiles despite 
steatosis development. Similar features were observed in murine models of lean and 
obese NAFLD. We suggest that the relative contribution of the systemic milieu versus 
that of the gut governs the lean versus non-lean phenotype. 
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Having demonstrated the metabolic adaptive capacity of lean NAFLD in humans, we 
proceeded to replicate the findings using mice models. Using mice fed a cholesterol 
rich diet to simulate lean NAFLD and mice fed a high sucrose diet to simulate non-
lean NAFLD, their bile acid profile, gut microbiota and bile acid regulatory 
components were investigated. We found that like in humans, lean NAFLD mice had 
significantly higher serum bile acid levels. In addition, further interrogation uncovered 
increased bile acid production and increased bile acid reabsorption through the ileum 
as possible underlying reasons for the increased bile acid levels. Interestingly, like in 
human cohorts, lean mice models also demonstrated better metabolic adaptive 
capacity as shown by increased serum fgf15 levels, the orthologue of human FGF-19. 
We also demonstrated a distinct gut microbiota profile further supporting a 
predominant gut-driven pathogenesis for lean NAFLD.  
 
Having explored the difference in the bile acid pathway between lean and non-lean 
NAFLD, we were interested to explore other potential pathways and markers, which 
may be useful for understanding pathogenesis. Although our experiment was 
underpowered with respect to the number of samples and the quality of the analysis, it 
did reveal a couple of salient findings. Firstly, bile acid metabolism remained 
significantly different between lean and non-lean NAFLD confirming our earlier 
findings. Secondly, a number of metabolites, namely fructose-6-phosphate, ATP and 
cysteine, which have been implicated in previous studies were significantly different 
between the two groups. 
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7.2 SIGNIFICANCE OF FINDINGS 
 
Our series of experiments have shown an evolution in our understanding of lean 
NAFLD pathogenesis through the integration of bile acid metabolism, gut microbiota, 
genetic background and lifestyle factors. Studies on lean NAFLD in the literature have 
previously focussed on descriptive reports comparing them to healthy controls or 
obese NAFLD. Hence, this is the first study to examine the pathogenesis of lean 
NAFLD in detail using large, well-characterised samples.  
 
This project is also the first to introduce the concepts of metabolic health and 
metabolic adaptation and describe their roles in the pathogenesis of lean NAFLD 
development and progression. While metabolic health governs an individual’s risk for 
developing metabolic diseases including NAFLD, a person’s metabolic adaptive 
capacity dictates when the person develops the metabolic disease. Given that 
metabolic health and metabolic adaptive capacity have an impact on the risk for and 
progression of NAFLD, BMI itself may be a less robust predictor of NAFLD 
outcomes. Instead, BMI should perhaps be better considered a marker of 
maladaptation.  
 
Moreover, an individual may respond to increased dietary cholesterol or caloric intake 
with appropriate metabolic adaptation to maintain body weight, or they may have 
complete loss of metabolic adaptation resulting in weight gain, increased adiposity and 
hepatic steatosis. In some individuals however, increased caloric intake may only 
result in partial loss of metabolic adaptation where the outcome is lean NAFLD. In 
this scenario, as outlined in Figure 47, increased dietary cholesterol intake in lean 
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NAFLD (as suggested by earlier studies) in the context of perturbed metabolic 
adaptive capacity associates with some metabolic adaptation through increased 
production of bile acids, especially secondary bile acids and increased FXR activity to 
maintain body weight and serum cholesterol levels, as well as maintain favourable 
liver histology (F. Chen et al. 2019; Enjoji et al. 2012; Schumacher et al. 2020). 
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Figure 47. The role of metabolic adaptation in lean NAFLD 
Schematic representation of differences in metabolic adaptation between individuals 
with lean and obese NAFLD. In obese patients there is relatively poor metabolic 
adaptation resulting in adiposity and the development of liver disease. In contrast, 
among lean NAFLD patients there is partial metabolic adaptation at least in the early 
stages of the disease. In the example shown, this is through increased bile acid 
production and FXR activity (other mechanisms may also be operative). This results in 
an “obesity resistant” phenotype” which appears to be lost as the disease progresses. 
Abbreviations: NAFLD – Non-alcoholic fatty liver disease; FXR – Farsenoid X 
receptor.  
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7.3 CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
 
In this thesis we presented data on the complex pathophysiology of lean NAFLD, a 
distinct subset of patients with poor metabolic health but good metabolic adaptation. 
In summary, lean and non-lean NAFLD represents one of the best examples of disease 
heterogeneity and the wide spectrum of fatty liver disease. An obvious implication is 
that future clinical trials should consider stratifying patients into lean and non-lean as 
the subgroups have a different underlying patho-biology and drivers, and likely 
differences in outcome. In addition, given the importance of metabolic health to 
NAFLD pathophysiology, classification of patients based on their metabolic health 
status warrants further attention.  
 
Future studies on lean NAFLD should be directed at longitudinal follow-up of lean 
NAFLD patients to better understand its underlying pathogenesis and what triggers the 
loss of metabolic adaptation as the disease progresses into more advanced fibrosis. 
This should incorporate an understanding of lifestyle factors such as detailed dietary 
histories as well as information on physical activity. Measurements of other non-bile 
acid mediated pathway of the FXR activity, such as through the actions of other 
factors such as Takeda G-protein coupled receptor 5 (TGR5), Glucagon like peptide 1 
(GLP1) or Peroxisome proliferator-activated receptor gamma (PPAR gamma) activity 
on liver histology and metabolism would also be of benefit to complete our 
understanding of the mechanism for which increased FXR acitivity protects against 
liver damage, especially in early stages of the lean NAFLD.  Furthermore, 
measurement of faecal bile acids in addition to serum bile acids would benefit to 
further understand bile acid metabolism in these patients. 
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Another potential source for improvement in our understanding would be to increase 
the number of samples analysed for the gut microbiota profile and metabolomics 
analysis in lean and non-lean patients as well as in lean healthy controls in order to 
increase the power of the analysis. 
 
Lastly, a potential application of our results would be to implement an FXR based 
treatment in the mouse models to determine if there is a role for this in the 
management of lean patients. Another potential application would be to use the bile 
acid metabolic signatures for the development of an algorithm to prognosticate in lean 
NAFLD patients to identify those with poorer metabolic adaptation who are at risk of 
rapid liver disease progression.  
 
 
7.4 CONCLUSIONS 
 
In conclusion, lean NAFLD presents as a unique sub-phenotype of patients with fatty 
liver disease. Metabolic health status plays a major role in the development of NAFLD 
and among lean individuals with the disease, their genetic, epigenetic, gut microbiota 
and bile acid profiles, enterohepatic circulation and lifestyle factors explain their 
phenotype despite a normal BMI. The distinct and better adaptation of lean patients 
allows them to respond to adverse metabolic inputs to maintain body weight despite an 
increase in cardiometabolic risk. Whether or not this partial metabolic adaptation is 
preserved in the long run and what triggers the switch to maladaptation with disease 
progression remains to be elucidated. 
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BaCKgRoUND aND aIMS: Nonalcoholic fatty liver dis-
ease (NAFLD) affects a quarter of the adult population. A 
significant subset of patients are lean, but their underlying 
pathophysiology is not well understood.
appRoaCH aND ReSUltS: We investigated the role of 
bile acids (BAs) and the gut microbiome in the pathogen-
esis of lean NAFLD. BA and fibroblast growth factor (FGF) 
19 levels (a surrogate for intestinal farnesoid X receptor 
[FXR] activity), patatin-like phospholipase domain contain-
ing 3 (PNPLA3), and transmembrane 6 superfamily member 
2 (TM6SF2) variants, and gut microbiota profiles in lean and 
nonlean NAFLD were investigated in a cohort of Caucasian 
patients with biopsy-proven NAFLD (n  =  538), lean healthy 
controls (n  =  30), and experimental murine models. Patients 
with lean NAFLD had a more favorable metabolic and his-
tological profile compared with those with nonlean NAFLD 
(P  <  0.05 for all). BA levels were significantly higher in 
NAFLD with advanced compared with earlier stages of liver 
fibrosis. Patients with lean NAFLD had higher serum sec-
ondary BA and FGF19 levels and reduced 7-alpha-hydroxy-
4-cholesten-3-one (C4) levels (P  <  0.05 for all). These
differences were more profound in early compared with ad-
vanced stages of fibrosis (P  <  0.05 for both). Lean patients
demonstrated an altered gut microbiota profile. Similar find-
ings were demonstrated in lean and nonlean murine models
of NAFLD. Treating mice with an apical sodium-dependent
BA transporter inhibitor (SC-435) resulted in marked in-
creases in fgf15, a shift in the BA and microbiota profiles,
and improved steatohepatitis in the lean model.
CoNClUSIoNS: Differences in metabolic adaptation be-
tween patients with lean and nonlean NAFLD, at least in 
part, explain the pathophysiology and provide options for 
therapy. (Hepatology 2020;0:1-15).
Nonalcoholic fatty liver disease (NAFLD) affects approximately 20% to 30% of the world’s population and is a leading cause for 
end-stage liver disease, cancer, and transplantation.(1) 
Despite this, the existence and clinical course of the 
entity known as “lean NAFLD” or “NAFLD in lean 
patients” has been the subject of intense debate and 
controversy. To many, “lean NAFLD” refers to indi-
viduals manifesting the disease in the context of a 
normal body mass index (BMI) but having excess 
visceral adiposity and insulin resistance as well as 
metabolic dysfunction that is typically observed in 
people with obesity,(2) the so-called metabolically 
obese normal-weight individual. The prevalence of 
lean NAFLD varies widely according to the criteria 
used for its definition but ranges from 5% to 45%.(3) 
By this interpretation, lean NAFLD is similar if not 
identical to NAFLD associated with obesity and 
being overweight, with insulin resistance at its core.
Accumulating evidence, however, suggests that lean 
NAFLD might be a distinct pathophysiological entity, 
Abbreviations: ALT, alanine aminotransferase; BA, bile acid; BMI, body mass index; C4, 7-alpha-hydroxy-4-cholesten-3-one; CA, cholic acid; CDCA, 
chenodeoxycholic acid; ChR, cholesterol-rich; CI, conf idence interval; DCA, deoxycholic acid; FGF, f ibroblast growth factor; FXR, farnesoid X receptor; 
NAFLD, nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; PERMANOVA, 
permutational multivariate analysis of variance; PNPLA3, patatin-like phospholipase domain containing 3; TM6SF2, transmembrane 6 superfamily 
member 2; UDCA, ursodeoxycholic acid.
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with approximately half (47%-65%) having nonalcoholic 
steatohepatitis (NASH).(4) Although lean NAFLD was 
first described in Asia, it has since been recognized 
globally.(1) Most aspects of lean NAFLD, including its 
operational classification, have not been systematically 
characterized. The most frequently used definition is 
that of hepatic steatosis with a BMI  <  25  kg/m2 (or 
<23  kg/m2 in Asians) in the absence of significant 
alcohol intake.(5) The natural history of lean NAFLD 
is even less well characterized; some data suggest that 
they have worse mortality and accelerated disease pro-
gression despite a more favorable metabolic risk pro-
file.(6,7) Finally, the pathogenesis and mechanisms for 
their favorable metabolic profile compared with obese 
NAFLD are puzzling and poorly understood, and ther-
apeutic options for lean NAFLD remain undefined.
For metabolic homeostasis, in addition to the 
neuroendocrine axis, caloric intake, and physical 
activity, the enterohepatic circulation, including bile 
acids (BAs) and their metabolites and gut microbi-
ota, are intimately involved. BAs are the principal 
route for cholesterol catabolism, and recent evidence 
demonstrates that a high intake of dietary choles-
terol,(8) elevated levels of hepatic cholesterol,(9-11) 
and disrupted hepatic cholesterol homeostasis are 
pivotal drivers of NAFLD.(9-11) However, individ-
ual responses to changes in dietary cholesterol vary 
widely, suggesting a modifying role for other envi-
ronmental or genetic factors. It is of interest that 
it has been suggested that cholesterol intake is 
higher in lean compared with obese NAFLD.(12-14)  
BAs also regulate glucose and lipid metabolism and 
energy expenditure,(15) and in turn their production, 
transport, and metabolism are regulated by spe-
cific nuclear BA receptors, the farnesoid X recep-
tor (FXR) and circulating fibroblast growth factor 
(FGF19), likely by means of dependent and inde-
pendent mechanisms.(15,16) The gut microbiome is 
also intimately involved in the pathogenesis of sev-
eral metabolic diseases, including body weight reg-
ulation, NAFLD, and liver cancer, in part through 
direct interactions with BAs.(17-19)
We hypothesized that the pathogenesis of lean 
and obese NAFLD and their distinct metabolic and 
histological profiles is caused by more than just dif-
ferences in body weight and BMI. We considered 
that the clinical phenotype of lean NAFLD might 
reflect differences in the integration of signals from 
the diet and the systemic metabolic milieu as well 
as the enterohepatic axis comprising both BAs 
and gut microbiota. We tested this hypothesis in 
a large, well-phenotyped, biopsy-proven cohort of 
538 Caucasian patients with NAFLD and 30 lean 
healthy controls.
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Patients and Methods
patIeNt SeleCtIoN
A total of 538 consecutive Caucasian patients with 
histologically characterized NAFLD and 30 lean healthy 
controls were included. The inclusion criteria and clin-
ical and laboratory assessments and histopathology 
are described in detail in the Supporting Information. 
Ethics approval was obtained and conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki, 
from the human ethics committee of the Western 
Sydney Local Health District and the University of 
Sydney. All other sites had ethics approval from their 
respective ethics committees. Written informed con-
sent was obtained from all patients.
Methods of genotyping, high-throughput BA 
profiling, and quantification of 7-alpha-hydroxy-4- 
cholesten-3-one (C4), FGF19, fgf15, and microbiome 
analysis are provided in the Supporting Information.
NaFlD MICe MoDelS
Male C57BL/6 mice obtained from the Animal 
Resources Centre (Perth, Australia) were used for diet 
studies commencing at week 8; details are provided in the 
Supporting Information. All procedures were approved 
by the Western Sydney Local Health District animal 
ethics committee and conducted in accordance with 
the animal experimentation guidelines of the National 
Health and Medical Research Council of Australia.
StatIStICal aNalySIS
Data were analyzed using SPSS version 24.0 (IBM, 
Armonk, NY). Values are expressed as mean ±  stan-
dard deviation, median, and interquartile range or 
frequency (percentage) as appropriate. Statistical 
significance was considered as P  <  0.05 throughout; 
details are provided in the Supporting Information.
Results
ClINICal, HIStologICal, aND 
geNetIC CHaRaCteRIStICS oF 
patIeNtS WItH leaN NaFlD
A total of 538 patients with biopsy-proven 
NAFLD were recruited for the study. Of the 
patients, 99 (18%) were lean. The clinical and bio-
chemical characteristics of lean NAFLD compared 
with their counterpart nonlean patients are pre-
sented in Table 1 and representative images of his-
tological images of liver biopsies are presented in 
Supporting Fig S1. In addition to lower BMI, lean 
patients had lower waist-to-hip ratios and better 
metabolic profiles, including significantly lower fre-
quency of diabetes, higher serum high-density lipo-
protein, and lower serum triglycerides, fasting blood 
glucose, and homeostasis model assessment of insu-
lin resistance values compared with their nonlean 
counterparts. Histologically, lean patients had lower 
fibrosis scores and nonalcoholic fatty liver disease 
activity scores (NAS; P  <  0.001 for both) as well 
as lower serum alanine aminotransferase (ALT). In 
total, lean patients have favorable metabolic and his-
tological features compared with nonlean NAFLD.
Patients with lean NAFLD had a significantly 
higher prevalence of carriage of the transmembrane 
6 superfamily member 2 (TM6SF2) rs58542926 (T) 
allele compared with nonlean patients but a similar 
prevalence of the patatin-like phospholipase domain 
containing 3 (PNPLA3) GG polymorphism (Table 1). 
To adjust for the effect of confounding factors, the 
TM6SF2 rs58542926 (T) allele still associated with 
lean NAFLD in a multivariable model adjusting for 
age, sex, ALT, diabetes, total cholesterol level, fibrosis, 
steatosis, and PNPLA3 genotype (odds ratio, 2.567; 
95% confidence interval [CI], 1.426-4.619; P = 0.002).
SeRUM Ba pRoFIle IS 
aSSoCIateD WItH NaFlD 
SeVeRIty BUt Not SteatoSIS
Although there is increasing evidence to suggest a 
critical role for BAs in metabolic diseases, including 
NAFLD, their correlation with disease severity is con-
flicting, which is likely because of the limited sample 
sizes of previous studies. We explored the association 
between the BA profile and liver histology.
No differences in total BA, total primary BA, or 
total secondary BA levels were noted between patients 
with mild steatosis (S1-S2) compared with those with 
severe steatosis (S3; Supporting Fig. S2C). Next, the 
association with steatohepatitis activity, including the 
severity of inflammation and hepatocyte ballooning, 
was tested. In this analysis, significantly higher total 
BAs (P  = 0.006), primary BAs (P  = 0.031), and sec-
ondary BAs (P < 0.001) were found in patients with 
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hepatocyte ballooning compared with those without 
ballooning (Supporting Fig. S2A).
When comparing degrees of inflammation, higher 
grades of lobular inflammation were associated with 
higher total and secondary BAs (P  =  0.027 and 
P  =  0.026, respectively), whereas there was no sig-
nificant difference in primary BA levels (P  =  0.073; 
Supporting Fig. S2B). Finally, the association of BAs 
with NAFLD fibrosis stage was tested. The distribu-
tion of all individual BAs between patients with none/
mild fibrosis and those with significant fibrosis is 
depicted in Fig. 1A. Patients with significant fibrosis 
(≥F2) had higher total (P = 0.017), primary (P = 0.018), 
and secondary (P  =  0.045) BA levels compared with 
those with none/mild fibrosis (F0-F1; Fig. 1B). 
At the level of individual BAs, the level of cholic acid 
(CA) was significantly higher in patients with signif-
icant fibrosis compared with those with none/mild 
fibrosis (P  =  0.026; Fig. 1C). Similarly, the levels of 
glycine and taurine-conjugated BAs were significantly 
higher in patients with significant fibrosis compared 
with those with none/mild fibrosis (P  =  0.002 and 
P  <  0.001, respectively; Fig. 1D,E). The association 
between BA levels and fibrosis remained significant 
taBle 1. Clinical and Histological Characteristics of patients with lean and Nonlean NaFlD
Lean NAFLD (n = 99) Nonlean NAFLD (n = 439) P Value
Age (years) 46 ± 11.7 47 ± 13.0 0.445
Male (%) 69 (69.7) 290 (64.9) 0.413
BMI (kg/m2) 23.2 ± 1.5 30.8 ± 4.7 <0.001
PNPLA3 I148M (CC/CG/GG) 32 (36.8)/39 (44.8)/16 (18.4) 145 (37.8)/172 (44.8)/67 (17.4) 0.973
TM6SF2 E167K (CC/CT/TT) 59 (70.2)/22 (26.2)/3 (3.6) 321 (85.1)/50 (13.3)/6 (1.6) 0.005
ALT (IU/mL) 57.9 ± 35.6 72.3 ± 46.8 <0.001
WHR* 0.919 ± 0.062 0.971 ± 0.079 <0.001
Normal WHR 25 (29.2) 46 (10.3)
Elevated WHR 29 (29.3) 189 (42.3)
Phosphatidylethanol level (ng/mL) 66.35 ± 48.59 66.45 ± 52.72 0.8829
Diabetes (%) 11 (11.1) 128 (28.6) <0.001
Hypertension (%) 25 (25.3) 158 (35.3) 0.060
Dyslipidemia (%) 43 (43.4) 242 (54.1) 0.059
Total cholesterol (mmol/L) 5.1 ± 1.2 5.2 ± 1.2 0.472
HDL-C (mmol/L) 1.5 ± 0.6 1.2 ± 0.3 <0.001
LDL-C (mmol/L) 3.6 ± 1.6 3.5 ± 1.6 0.667
Triglyceride (mmol/L) 1.6 ± 1.4 1.9 ± 1.2 0.083
Fasting BSL (mmol/L) 5.3 ± 1.8 5.9 ± 1.8 0.006
HOMA-IR 2.8 ± 1.9 5.4 ± 5.9 <0.001
Fibrosis (%)
F0-F1 (%) 75 (75.8) 239 (54.6) <0.001
F2-F4 (%) 24 (24.2) 200 (45.4)
Ballooning (%)
No ballooning (%) 37 (37.4) 131 (30.4) 0.1510
Any ballooning (%) 62 (62.6) 308 (69.6)
Steatosis (%)
Grades 1-2 (%) 85 (85.9) 351 (81.2) 0.2530
Grade 3 (%) 14 (14.1) 88 (18.8)
Lobular inflammation
Grades 0-1 (%) 88 (88.9) 352 (80.5) 0.0782
Grade 2 or more (%) 11 (11.1) 87 (19.5)
NAS 3 ± 2 4 ± 2 0.001
Values are mean ± SD or n (%). P value was calculated using Fisher’s exact test and Student t test.
*WHR based on 54 lean patients and 235 nonlean patients. Normal WHR defined as <0.90 for males and <0.85 for females. DNA was
available for 471 patients (86%). The bold values indicate statistically significant results. Abbreviation: HOMA-IR, homeostasis model
assessment of insulin resistance.
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after adjusting for age, BMI, sex, diabetes, ALT, and 
platelets in a multivariable linear regression analysis 
(β  =  0.115; 95% CI, 0.061-0.168; P  <  0.01 for total 
secondary BA levels, and β  =  0.302; 95% CI, 0.145-
0.458; P < 0.01 for ursodeoxycholic acid [UDCA]).
Higher levels of total BAs (P  =  0.001), primary 
BAs (P  =  0.001), and secondary BAs (P  =  0.002) 
were seen in patients with higher NAS, defined as >3, 
compared with patients with lower scores (Supporting 
Fig. S3). Similarly, patients with NASH had higher 
levels of total, primary, and secondary BAs compared 
with patients with steatosis, but only the secondary 
BA levels were significantly different between the two 
groups (P = 0.047).
leaN NaFlD patIeNtS HaVe 
HIgHeR SeRUM Ba leVelS
Next, we explored the differential BA profile 
between patients with lean and nonlean NAFLD. 
FIg. 1. Serum BA levels and liver fibrosis. (A) BA composition as a percentage according to hepatic fibrosis. The x axis shows patients 
with absent/mild (F0-F1, left, n = 314) and moderate/severe (F2-F4, right, n = 224) fibrosis, and the y axis shows the composition of each 
individual BA in percent. (B) Mean concentration of total BAs, total primary BAs, and total secondary BAs according to hepatic fibrosis. 
The x axis shows hepatic fibrosis dichotomized as absent/mild (F0-F1, n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows 
the mean concentration of BA levels in µmol/L. (C) Mean concentration of CA according to hepatic fibrosis. The x axis shows hepatic 
fibrosis dichotomized as absent/mild (F0-F1, n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows the mean concentration 
of BA levels in µmol/L. (D) Mean concentration of glycine-conjugated BAs according to hepatic fibrosis. The x axis shows hepatic fibrosis 
dichotomized as absent/mild (F0-F1, n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows the mean concentration of 
BA levels in µmol/L. (E) Mean concentration of taurine-conjugated BAs according to hepatic fibrosis. The x axis shows hepatic fibrosis 
dichotomized as absent/mild (F0-F1, n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows the mean concentration of BA 
levels in µmol/L. Results are expressed as mean ± SEM, and P value was calculated using the Mann-Whitney nonparametric t test. *P < 0.05, 
**P < 0.01, ***P < 0.001. Abbreviations: CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; 
GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; GLC, glycolithocholic acid; GUDCA, Glycoursodeoxycholic acid; 
HCA, hyocholic acid; HDCA, hyodeoxycholic acid; LC, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; 
TDCA, taurodeoxycholic acid; TLC, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid.
0
50
100
B
A
 c
om
po
si
tio
n 
(%
)
GUDCA
TUDCA
UDCA
HDCA
GDCA
TDCA
DCA
GLC
TLC
LC
GCDCA
TCDCA
CDCA
HCA
GCA
TCA
CA
A
0
2
4
6
M
ea
n 
co
nc
en
tr
at
io
n 
(µ
m
ol
/L
)
F0-F1
F2-F4
B
0.0
0.1
0.2
0.3
C
A
 c
on
ce
nt
ra
tio
n 
(µ
M
)
C
0
1
2
3
4
D
F0-F1 F2-F4 Total Primary Secondary
F0-F1 F2-F4 F0-F1 F2-F4 F0-F1 F2-F4
0.0
0.2
0.4
0.6
0.8
1.0
Ta
ur
in
e-
co
nj
ug
at
ed
 B
A
 (µ
M
)
G
ly
ci
ne
-c
on
ju
ga
te
d 
B
A
 (µ
M
) E
Hepatology, Month 2020CHEN, ESMAILI, ET AL.
186
Interestingly, patients with lean NAFLD had higher 
total, primary, and secondary BA levels compared with 
those with nonlean NAFLD, although this was only 
significant for the secondary BAs (P = 0.010; Fig. 2B). 
The composition of individual BAs also differed 
between patients with lean and nonlean NAFLD, 
wherein lean patients had lower deoxycholic acid 
(DCA), glycochenodeoxycholic acid, and chenode-
oxycholic acid (CDCA) but more glycocholic acid 
(GCA) compared with the nonlean patients (Fig. 2A). 
Patients with lean NAFLD also had nonsignificantly 
higher total conjugated and total unconjugated BAs 
compared with patients with nonlean NAFLD.
Given the strong correlation between BA profiles 
and fibrosis, we examined the relationship between 
BAs and lean NAFLD stratified by fibrosis stage. 
FIg. 2. Serum BA levels in patients with lean and nonlean NAFLD. (A) BA composition in percentage between patients with lean and 
nonlean NAFLD. The x axis shows patients with lean (n = 99) and nonlean (n = 439) NAFLD, and the y axis shows the composition of 
each individual BA in percent. (B) Mean concentration of total BAs, total primary BAs, and total secondary BAs in patients with lean and 
nonlean NAFLD. The x axis shows patients with lean (n = 99) and nonlean (n = 439) NAFLD, and the y axis shows the mean concentration 
of BA levels in µmol/L. (C) Mean concentration of total BAs, total primary BAs, and total secondary BAs in lean and nonlean patients 
with absent/mild fibrosis. The x axis shows lean (n = 75) and nonlean (n = 239) patients with absent/mild (F0-F1) hepatic fibrosis, and the 
y axis shows the mean concentration of BA levels in µmol/L. (D) Mean concentration of total BAs, total primary BAs, and total secondary 
BAs in lean and nonlean patients with moderate/severe fibrosis. The x axis shows lean (n = 24) and nonlean (n = 200) patients with 
moderate/severe (F2-F4) hepatic fibrosis, and the y axis shows the mean concentration of BA levels in µmol/L. (E) Mean concentration 
of DCA. The x axis shows lean (n = 99) and nonlean (n = 439) patients, and the y axis shows the mean concentration of BA levels in 
µmol/L. (F) Mean concentration of UDCA. The x axis shows patients with lean (n = 99) and nonlean (n = 439) NAFLD, and the y axis 
shows the mean concentration of BA levels in µmol/L. Results are expressed as mean ± SEM, and P value was calculated using the Mann-
Whitney nonparametric t test. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, 
deoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; GLC, glycolithocholic 
acid; GUDCA, Glycoursodeoxycholic acid; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; LC, lithocholic acid; TCA, taurocholic 
acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TLC, taurolithocholic acid; TUDCA, tauroursodeoxycholic 
acid; UDCA, ursodeoxycholic acid.
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When stratified in this way, in those with mild fibro-
sis (F0-F1), higher total secondary BA levels were 
observed in patients with lean NAFLD compared 
with patients with nonlean NAFLD (P  =  0.004). 
No significant difference between lean and nonlean 
patients was observed in those with more severe 
fibrosis (Fig. 2C,D). The predominant secondary 
BAs contributing to this difference were DCA and 
UDCA (P < 0.05 for both; Fig. 2E,F). GCA was also 
higher in patients with lean NAFLD; however, this 
difference was not significant (Supporting Fig. S4B). 
The secondary to primary BA ratio was significantly 
higher in patients with lean compared with nonlean 
NAFLD (P = 0.018; Supporting Fig. S4A).
In a subsequent analysis, we determined the rel-
evant clinical factors associated with secondary BA 
levels. Consistently, on univariable analysis, BMI, 
fibrosis, and ballooning were associated with second-
ary BA levels. On multivariable analysis, only BMI 
and fibrosis stage remained independently, negatively, 
and positively associated with secondary BA levels, 
respectively (Supporting Table S1).
patIeNtS WItH leaN NaFlD 
HaVe HIgHeR SeRUM FgF19 
leVelS
FXR dysregulation has been implicated in the 
pathogenesis of NAFLD; therefore, we were inter-
ested to determine if differential effects are observed 
in lean versus nonlean NAFLD.(20,21) To examine 
for this, serum FGF19, a surrogate marker of FXR 
activity, was measured. In this analysis, reduced lev-
els of FGF19 were observed with the advancement of 
fibrosis stage (P = 0.030; Fig. 3A). Patients with lean 
NAFLD had significantly higher FGF19 levels com-
pared with patients with nonlean NAFLD (P = 0.028; 
Fig. 3B). Interestingly, when stratified according to 
fibrosis severity, the differences were more profound 
in those with mild fibrosis (F0-F1; P  =  0.005), with 
the reverse being true as fibrosis severity increased; 
this was, however, not significant (Fig. 3C).
patIeNtS WItH leaN NaFlD 
HaVe loWeR C4 leVelS
To investigate differences in BA metabolism 
between lean and nonlean NAFLD, levels of C4, a BA 
synthesis intermediate, were measured as a marker of 
de novo BA synthesis. In this analysis, no difference in 
levels of C4 was observed according to fibrosis stage 
(Fig. 3D). However, as expected, patients with lean 
NAFLD had significantly lower C4 levels compared 
with their nonlean counterparts (P = 0.016; Fig. 3E). 
This difference was more predominant in those with 
mild fibrosis (F0-F1; P = 0.010) but not in those with 
moderate/severe fibrosis (F2-F4; Fig. 3F).
patIeNtS WItH leaN NaFlD 
HaVe a DIStINCt MICRoBIota 
pRoFIle
The composition of the gut microbiome and its 
interaction with BAs affects FXR-mediated signaling 
in both the liver and intestine and is implicated in 
NAFLD pathogenesis.(20,22) Hence, we determined 
gut microbiome composition in a small exploratory 
subset of patients with available stool samples by 16S 
ribosomal RNA amplicon sequencing. The clinical 
characteristics of these patients is found in Supporting 
Table S2. At the phylum level, no differences in tax-
onomic composition of the gut microbiome were 
observed according to lean versus obese BMI status. 
At the genus level, Erysipelotrichaceae UCG-003 as 
well as several bacterial genera within the Clostridiales 
order, including Ruminococcus, Clostridium sensu stricto 
1, Romboutsia, and Ruminococcaceae UCG-008, were 
enriched in lean patients, and Ruminiclostridium and 
Streptococcus were enriched in patients with NAFLD 
who were obese (Mann-Whitney test; P  <  0.05; 
Fig. 4A-F). These changes remained significant for 
Ruminococcaceae UCG-008 when corrected for 
multiple comparison testing (false discovery rate; 
P = 0.010).
patIeNtS WItH leaN NaFlD 
HaVe DIFFeReNtIal Ba 
aND MICRoBIota pRoFIleS 
CoMpaReD WItH leaN HealtHy 
CoNtRolS
We next compared our cohort of patients with lean 
NAFLD with lean healthy controls matched by age 
and sex. Their baseline demographics in comparison to 
patients with lean NAFLD are shown in Supporting 
Table S3. Patients with lean NAFLD had significantly 
higher total BAs, total primary BAs, and total sec-
ondary BAs compared with the lean healthy controls 
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(Supporting Fig. S5A). There was no significant differ-
ence in levels of FGF19 between lean healthy controls 
and patients with lean NAFLD with none/mild fibro-
sis (F0-F1). However, in patients with lean NAFLD 
and moderate/severe fibrosis (F2-F4), the level of 
FGF19 was significantly lower compared with that in 
lean healthy controls (Supporting Fig. S5B). Analysis 
of microbiota demonstrated a distinct separation 
in profiles between lean healthy controls and lean 
NAFLD (permutational multivariate analysis of vari-
ance [PERMANOVA] P = 0.069, Pseudo-F = 2.019; 
Supporting Fig. S5C). More specifically, in the lean 
NAFLD group, there was an increased abundance of 
the species Dorea and a reduction in the relative abun-
dance of a number of species, including Marvinbryantia 
and the Christensellenaceae R7 group.
FIg. 3. Serum FGF19 levels and C4 levels. (A) Mean concentration of FGF19 according to hepatic fibrosis. The x axis shows hepatic 
fibrosis dichotomized as absent/mild (F0-F1, n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows the mean concentration 
of FGF19 in pg/mL. (B) Mean concentration of FGF19 in patients with lean and nonlean NAFLD. The x axis shows patients with 
lean (n = 99) and nonlean (n = 439) NAFLD, and the y axis shows the mean concentrations of FGF19 levels in pg/mL. (C) Mean 
concentration of FGF19 levels in lean and nonlean patients according to BMI and hepatic fibrosis. The x axis shows patients with lean 
and nonlean NAFLD with absent/mild fibrosis (F0-F1, left panel, n = 75 for lean and n = 239 for nonlean NAFLD) and moderate/severe 
fibrosis (F2-F4, right panel, n = 24 for lean and n = 200 for nonlean), and the y axis shows the mean concentrations of FGF19 levels in pg/mL. 
(D) Mean concentration of C4 according to hepatic fibrosis. The x axis shows hepatic fibrosis dichotomized as absent/mild (F0-F1,
n = 314) or moderate/severe (F2-F4, n = 224), and the y axis shows the mean concentration of C4 in μmol/mL. (E) Mean concentration
of C4 in patients with lean and nonlean NAFLD. The x axis shows patients with lean (n = 99) and nonlean (n = 439) NAFLD, and the
y axis shows the mean concentrations of C4 in μmol/mL. (F) Mean concentration of C4 levels according to BMI and hepatic fibrosis.
The x axis shows patients with lean and nonlean NAFLD with absent/mild fibrosis (F0-F1, left panel, n = 75 for lean and n = 239 for
nonlean NAFLD) and moderate/severe fibrosis (F2-F4, right panel, n = 24 for lean and n = 200 for nonlean), and the y axis shows the
mean concentration of C4 in μmol/mL. Results are expressed as mean ± SEM, and P value was calculated using the Mann-Whitney
nonparametric t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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a MURINe leaN NaFlD MoDel
HaS INCReaSeD Bas aND 
alteReD gUt MICRoBIota
To further test our hypothesis, we investigated alter-
ations in BA levels and the gut microbiome in a murine 
model of lean versus nonlean NAFLD. Mice were fed 
either a cholesterol-rich (ChR) or a high-sucrose diet 
for 16  weeks. Mice fed the ChR diet remained lean 
despite the development of NAFLD, which is con-
sistent with other studies,(23,24) whereas those fed the 
high-sucrose diet demonstrated significant weight 
gain. Histology images are shown in Fig. 5A. Like our 
human results, mice fed the ChR diet had significantly 
higher total (P = 0.01), primary (P = 0.02), and second-
ary (P  =  0.06) BAs (Fig. 5B). Analysis of ileal fgf15, 
the mouse equivalent of human FGF19, showed signifi-
cantly higher levels in mice fed the ChR compared with 
the high-sucrose diet (Fig. 5C).
Analysis of the microbiota demonstrated a change 
in composition (PERMANOVA P  =  0.009, pseu-
do-F = 18.58, 126 permutations) as reflected broadly 
by significant changes in the relative abundances of 
the two major phyla, Firmicutes and Bacteroidetes, 
as well as in Actinobacteria, Cyanobacteria, and 
Proteobacteria. Mice fed the ChR diet were 
observed to have an increased relative abundance of 
Bacteroidetes and a decrease in Firmicutes compared 
with those fed with high sucrose (Fig. 5D). As we 
observed in humans, similar trends were noted for the 
abundance of members of the Ruminococcaceae bac-
terial family in the mice fed the high-cholesterol diet 
FIg. 4. Gut microbiota associated with lean NAFLD. Abundance of bacterial genera and species that differ between patients with 
lean (n = 5) and obese (n = 24) NAFLD. Results are expressed as mean ± SEM, and P value was calculated using the Mann-Whitney 
nonparametric t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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(lean NAFLD). These changes were also observed for 
several phylotypes within the Erysipelotrichaceae. A 
correlation plot between different BAs and the bacte-
rial taxa altered in both models is shown in Supporting 
Fig. S6F.
INHIBItINg Ba ReaBSoRptIoN 
ReSUlteD IN IMpRoVeD 
SteatoHepatItIS IN a leaN 
NaFlD MoDel
Finally, to investigate the therapeutic implications of 
our findings, we treated the ChR diet–fed mice (lean 
model) with or without apical sodium-dependent BA 
transporter inhibitor (SC-435), which mediates the 
active reabsorption of BAs into the enterohepatic cir-
culation. Supplementing with SC-435 led to a reduc-
tion in liver/body weight ratio (Supporting Fig. S6A) 
and hepatic total and free cholesterol accumulation 
(Supporting Fig. S6B,C) but not body or epididymal 
weights. Histologically, SC-435 treatment resulted in 
reduced inflammation and fibrosis on hematoxylin 
and eosin and sirius red staining and reduced NAS 
(Fig. 6A) and serum ALT levels (Fig. 6B). As expected, 
this was accompanied by a reduction in the messenger 
RNA expression of inflammatory and fibrosis markers 
(Fig. 6C).
In additional analyses, treatment with SC-435 
resulted in a shift in the BA profile to one with 
increased FXR agonistic BAs, such as DCA and 
FIg. 5. Serum BA levels and microbiota profile in a murine experimental model of NAFLD. (A) Histology images from a mouse model 
of lean NAFLD. Hematoxylin and eosin (H&E) image of liver biopsy section from a mouse fed the ChR diet and a mouse fed the high-
sucrose (HS) diet. (B) Mean concentrations of total BAs, total primary BAs, and total secondary BAs in a mouse model of lean NAFLD. 
The x axis shows mice fed a diet high in cholesterol (blue bar, n = 9) and mice fed a diet high in sucrose (red bar, n = 5), and the y axis 
shows the mean concentrations of BA levels in µmol/L. (C) Mean concentrations of ileal fgf15 in a mouse model of lean NAFLD. The x 
axis shows mice fed a diet high in cholesterol (blue bar, n = 9) and mice fed a diet high in sucrose (red bar, n = 5), and the y axis shows the 
mean concentrations of ileal fgf15 levels in pg/mL. (D) Relative abundance of the phyla Firmicutes and Bacteroidetes in ceca of mice fed 
the high-cholesterol or the high-sucrose diet, as determined by 16S ribosomal RNA sequencing. Results are expressed as mean ± SEM, 
and P value was calculated using the Mann-Whitney nonparametric t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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taurochenodeoxycholic acid (Fig. 6D), increased 
ileal fgf15 levels (Supporting Fig. S6E), and hepatic 
mRNA expression of genes involved in the regula-
tion of BAs, such as retinoid X receptor and FXR 
(Fig. 6E). Interestingly, SC-435 increased the weight 
of ceca of mice that were fed the diet (Supporting 
Fig. S6D) and altered the gut microbiota, with an 
increase in the relative abundances of Bacteroides and 
a decreased relative abundance of members of the 
Lachnospiraceae family compared with control mice 
(Fig. 6F).
Discussion
Lean NAFLD constitutes a significant proportion 
of patients with NAFLD, although its pathogenesis 
is not well understood. Here, we provide a testable 
hypothesis for the pathophysiological distinction 
between lean and nonlean NAFLD that can be exam-
ined in other cohorts. Using biopsy-proven Caucasian 
patients in whom the lean NAFLD entity is less fre-
quent than in cohorts from Asia, we demonstrate that 
lean patients have distinct metabolic, genetic, histo-
logic, and BA profiles and C4 levels, as well as differ-
ences in FXR activity and gut microbiota, compared 
with their nonlean counterparts and lean healthy 
controls.
Consistent with other reports,(1) approximately 1 
in 5 Caucasian patients with NAFLD are lean and 
have a favorable metabolic and pathological profile, 
with less insulin resistance and dyslipidemia and 
milder liver histology. A reciprocal and intimate inter-
action between BAs and gut microbiota is associated 
with, and thought to regulate, metabolic and hepatic 
traits.(15,18) Although myriad factors could explain 
FIg. 6. Administration of SC-435 reduces NASH and alters BA and microbiota profiles in a lean NAFLD model. (A) H&E staining 
of liver sections indicates reductions in liver inflammation. Sirius red staining shows reduced liver fibrosis (scale bars, 250 µm). (B) NAS 
indicates a lower level of inflammation in mice treated with SC-435. (C) Serum ALT levels are decreased in mice treated with SC-435. 
(D) Reduction in mRNA expression of CD68, MCP-1 (macrophage and inflammatory markers), and Col1a1 (fibrotic marker). Data
are presented as relative expression or log2 RNA expression. (E) SC-435 led to a shift in BA profiles. (F) SC-435 increased mRNA
expression of FXR and retinoid X receptor, which are involved in BA regulation and FXR activity. (G) Analysis of taxa indicates significant 
differences between mice treated with and without SC-435 (PERMANOVA; pseudo-F = 8.64, p [perm] = 0.012). Data are presented
as mean ± SEM, and P value was calculated using the Mann-Whitney nonparametric t test. *P < 0.05, **P < 0.01, ***P < 0.001; n = 5-6
mice per group. Abbreviations: b-MCA, beta muricholic acid; CA, cholic acid; ChR, cholesterol rich; DCA, deoxycholic acid; FXR,
farsenoid X receptor; HDCA, hyodeoxycholic acid; NAS, NAFLD activity score; RXR, retinoid X receptor; T-CA, taurocholic acid;
T-CDCA, taurochenodeoxycholic acid; T-DCA, taurodeoxycholic acid; T-HDCA, tauro hyodeoxycholic acid; T-LC, tauro lithocholic
acid; T-UDCA, tauro ursodeoxycholid acid; UDCA, ursodeoxycholic acid; w-MCA, omega muricholic acid.
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the differences we observed, our results in toto sug-
gest that the balance and interaction between the sys-
temic metabolic milieu and changes in the intestinal 
microbiome and BA physiology govern the expression 
of hepatic disease and the onset and progression of 
NAFLD in patients with a normal BMI.
To elaborate, increased BA levels, as we observed 
in lean NAFLD, are reported to mediate resistance 
to diet-induced obesity, a phenomenon called “obesity 
resistance.”(25,26) Obesity-resistant rodents can burn 
more dietary fat by increasing energy expenditure. It is 
of relevance, BAs (including major BA species, such as 
CA, trichloroacetic acid, DCA, and CDCA) increase 
energy expenditure,(26) and CDCA increases human 
brown adipose tissue activity.(27) FGF19, which was 
also increased in lean NAFLD, is reported to be a key 
regulator of energy expenditure and improves glucose 
and lipid homeostasis,(28) and gut-restricted FXR ago-
nism promotes metabolic improvements and enhances 
thermogenesis and browning of white adipose tissue 
in mice.(29) At the microbiota level, patients with 
lean NAFLD had distinct gut microbiota compared 
with those who were nonlean. Lean NAFLD had an 
increased abundance of members belonging to the 
Clostridium genus as well as Ruminococcaceae, which are 
involved in the formation of BAs.(30,31) Consistently, 
in an experimental model that involved feeding mice 
a ChR diet,(23,24) we recapitulated several features of 
the phenotype, including lean body weight, steatohep-
atitis, and less insulin resistance, compared with mice 
receiving a high-sucrose diet, with similar changes in 
BA profiles with higher total BAs and fgf15 levels 
and similar trends observed in gut microbiota. Thus, 
we surmise that patients with lean NAFLD have an 
obesity-resistant phenotype in part mediated by greater 
levels of BAs and FGF19 and microbiota changes. 
The decreased levels of C4 in lean NAFLD further 
support the concept of metabolic adaptation whereby 
the increased FXR activity (as represented by FGF-19 
levels) results in negative feedback on BA synthesis.
The milder disease and favorable metabolic pro-
file of patients with lean NAFLD could be explained 
by the current findings. There is strong evidence that 
activation of BA signaling induces improvements in 
metabolic (glucose and lipid) phenotypes in murine 
models.(32) Furthermore, in both humans and murine 
models, elevated BAs play a role in the metabolic 
improvements after bariatric surgery, including in 
type 2 diabetes, dyslipidemia, and NASH, even before 
significant weight loss.(33-35) Thus, we suggest that 
patients who are lean can adapt metabolically and 
excrete greater amounts of BAs, whereas their obese 
counterparts are those less able to excrete adequate 
amounts of BAs to rid themselves of excess cholesterol, 
even if they are able to maintain a plasma cholesterol 
level comparable to that of lean patients. Consistently, 
in humans, patients who are lean and patients who are 
obese have differential defense mechanisms to main-
tain stable serum cholesterol levels, wherein dietary 
cholesterol appears to preferentially induce BA syn-
thesis in patients who are lean compared with patients 
who are obese.(36)
Notably, we did not observe any association between 
BA levels and hepatic steatosis, indicating a potential 
lack of a protective effect of BAs on the development 
of steatosis, as opposed to changes in peripheral tissues. 
Alternatively, changes in microbiota might explain 
the development of steatosis.(37) Lean NAFLD had 
a distinct separation in microbiota profile compared 
with the healthy controls, with an increased abun-
dance of Dorea that has been implicated in the patho-
genesis and progression of NASH(38) and a decrease 
of several species protective for NAFLD, such as 
Marvinbryantia and Christensellenaceae R7 group.(39,40) 
Similarly, compared with nonlean NAFLD, they had 
an increased relative abundance of several phylotypes 
within the Erysipelotrichaceae family in both patient 
and murine models that have been repeatedly linked 
to host lipid and cholesterol phenotypes in different 
species (humans, mice, and hamsters) and positively 
associate with changes in liver fat in humans.(41) Use 
of plant sterol esters to reduce cholesterol in hamsters 
likewise reduced Erysipelotrichaceae abundance.(41) 
Ruminococcaceae UCG-008, Clostridium sensu stricto 
1, and Romboutsia, which were also enriched in lean 
NAFLD, are reported to be strongly correlated with 
hepatic triglycerides.(42)
At a genetic level, we demonstrated that although 
there was no significant difference in the proportions 
of patients with PNPLA3 rs738409 GG genotype, a 
significantly greater proportion of patients with lean 
NAFLD carried the TM6SF2 rs58542926 (T) allele 
than patients with nonlean NAFLD. Interestingly, 
TM6SF2 has been implicated in cholesterol synthe-
sis.(43) In addition, TM6SF2, but not PNPLA3, geno-
types correlate with endotoxemia.(44) Hence, the lean 
NAFLD phenotype might be consistent with obe-
sity resistance, in which individuals are still prone to 
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develop steatosis in response to an obesogenic envi-
ronment (and perhaps a diet enriched in cholesterol), 
likely by genetic and gut-driven mechanisms.
We observed that differences between lean and 
nonlean patients or lean controls were more profound 
in those with early stages of liver fibrosis. This suggests 
that with disease progression, homeostatic responses 
might possibly no longer be able to limit inflammation 
and fibrosis, leading ultimately to long-term adverse 
outcomes despite a favorable baseline metabolic and 
histological profile.(6,7) This hypothesis is supported by 
the higher serum BA levels and lower FGF19 levels in 
patients with significant fibrosis. Longitudinal studies 
would be needed to confirm the findings.
To investigate the therapeutic implications of our 
findings, we demonstrated that use of the apical 
sodium-dependent BA transporter inhibitor SC-435 
results in marked increases in fgf15 and a shift in BA 
and microbiota profiles as well as improved steatohep-
atitis in the lean model.
The strengths of our report include the study of 
a large, well-defined, biopsy-proven Caucasian cohort 
and as detailed an investigation as possible from 
cross-sectional data and complementary mouse stud-
ies. However, our study also has limitations. First, 
patients were seen in tertiary referral centers and may 
suffer from selection bias. In addition, dietary histories 
were not available given the accumulation of cohorts 
over several years, and the cross-sectional design did 
not allow for interventions or longitudinal outcomes; 
thus, a causal relationship cannot be demonstrated. 
Finally, our study is limited by the small sample size 
FIg. 7. Proposed model for the differential pathophysiology between patients who are lean and obese with NAFLD. Patients who were 
lean had better metabolic and liver histology profiles. Consistent with the notion that lean patients have appropriate metabolic adaptation 
to an obesogenic environment, they are obesity resistant. The compensatory mechanisms include increases in BAs and FXR activity and 
distinct gut microbiota profiles that explain the favorable profile despite steatosis development. Similar features were observed in murine 
models of lean and obese NAFLD.
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with regard to microbiome analysis. It would also be 
interesting in future studies to measure differences in 
fecal BAs.
In conclusion, in contrast to nonlean NAFLD, 
lean patients are likely to have a distinct pathophys-
iology. We suggest that the onset of disease occurs 
at a lower BMI set point (with lower measures of 
insulin resistance and dyslipidemia) and is shaped by 
the genetics background and early alterations in the 
BA and gut microbiota profile. These changes might 
reflect altered dietary composition (perhaps with an 
excess of dietary cholesterol, as reported in patients 
with lean NAFLD(12-14)), altered cholesterol metabo-
lism, limitations in adipocyte numbers in childhood, 
or differences in mucosal immunology. Secondary or 
concomitant alterations in gut microbiota composi-
tion also drive the phenotype to a greater extent than 
in patients with nonlean NAFLD. This hypothesis 
does not negate the possibility that there are patients 
who are overweight/obese with NAFLD with a simi-
lar pattern of compensatory mechanisms but suggests 
that lean patients have a preponderance of a gut- 
mediated phenotype (Fig. 7). Further studies are 
needed to investigate the contribution of early-stage 
adaptive mechanisms on the long-term hepatic and 
extrahepatic outcomes of this disease. Our hypoth-
esis would suggest that these individuals will have 
more severe and progressive liver disease, as has 
been suggested,(6,7) but this hypothesis needs further 
confirmation.
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) affects about 20-30% of the global population 
and increases the risk of hepatic and extra-hepatic complications including cardiovascular 
disease, diabetes and some types of cancer (Z. Younossi et al. 2018a).  While NAFLD is 
strongly associated with obesity, not all obese subjects will develop disease; conversely, a 
significant proportion of patients will have a normal body mass index (BMI) and are 
commonly referred to as having ‘lean NAFLD’ or NAFLD in a lean person.  
Definition  
Lean NAFLD is defined as disease that develops in subjects with a normal BMI based on 
ethnic-specific cut-offs of 25 kg/m2 in Caucasians and 23 kg/m2 in Asian patients. A 
limitation of this definition is that it relies solely on BMI, an imperfect index of body fat 
topography and fails to identify body fatness in nearly half of adults. Notably, visceral 
adiposity is more strongly implicated in the predisposition to NAFLD development 
irrespective of BMI. Similarly, there is a lack of incorporation of concepts surrounding 
metabolic health in the current definition with nearly a third of lean individuals likely being 
metabolically unhealthy (Figure 1).  
Prevalence 
Lean NAFLD prevalence ranges from 5 to 26%; 5% to 45% in Asians and 5-20% in 
European populations (Z. Younossi et al. 2018a) (Figure 2). In China, of 6,905 subjects 
with a BMI <25 kg/m2, 7.27% had ultrasonographic evidence of hepatic steatosis while in 
another study of 2,000 Chinese with BMI <24 kg/m2, 18% had NAFLD. In Hong Kong the 
prevalence of NAFLD based on proton-magnetic resonance spectroscopy (1HMRS) 
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spectroscopy was 19% in subjects with a BMI <25 kg/m2.  Other countries in Asia 
demonstrate a similar prevalence of BMI-based lean NAFLD (Japan: 15.2% in 3,271 non-
obese subjects; India (urban West Bengal): 5% in those with BMI<25 kg/m2 based on 
ultrasonography and subsequent CT validation; Korea: 12.6% in 29,994 health check non-
obese participants). In western populations, the Dallas Heart Study revealed a prevalence of 
hepatic steatosis by 1H-MRS that ranged from 11% in African Americans to 20% in 
Caucasians and 26% in Hispanics with a BMI <30 kg/m2. Similarly, a large study including 
subjects from Australia and Italy suggested that the prevalence of NAFLD was 20% in 
those of Caucasian descent with BMI <25 kg/m2(F. Chen et al. 2019). Data on the true 
population prevalence and ethnicity-based variations in lean NAFLD prevalence are still 
limited. 
Clinical, histological characteristics and outcome of lean NAFLD  
By definition, patients with lean NAFLD have a lower BMI but they also have a lower 
waist circumference and a more favourable metabolic profile with lower levels of 
dyslipidemia, diabetes, hypertension, glycemia and homeostasis model assessment insulin 
resistance index (HOMA-IRI) compared to their obese counterparts. In cross-sectional 
studies, lean patients also have less hepatic inflammation and fibrosis. Despite the 
favourable phenotype however (F. Chen et al. 2019; J. C. F. Leung et al. 2017b), lean 
patients with NAFLD may have a worse outcome and accelerated disease progression (A. 
C. Dela Cruz et al. 2014; Hagstrom et al. 2018), though one study in Chinese patients with 
shorter follow up (4 years) suggested that non-obese patients may have a better prognosis, 
though this was not significant (J. C. F. Leung et al. 2017b). As would be expected from 
the underlying metabolic abnormalities, lean NAFLD is associated with an increased risk 
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of incident diabetes and cardiovascular disease compared to those without NAFLD (Sinn et 
al. 2019).  
 
Pathophysiology 
The pathophysiological pathways underlying the development and progression of NAFLD 
in lean subjects are not entirely clear. However, emerging evidence indicates that lean 
NAFLD is a distinct entity shaped by the dynamic interaction of genetic predisposition, 
metabolic dysregulation, the gut microbiota and the enterohepatic circulation. Comparing 
lean and non-lean patients with NAFLD, the prevalence of the PNPLA3 (G) allele was 
reported to be higher in lean individuals in some but not others reports (Eslam et al. 2018b; 
Feldman et al. 2017a). An increased prevalence of the TM6SF2 (T) (F. Chen et al. 2019) 
and IFNL3/IFNL4 (C) allele among lean patients has also been demonstrated (Eslam et al. 
2015a; Petta et al. 2017a).   
Lean NAFLD patients tend to have a distinct metabolic and gut microbiota profile with 
higher concentrations of lysine that is implicated in visceral fat accumulation (Feldman et 
al. 2017a). In another study, patients were reported to have increased bile acids and FXR 
activity (measured by FGF15/19), implying that they have better metabolic adaptation and 
are perhaps relatively obese resistant. Notably, this adaptation attenuates with progression 
of disease (F. Chen et al. 2019) (Figure 3). Intriguingly, pilot data suggest that patients 
with lean NAFLD may have a distinct gut microbiota profile with enrichment of species 
implicated in the generation of liver fat (F. Chen et al. 2019).  
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Approach to management 
No specific guidelines exist for the management of lean, as opposed to non-lean NAFLD. 
The current recommendations of the American Association for the Study of Liver Disease 
and the European Association for the Study of the Liver recommends weight loss alone or 
accompanied by increased physical activity for all patients with NAFLD. Although weight 
loss might intuitively appear to be less beneficial in lean patients, there are demonstrable 
effects of lifestyle intervention even in this sub-group (V. W. S. Wong et al. 2018). High 
fructose and cholesterol intake has been reported in patients with lean NAFLD and it would 
seem appropriate to recommend reducing intake of these nutrients, while encouraging 
adoption of a Mediterranean-type diet. The latter also has beneficial effects on 
cardiovascular disease and visceral fat accumulation (Estruch et al. 2018). Similarly, 
emerging evidence indicates that exercise can reduce liver fat independent of weight loss 
(Johnson et al. 2009).  
Lean NAFLD patients are underrepresented in ongoing clinical trials; thus, the impact of 
current investigational agents on lean disease is unclear. Of interest, inhibition of ileal bile 
acid uptake led to resolution of steatohepatitis in a mouse model (F. Chen et al. 2019), 
while liraglutide, a glucagon-like peptide- 1 (GLP-1) analogue improved liver histology in 
lean patients (Ipsen et al. 2018). 
Conclusion 
A significant proportion of patients with NAFLD are lean, however this entity remains 
poorly characterized and understood. While these patients demonstrate distinct 
pathophysiological mechanisms culminating in similar liver histology to obese patients, 
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individuals with lean NAFLD remain at risk of developing hepatic and extra-hepatic 
complications. Targeted studies are required to further clarify lean NAFLD pathogenesis 
and to develop appropriate management approaches.  
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Figures and legends: 
 
Figure 1: Relationship between body mass index (BMI) and metabolic health status. 
Subjects who are obese by BMI criteria can be metabolically healthy, while a proportion of 
those who have a normal BMI are metabolically unhealthy. The term “metabolic health” 
refers to the metabolic health status of an individual and is a composite of a number of 
metabolic indicators. A metabolically healthy individual has a low risk of impending 
cardiometabolic disease. Metabolic health is related to, but not the same as, the absence of 
metabolic syndrome. Currently there are different subsets of variables that define 
“metabolic health”, with no universal consensus(Maclagan and Tu 2015).  
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Figure 2: Prevalence of NAFLD in lean patients in the published literature.  In these 
studies, BMI < 25 Kg/m2 was used as a cut-off for definition of leanness in most of the 
studies.  
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Figure 3: Metabolic adaptation in patients with NAFLD. Conceptually, the evolution of 
NAFLD in lean patients can be divided in three stages: 1. Subjects at high risk of NAFLD 
have increase susceptibility likely from genetic factors, the foetal microenvironment, 
dietary intake including its composition, changes in the epigenetic code during the 
intrauterine period and early life, as well as changes in gut microbiota; 2. in lean patients 
with NAFLD, there is a phase of adaptation through increasing bile acids, FXR activity and 
potentially other mechanisms; 3. with advancement of disease, individuals with lean 
NAFLD have a failure of metabolic adaptation brought about by the interaction of various 
and complex systemic processes. 
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Abstract 
Metabolic associated fatty liver disease (MAFLD) affects between 20-30% of the 
population in many countries; its incidence and prevalence have risen in parallel with rising 
rates of obesity and type 2 diabetes. MAFLD is a leading cause for end-stage liver disease, 
cancer and liver transplantation, as well as for death from associated extrahepatic 
consequences including cardiometabolic disease. However, there is growing evidence that 
not all obese individuals suffer from the metabolic consequences of obesity, including 
MAFLD. Conversely, not all lean people are metabolically healthy compared to their obese 
counterparts and a significant proportion develop fatty liver disease, referred to as lean 
MAFLD. The clinical characteristics, natural history and pathophysiology of this subgroup 
of patients is poorly characterised. In this review we describe the epidemiology and natural 
history of MAFLD and outline the concepts of metabolic health and metabolic adaptation 
that can be used as a framework to understand the development of MAFLD, including in 
lean people. It is hoped this will lead to a better understanding of the entity and result in 
improved methods for diagnosis and management. 
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Introduction 
 
The global rise in the prevalence of obesity and type 2 diabetes has been the impetus for 
the growth in non-communicable chronic diseases that places a considerable burden on 
health systems, both in developed and developing nations(Agbim et al. 2019). Worldwide, 
the prevalence of overweight and obesity has risen between 1980 to 2013 in both men 
(from 28.8% to 36.9%) and women (from 29.8% to 38.0%) and is continuing to rise at 
pandemic rates(Bluher 2019; Ng et al. 2014). Similarly, the prevalence of overweight and 
obesity in children and adolescents has increased in both developing (up to 12.9% in boys 
and 13.9% in girls) and developed countries (up to 23.8% in boys and 22.6% in girls)(Ng et 
al. 2014). Nearly a third of adults in the USA are obese (defined as having a body mass 
index (BMI) of more than 30 kg/m2)(Ng et al. 2014), while at least 50% of men in Tonga 
and women in Kuwait, Kiribati, Libya, Qatar and Samoa are overweight or obese (defined 
as having a BMI of more than 25 kg/m2 or 30kg/m2, respectively)(Ng et al. 2014).  
These increases are driven by a combination of excess energy intake relative to 
expenditure, nutritionally imbalanced diets, and a sedentary lifestyle with increased 
physical inactivity. The societal changes are an outcome of increased urbanisation, access 
to energy dense foods in rural and urban areas and increased availability of labour saving 
devices and technologies(Bluher 2019; Popkin 2006). A recent study estimated the 
prevalence of insufficient physical activity at around 23.3% in 2010(Hallal et al. 2012). 
Alarmingly, a more recent report on worldwide trends in physical inactivity between 2001-
2016 suggested that the prevalence of physical inactivity has not altered since 2001, with 
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the rate being twice as high in high income countries, and rising over time(Guthold et al. 
2018). 
One of the non-communicable diseases with well-described adverse clinical outcomes that 
has risen in parallel with obesity is metabolic associated fatty liver disease (MAFLD) 
(formerly known as NAFLD), which affects about 20-30% of the population(Eslam et al. 
2019; Sarin et al. 2020; Z. Younossi et al. 2018a). MAFLD is a leading cause for end-stage 
liver disease, cancer and liver transplantation, with an estimated 20 million likely to 
eventually die from liver disease(Bellentani 2017; Le et al. 2017; Z. Younossi et al. 2018b). 
Using Global Burden of Disease dataset, it has been shown that MAFLD is fastest growing 
global driver of cirrhosis and liver cancer(Paik et al. 2019). In addition, MAFLD represents 
a significant economic burden to society that reduces quality of life including through 
increased symptoms of fatigue and decreased mental well-being. This affects how well a 
person is able to function in their daily activities (Sayiner et al. 2016). In the United States, 
patients with MAFLD are reported to have higher annual health care expenditure ($19,390 
versus $5,567) with higher rates of unemployment (55% versus 30%) and disability related 
unemployment (30.5% versus 6.6%) compared to those without chronic liver disease. In 
Europe, MAFLD is estimated to have an annual cost of about €35billion (from €354 to 
€1,163 per patient; highest in patients aged 45-65) (Stepanova et al. 2017; Z. M. Younossi 
et al. 2016b). Although MAFLD and its subtype of NASH have been considered 
“asymptomatic” diseases, they are associated with significant impairment pf patient 
reported outcomes(Golabi et al. 2016). In fact, as NASH progresses this negative impact on 
PROs become even more pronounced(Huber et al. 2019; Z. M. Younossi et al. 2019b; Z. 
M. Younossi et al. 2019a). 
  
213 
MAFLD classically presents in close association with metabolic syndrome or one of its 
components, including obesity, hypertension, type 2 diabetes mellitus and dyslipidaemia. 
Some regard excess liver fat deposition as the hepatic manifestation of the metabolic 
syndrome (Chalasani et al. 2012; Z. M. Younossi et al. 2016a). Attesting to this link, a 
2016 meta-analysis of 21 cohort studies found obesity to be associated with a 3.5-fold 
increased risk of developing MAFLD, with a dose-dependent relationship to BMI(L. Li et 
al. 2016). Similarly, dual biopsy natural history studies indicate that incident type 2 
diabetes and hypertension are key factors linked to disease progression (McPherson et al. 
2015; Singh et al. 2015). In addition to high prevalence, increasing number of components 
of metabolic syndrome also increases the risk for mortality in MAFLD(Golabi et al. 2018). 
Finally, it is important to note that MAFLD is not only associated with adverse liver related 
outcomes (cirrhosis, HCC and liver mortality) but also extrahepatic manifestation such as 
CVD, extra-hepatic cancers, CKD, Osteoarthritis, obstructive sleep apnea, gallbladder 
disease and psoriasis(Z. M. Younossi 2019).  
Routine assessment of obesity has thus become part of clinical practice with several 
methods used for its assessment. They include anthropometric methods such as calculating 
the body mass index (BMI), waist/hip ratio (WHR), densitometry measurements and 
imaging (Han et al. 2006). BMI and WHR when done together and correctly, provide a 
rapid and inexpensive measure to estimate body fat and body fat distribution. However, 
there are inter-operator variations and the cut-offs for different ethnic backgrounds have 
not been fully defined (Han et al. 2006). Importantly, BMI, the single most frequently used 
measure of adiposity cannot adequately distinguish lean body mass from fat mass(Agbim et 
al. 2019). Densitometry measurements and imaging techniques on the other hand can be 
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used in small-scale studies and provides better information about lean body mass and 
visceral fat depot distribution. However, these techniques are expensive, time-consuming, 
involves exposure to radiation, and are not suitable for population level data gathering (Han 
et al. 2006).  
The outcome from many of the reported studies reveals a remarkable and less well-
understood paradox that not all obese patients (as defined by BMI) suffer from the 
metabolic disturbances related to obesity, including MAFLD. Conversely, not all lean 
people are metabolically healthy compared to their obese counterparts. The concept of 
“metabolically healthy obesity” present in up to 30% of all obese individuals refers to those 
with no evidence of metabolic or cardiovascular complications(Wildman et al. 2008). At 
the other end of the spectrum, 20% of the normal weight adult population are considered 
metabolically unhealthy with a higher risk for developing MAFLD and greater than a 3-
fold higher all-cause mortality and/or cardiovascular event rate compared to those who 
have normal weight and are metabolically healthy(Das and Chowdhury 2013; Stefan et al. 
2017; Z. M. Younossi et al. 2012). This subset of lean individuals with MAFLD is often 
referred to as lean MAFLD, or as MAFLD arising in lean individuals. Lean MAFLD is 
usually defined as fatty liver disease in people with a BMI less than 25 kg/m2 in reports 
from Caucasian populations and less than 23 kg/m2 in studies from Asia (D. Kim and Kim 
2017). The existence, pathogenesis and long-term outcomes of lean MAFLD are still 
debated due to inconsistencies in the literature, the heterogeneity of studies and the lack of 
generally accepted criteria for its definition(A. C. e. a. Dela Cruz 2014; Fracanzani et al. 
2011; D. Kim and Kim 2017; J. C. Leung et al. 2017a; Sookoian and Pirola 2017; Z. M. 
Younossi et al. 2012).  
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In this review, we describe the epidemiology and natural history of MAFLD and outline 
concepts of metabolic health and metabolic adaptation that can be used as a framework to 
understand the development of MAFLD, including disease in lean people. It is hoped that 
these concepts will lead to a better understanding of the entity and result in improved 
methods for diagnosis and management.  
Lean MAFLD  
Epidemiology 
The first population study describing lean MAFLD was conducted in Korea in 2004, where 
lean MAFLD was present in 23.4% of the non-obese population with associated metabolic 
disorders (H. J. Kim et al. 2004). Since then, lean MAFLD has been described in several 
Asian and Caucasian reports. (Figure 1 and Supplementary Table 1) These data indicate 
that there are patients with fatty liver who are lean by BMI criteria and secondly that 
disease prevalence is between 5 - 26% in Asian and 7 - 20% in Western populations 
(Younes and Bugianesi 2019). In one study, up to 75% of patients with MAFLD and 
significant liver disease prevalence was shown to have normal BMI in a rural Indian 
population (Das et al. 2010). However, owing to the lack of a widely accepted definition of 
“lean” across studies, as well as the heterogeneity in MAFLD diagnostic criteria, the 
current data suffers from many limitations.  
Histological characteristics 
The histological characteristics of MAFLD vary between ethnic groups irrespective of BMI 
classification.  A recent systematic review from cross sectional studies shows that liver 
fibrosis stage is significantly lower in lean compared to overweight/obese 
MAFLD(Sookoian and Pirola 2018). Similarly, the MAFLD activity scores and presence 
  
216 
of steatohepatitis are lower compared to overweight/obese patients, although there was 
substantial heterogeneity in the results (Sookoian and Pirola 2018). In contrast, some 
studies however have reported a more severe histological picture in lean patients with 
higher rates of advanced fibrosis, ballooning and lobular inflammation, as well as greater 
steatohepatitis compared to their non-lean counterparts (Denkmayr et al. 2018; Q. Wang et 
al. 2019).  
Genetic contribution  
Several gene loci are associated with the risk of MAFLD development and progression; 
some have been studied after stratification to lean versus non-lean. The most widely 
examined variant is the PNPLA3 isoleucine to methionine substitution at position 148 
(rs738409 C>G encoding for PNPLA3 I148M) that induces loss of function of the 
enzymatic hydrolase activity resulting in entrapment of triglycerides and retinyl esters in 
lipid droplets within hepatocytes and hepatic stellate cells. The polymorphism 
consequently leads to liver lipid retention and injury with the end result being fibrosis 
development and hepatocellular carcinoma (Eslam et al. 2018a; Eslam and George 2020; 
Liu et al. 2014a). The allele frequency of rs738409 C>G appears to be higher in Asian 
patients with lean- compared to obese MAFLD, although in a study of Western lean 
patients, no difference in the risk allele frequency was observed (Fracanzani et al. 2017; 
Wei et al. 2015). Nevertheless, many reports have demonstrated independent associations 
of the PNPLA3 risk allele with steatohepatitis development and higher stages of fibrosis 
(stage 2 or more) in lean patients (Fracanzani et al. 2017; Wei et al. 2015).  
Another variant strongly implicated with MAFLD is the rs58542926 C>T variant in the 
transmembrane 6 superfamily member 2 (TM6SF2) gene which encodes an amino acid 
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substitution (E167K) involved in the enrichment of triglycerides to apolipoprotein B100 in 
the pathway for very low density lipoprotein (VLDL) secretion by hepatocytes (Eslam et 
al. 2016b; Liu et al. 2014b). Carriers of the mutation have higher liver triglyceride content 
and lower circulating lipoproteins resulting in a greater risk for MAFLD but a lower risk of 
cardiovascular disease (Eslam et al. 2018a; Kahali et al. 2015). In a recent study, carriers of 
the risk variant had significantly more endotoxemia (Pang et al. 2017). A report comparing 
obese to lean MAFLD patients reported higher rates of carriage of the rs58542926 C>T 
allele in the latter(Fracanzani et al. 2017; Q. Wang et al. 2019). 
Recently, the membrane bound O-acyltransferase domain-containing 7 (MBOAT7) 
rs641738 C>T variant was found to be associated with the risk of MAFLD, inflammation 
and fibrosis, as well as risk of progression to hepatocellular carcinoma (HCC) (Thabet et al. 
2016; Thabet et al. 2017). This protein is involved in remodelling of phosphatidylinositol 
with arachidonic acid as part of the Land’s cycle. The rs641738 C>T variant results in 
downregulation of MBOAT7 at the mRNA and protein level, which reduces the level of 
phosphatidyl-inositol containing arachidonic acid in hepatocytes and in the 
circulation(Mancina et al. 2016). In a large study from Austria, there was no significant 
difference in carriage of the MBOAT7 rs641738 C>T allele between lean and obese 
MAFLD patients (Denkmayr et al. 2018). Finally, interferon (IFN) lambda 3/4 variants, 
initially described to be associated with severity of hepatitis and fibrosis progression in 
hepatitis C virus infection, has now been recognised to be associated with liver damage in 
patients with MAFLD, with more profound effect on lean individuals (Eslam et al. 2015b; 
Petta et al. 2017b). 
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Prognosis 
In contrast to studies that examine the prevalence and presentation of lean MAFLD, data 
on its long-term prognosis have been scarce and conflicting. Some reports suggest that 
clinical events and prognosis are worse in the obese compared to the lean MAFLD 
population, with higher cardiovascular events and death (Fracanzani et al. 2011; J. C. 
Leung et al. 2017a). One recent study with a median follow up of 49 months reported a 
clinical event rate of 11.9% in obese compared to 8.3% in the lean MAFLD population (J. 
C. Leung et al. 2017a).  However a study in 2014 by Delacruz et al. looking at the long-
term prognosis of lean patients with MAFLD and a median follow up of 11 years has 
challenged this finding (A. C. e. a. Dela Cruz 2014). This international cohort study 
included 483 patients with biopsy-proven disease and suggested that the median survival 
free of liver transplantation was in fact lower in those who were lean compared to obese. 
This occurred despite having a better metabolic profile and less advanced liver fibrosis (A. 
C. e. a. Dela Cruz 2014). This result was supported by another report of 646 Swedish 
patients with biopsy proven MAFLD and a median 19.9 years follow up where although 
patients with lean disease did not have increased mortality, they had an increased risk for 
the development and progression to severe liver disease compared to obese patients (hazard 
ratio 2.69, p = 0.007) (Hagstrom et al. 2018). 
While lean MAFLD reflects the hepatic manifestation of a metabolically unhealthy normal 
weight, studies involving other organ systems also indicate that individuals with a 
metabolically unhealthy phenotype may suffer a worse prognosis despite a normal BMI. 
Studies of diabetes mellitus in underweight or normal weight people suggest a distinct, 
albeit less well characterized pathophysiology to disease in the overweight/obese 
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population, with higher mortality rates(George et al. 2015). Similarly, metabolic health (as 
measured by the number of components of metabolic syndrome) has been shown to be a 
stronger predictor for myocardial dysfunction than simply BMI or fat mass alone (Dobson 
et al. 2016). 
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Explaining MAFLD pathogenesis in lean individuals: metabolic health 
and metabolic adaptation 
Metabolic health – not all fat is the same 
The most widely accepted definition of metabolic health is the absence of insulin 
resistance, no evidence of subclinical inflammation as determined by high sensitivity C-
reactive protein (CRP), together with only one component of the metabolic syndrome 
according to the Adult Treatment Panel III criteria (Table 1)(Lorenzo et al. 2007; Wildman 
et al. 2008).  
Table 1. Clinical parameters used for the diagnosis of metabolic health  
Systemic inflammation hs-CRP level < 0.1mg/L 
Insulin resistance HOMA-IR < 5.13 
Plus only one (or none) of the following components: 
Clinical parameter Criteria for metabolic abnormality 
Blood pressure Systolic/diastolic blood pressure ≥ 130/85 mmHg or anti-
hypertensive drug use 
Triglyceride level Fasting triglyceride level ≥ 150mg/dL (or ≥ 1.7 mmol/L) 
HDL-C level HDL-C level < 40mg/dL (or < 1.0 mmol/L) in men or < 
50mg/dL (or < 1.3 mmol/L) in women or use of lipid lowering 
medication 
Glucose level Fasting glucose level ≥ 100mg/dL (or ≥ 5.6 mmol/L) or use of 
anti-diabetic medication 
Metabolic health is defined as absence of systemic inflammation with only one (or none) 
other component of metabolic syndrome. Abbreviations: hs-CRP, high sensitivity C-
  
221 
reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic 
model of insulin resistance. 
 
Mechanisms for variation in metabolic health  
While it is not entirely clear as to the underlying mechanisms explaining individual 
variation in metabolic health, the term “adiposopathy” or defective/sick adipose tissue has 
been introduced. Adiposopathy governs an individual’s cardiometabolic risk, above and 
beyond BMI alone(H. E. Bays 2011) and refers to the pathogenic enlargement of fat cells 
and fat tissue, resulting in anatomic and functional disturbances leading to altered lipid 
metabolism, adipose inflammation and adverse clinical outcomes(H. E. Bays et al. 2008).  
However, given that adipose tissue is not a single, functionally uniform organ, it is not only 
how fat is stored (adipocyte proliferation versus adipocyte hypertrophy) that matters, but 
where the fat is stored (visceral versus subcutaneous, upper body versus lower body) and 
the type of fat (brown versus white). The ‘where’ and ‘type’ of adiposity has a greater 
impact on an individual’s metabolic health than total fat mass(Iacobini et al. 2019). Thus, 
visceral and subcutaneous adipose tissues differ with regards to their contribution to 
metabolic risk. Visceral adipose tissue (VAT) as well as ectopic fat in or around the liver, 
heart and skeletal muscle lipid content (intramyocellular) has been linked to impaired 
glucose homeostasis, insulin resistance and cardiovascular disease(Lim and Meigs 2013). 
Generally, subcutaneous adipose tissue (SAT) is believed to confer significantly lower 
metabolic risk.  However the distribution of SAT seems to matter with lower body SAT 
(gluteofemoral body fat) being characteristic of metabolically healthy individuals and aa 
lower risk for metabolic diseases (Goodpaster et al. 2005; Manolopoulos et al. 2010). In 
contrast, and upper body subcutaneous fat, the primary source of circulating free fatty acids 
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and hence an important determinant of insulin resistance and metabolic impairment. This 
has been demonstrated in several disease states associated with accumulation of upper body 
fat, including Cushing’s syndrome, lipodystrophy and human immunodeficiency virus 
associated lipodystrophy (Ebbert and Jensen 2013; J. J. Lee et al. 2017) (Figure 2). 
The adipocyte responds to positive energy balance through adipocyte hypertrophy as well 
as adipocyte hyperplasia (i.e. recruitment and proliferation of adipocyte precursors). 
Adipose tissue expandability and the increase in fat mass, especially SAT expansion, has 
been linked in previous studies to metabolic improvement and protection from type 2 
diabetes(J. Y. Kim et al. 2007; McLaughlin et al. 2011). Whereas SAT expansion protects 
from metabolic risk, expansion of VAT or limited expansion of SAT is strongly associated 
with insulin resistance due to its hyperlipolytic state that is resistant to the anabolic actions 
of insulin, thereby producing larger amounts of circulating free fatty acids(Despres and 
Lemieux 2006; O'Connell et al. 2010). Although both SAT and VAT sizes correlate with 
the degree of fatty liver, only VAT size is related to metabolic health and progression from 
hepatic steatosis to fibrosis(O'Connell et al. 2010). Previous studies have shown that 
surgical removal of abdominal SAT through liposuction does not improve insulin 
resistance in obese individuals, whereas transplantation of SAT into the abdominal cavity 
results in improved insulin sensitivity and glucose metabolism. This supports the notion 
that differences in metabolic health appear to be reflected by the “fitness” of SAT, while 
dysfunctional SAT (adiposopathy) is characteristic of the metabolically unhealthy state 
(Iacobini et al. 2019; Klein et al. 2004; Tran et al. 2008). 
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Factors that influence metabolic health (adiposopathy) 
Ethnic differences 
Racial/ethnic differences impact fat distribution and obesity and through this, metabolic 
health. For example, data from population datasets of the Framingham Heart Study (FHS) 
and the Jackson Heart study (JHS) as well as the National Health and Nutrition 
Examination Survey (NHANES) reveal that age-adjusted adult obesity prevalence is higher 
in Hispanics and non-Hispanic blacks compared to non-Hispanic whites and Asians(Agbim 
et al. 2019). Plasma adiponectin levels, an adipocytokine associated with cardiometabolic 
health is higher in non-Hispanic whites compared to non-Hispanic blacks and higher in 
women than men (Jiang et al. 2016).  
Correspondingly, studies of fat distribution between ethnic groups suggest that when total 
body fat is controlled, persons of South Asian and Chinese ancestry have more VAT than 
Europeans, with the impact of body weight gain more detrimental in Asians compared to 
non-Hispanic whites, Hispanics and non-Hispanic blacks. Each one unit increase in BMI is 
thus associated with a higher risk of hypertension and diabetes in Asians(Agbim et al. 
2019; R. J. Wong et al. 2014). As a result, the WHO has proposed a BMI cut-off as a 
trigger for public health action for Asians, with a BMI of ≥ 23 kg/m2 as increased risk, 
≥27.5 kg/m2 as high risk, ≥32.5 kg/m2 as higher than high risk and ≥37.4 kg/m2 as the 
highest risk, as they have higher body fat percentage at a lower BMI compared with non-
hispanic whites(WHO 2004). While the underlying mechanism(s) governing these ethnic 
differences remain unclear, the increased risk of cardiometabolic disorders seen in lower 
obesity prevalence ethnicities suggest that metabolic health plays a greater role than BMI 
alone, and might explain why lean MAFLD exists. 
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Environmental factors 
Lifestyle habits clearly contribute to the heterogeneity of metabolic health between 
individuals. Population based cross-sectional studies have also shown that metabolically 
healthy obesity is more prevalent in younger and female adults, and that these individuals 
are more likely to exercise and less likely to smoke or drink heavily (Goday et al. 2016; 
Matheson et al. 2012). The possible mechanisms governing this difference may lie in how 
individuals modulate whole body energy metabolism as evidenced by the fact that 
concurrent physical activity increases fatty acid oxidation during high calorie intake 
periods (S. R. Smith et al. 2000). In addition, a healthy diet and lifestyle is associated with 
a lower fasting respiratory quotient (which assesses nutrient utilization using indirect 
calorimetry by measuring the ratio between carbon dioxide production and oxygen 
consumption) and an increased ability to extract energy from fat (Pujia et al. 2016). Other 
lifestyle factors contributing to cardio metabolic health risk include sleep duration and 
sleep quality factors (Koren and Taveras 2018). A study in China for example found that 
patients with MAFLD had a shorter duration of sleep compared to healthy controls (C. Li 
et al. 2019). The most commonly used definition of a healthy lifestyle includes the 
incorporation of four healthy habits which include moderate alcohol intake, not smoking, 
30 minutes of daily exercise and eating five or more servings of vegetables and fruits a day 
(Matheson et al. 2012).   
In the first study on the lifestyle of patients with different types of MAFLD, total caloric 
intake as well as carbohydrate, protein, fat and iron intake was similar between lean and 
non-lean MAFLD patients compared to healthy controls (C. Li et al. 2019). Another study 
demonstrated that the percentage of carbohydrate energy intake is higher in lean MAFLD 
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patients compared to healthy controls (Kwak et al. 2018). This suggests that an unhealthy 
diet in those with lean MAFLD further contributes to their adverse metabolic health status. 
Genetic factors 
Considerable inter-individual variation exists with regards to the metabolic risk for a given 
BMI. Evidence for a role for genetics in determining how an individual responds to excess 
energy dates back over 25 years ago where a study involving 12 pairs of identical twins 
demonstrated variations in weight gain and fat distribution among the pairs in response to 
overfeeding(Bouchard et al. 1990). In that study, monozygotic young male twins were 
overfed a total of 84,000 kCal over 100-days. There were significant similarities within 
each pair with respect to weight gain, changes in regional fat distribution and amount of 
abdominal visceral fat, but about six times as much variance between pairs (Bouchard et al. 
1990) 
The waist hip ratio used as a surrogate measure of regional fat distribution is estimated to 
have a heritable contribution of up to 60%, independent of the risk for overall obesity 
(Schleinitz et al. 2014). In the era of genome wide association studies (GWAS), many loci 
have been identified that regulate obesity and control body fat distribution, as well as the 
metabolic profile of excess adiposity (i.e. metabolically healthy obesity versus 
metabolically unhealthy obesity)(Iacobini et al. 2019). As an example, a single nucleotide 
polymorphism (SNP) near the MC4R (melanocortin 4 receptor) gene that is involved in 
insulin resistance and obesity is one of the major loci associated with waist circumference 
(J. C. Chambers et al. 2008).  A meta-analysis of GWAS in 2010 uncovered 13 loci 
associated with WHR adjusted for BMI; the known association signal at LYPLAL1 
involved in lipase activity was confirmed, with effect sizes reaching 0.059 per risk allele in 
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women (Heid et al. 2010). Many of these loci are associated with metabolic traits such as 
fasting glucose, insulin, adiponectin levels and BMI, as well as with diseases such as type 2 
diabetes, hypertension and coronary artery disease(Kilpelainen et al. 2011; Schleinitz et al. 
2014). Equally, several gene variants have been associated with a lower risk of metabolic 
abnormalities despite having a BMI in the obese range(Yaghootkar et al. 2016). 
Interestingly, the same genetic variants seem to share similar patterns of metabolic trait 
association with the monogenic lipodystrophy phenotype, including lower BMI, higher 
VAT to SAT ratio, impaired insulin sensitivity and increased risk of type 2 diabetes 
(Iacobini et al. 2019; Yaghootkar et al. 2014). This suggests that unlike in specific altered 
fat distribution phenotypes like lipodystrophy where there is a clear genetic mutation 
involved, the common type of obesity and leanness is polygenic in nature and influences 
fat distribution (visceral versus subcutaneous) and metabolic traits, with individual variants 
having low effect sizes and with further modulation by factors such as epigenetic, 
environmental and biologic factors (Schleinitz et al. 2014).  
Although there have been no specific studies looking into the genetic variations in lean 
MAFLD patients, the studies above shed light into the heritability of adiposity and fat 
distribution, which may partly explain the underlying pathophysiology of lean MAFLD. 
Epigenetic factors  
Despite advances in genetic analyses to identify polymorphisms associated with waist hip 
ratio and fat distribution, the reported variants only explain a small proportion of the 
phenotypic variance and genetic heritability(Eslam et al. 2018a). Therefore, other factors 
linking genetic to environmental risks such as epigenetics need to be considered (Hardy 
and Mann 2016). Epigenetic changes link an individual’s genetic background with 
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environmental (exposure) cues and are dynamically regulated throughout an individual’s 
lifespan(Hardy and Mann 2016). Known epigenetic modifiers include DNA methylation, 
histone modifications and chromatin remodeling, and non-coding RNAs (Hardy and Mann 
2016).  
Strong adipose tissue-specific gene expression patterns in early development seem to be 
preserved from one pre-adipocyte to the next over several generations, suggesting the 
existence of yet unknown mechanisms to maintain these expression profiles over 
time(Schleinitz et al. 2014). Genome-wide methylation analysis using methylated DNA 
immunoprecipitation sequencing of eight different adipose depots in three pig breeds 
displaying different fat levels despite living in a comparable environment demonstrated 
functionally relevant methylation differences between different adipose depots. Visceral 
adipose tissue which carries the highest metabolic risk was associated with impaired 
inflammatory and immune responses(M. Li et al. 2012). Whether similar differences occur 
in humans is not yet known. 
Several human studies support a role for epigenetics in the regulation of fat distribution. 
The expression of leptin, an important adipokine involved in regulation of energy 
homeostasis primarily in adipocytes, is positively correlated to adiposity. The overall 
expression and tissue distribution of leptin is influenced to a degree by the DNA 
methylation pattern at the leptin promoter, which is determined during embryogenesis, and 
remains stable despite alterations in leptin expression levels in white adipose tissue during 
changes in body weight(Marchi et al. 2011). In another recent study, altered DNA 
methylation at the IGF2/H19 locus as a result of an adverse in-utero environment was 
associated with changes in subcutaneous fat measures, but not visceral or central 
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adiposity(Huang et al. 2012). This suggests an important role for epigenetics in 
determining fat distribution from very early life.  
Studies involving several species have demonstrated that oscillations in intrauterine and 
early postnatal nutritional, metabolic and hormonal environments increase the 
susceptibility to develop metabolic disorders and diseases in later life(Plagemann 2004). 
For example, maternal gestational diabetes and early postnatal overfeeding have been 
associated with fetal and neonatal hyperinsulinemia (Plagemann 2004). Furthermore, 
maternal nutrition during pregnancy contributes to perinatal programming of the genome 
which has an influence on fetal body composition and fat distribution, and ultimately the 
risk of obesity and metabolic diseases later in life(Blumfield et al. 2012). This ‘embryonic 
or fetal programming’ suggests that metabolic health and adiposopathy is trans-
generational (H. Bays and Scinta 2015).  
Overall the metabolic health of an individual plays a large part in the pathogenesis of 
MAFLD, is partly determined in the early stages of life, and remains stable throughout a 
life, despite variations in environmental stimuli. 
The world within – Gut microbiota, bile acids and the enterohepatic circulation 
Aside from calorie content, the nutrient composition of a person’s diet plays an important 
role in overall physiological responses including the gut microbiota profile, adiposity and 
insulin resistance. About 10-100 trillion micro-organisms composed of bacteria, fungi, 
archae and viruses reside inside or on the body. The majority of these microbial symbionts 
(collectively known as the microbiota) reside within the digestive tract (Turnbaugh et al. 
2007). Four main phyla of bacteria make up the human microbiome: Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria, although the Firmicutes and 
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Bacteroidetes make up about more than 90% of the gut microbiota species (Turnbaugh et 
al. 2007).  
Diet exerts a dominant effect on microbiota composition, irrespective of the host genotype 
(Carmody 2015). Studies have also shown that long-term dietary habits are strongly 
associated with specific enterotype clustering of microbiota, where a Bacteroides 
enterotype is associated with a diet rich in animal fat and protein and the Prevotella 
enterotype with carbohydrate rich diets (De Filippo et al. 2010; Wu et al. 2011). 
Furthermore, although alterations in diet can lead to changes in microbiota composition 
within 24 hours, an individual’s enterotype identity is only affected by their long-term 
dietary habits (Wu et al. 2011).  Common to all published studies in the literature on the 
role of microbiota in MAFLD and lean MAFLD, is that there are measurable differences in 
the microbiome diversity and composition between different stages of MAFLD and 
steatohepatitis compared to healthy controls (B. Wang et al. 2016; Wieland et al. 2015). 
In the gut, in addition to their roles in energy harvest of nutrients and regulation of mucosal 
permeability and inflammation, the microbiome also plays important roles in bile acid 
physiology, through the conversion of primary to secondary bile acids (Tremaroli and 
Backhed 2012). Bile acids (BA) are steroid molecules synthesized in the liver from 
cholesterol through the actions of about 15 enzymes. The primary bile acids 
chenodeoxycholate (CDCA) and cholate (CA) are synthesized from cholesterol, mostly 
through the classical pathway, initiated by the rate-limiting enzyme cytochrome P450 
cholesterol 7α-hydroxylase (CYP7A1)(Arab et al. 2017). A small proportion of the BA 
pool (between 3% to 18%) is synthesized through an alternative pathway initiated by 
cytochrome P450 27α-hydroxylase (CYP27A1)(Khalid et al. 2015). Primary BAs are then 
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conjugated into their taurine or glycine conjugates and excreted into bile where they assist 
in fat emulsification and absorption. Primary bile acids undergo conversion to the 
secondary bile acids deoxycholate (DCA), lithocolic acid (LCA) and ursodeoxycholic acid 
(UDCA) by intestinal bacteria and are mostly reabsorbed in the distal ileum via the 
enterohepatic circulation (Arab et al. 2017; Khalid et al. 2015). The conversion of primary 
to secondary bile acids requires an initial deconjugation by bile salt hydrolase (BSH) 
before downstream modifications by 7-alpha dehydroxylase to produce deoxycholic acid 
(DCA) and lithocholic acid (LCA) or by 7-alpha hydroxysteroid dehydrogenase to produce 
ursodeoxycholic acid (UDCA) (Jiao et al. 2017; Ridlon et al. 2006). BSH activity is present 
in all major gut bacterial species, however the conversion of primary to secondary bile 
acids by 7-dehydroxylation is restricted to bacteria with bile acid inducible genes. These 
include those belonging to the genera Clostridium (clusters XIVa and XI), Eubacterium, 
Blautia, Ruminococcaceae and Lachnospiraceae, all of which belong to the Firmicutes 
phylum (Wahlstrom et al. 2016a; Yokota et al. 2012).  
Alteration in the gut microbiota profile therefore, concert with an individual’s genetic 
make-up and dietary intake, contributes to the propensity to develop metabolic diseases 
including obesity and MAFLD through regulation of bile acid composition which 
eventually affects lipid and glucose metabolism (Dabke et al. 2019) (Figure 3). 
Besides their role in the digestion and absorption of fat and fat soluble vitamins, bile acids 
are signalling molecules involved in the regulation of lipid and glucose metabolism, as well 
as inflammatory modulators in the liver and several other tissues (Arab et al. 2017; 
Chavez-Talavera et al. 2017; Khalid et al. 2015). These actions are mediated through 
binding specific bile acid receptors, including members of the farsenoid X receptor (FXR), 
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pregnane X receptor (PXR), Vitamin D receptor and Takeda G protein coupled receptor 5 
(TGR5) families (Arab et al. 2017).  
The binding of bile acids to FXR in ileocytes trigger transcription and production of 
Fibroblast Growth Factor 19 (FGF-19), which is then transported to the liver where it binds 
to the tyrosine kinase FGF receptor 4 (FGFR4)/beta Klotho complex(Khalid et al. 2015). 
This activates c-Jun N terminal-kinases 1/2 signalling and subsequently down regulates 
CYP7A1 the key P450 enzyme in the classical bile acid synthesis pathway (Khalid et al. 
2015). FXR can be stimulated by most bile acids although at varying potency, with CDCA 
displaying the highest potency, followed by DCA and CA, then LCA (Khalid et al. 2015). 
In addition to regulating bile acid synthesis, FGF-19 plays a significant role in glucose and 
cholesterol homeostasis by promoting hepatic glycogen storage, fatty acid beta oxidation 
and decreasing hepatic lipogenesis, as well as playing a role in liver regeneration/ repair 
(Arab et al. 2017; Chavez-Talavera et al. 2017; Khalid et al. 2015). BA can also activate 
TGR5 receptors with different potencies (LCA>DCA>CDCA>CA) in the enteroendocrine 
L cells along the gastrointestinal tract (mostly in the colon) which subsequently induces 
preproglucagon gene expression and glucose like peptide-1 (GLP-1) secretion (Chavez-
Talavera et al. 2017). Both FXR and TGR5 are also expressed in pancreatic β-cells where 
they have positive effects on the synthesis and secretion of insulin, in response of glucose 
intake, suggesting a crucial role for BA in glucose homeostasis (Chavez-Talavera et al. 
2017). 
FXR and TGR5 receptors are also differentially expressed in adipocytes, FXR in white, 
and TGR5 in brown adipocytes, respectively, as well as in certain immune-inflammatory 
cells in adipose tissue(E. P. Broeders 2015). In adipocytes, FXR regulates the 
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differentiation and functions of adipocytes and promotes peroxisome proliferator-activated 
receptor-γ (PPARγ) activity which interferes with the Wnt/β-catenin pathway, while TGR5 
activates the thyroid hormone receptor to uncouple mitochondrial function and increase 
thermogenesis in brown adipose tissue, which further contributes to their anti-inflammatory 
and insulin-sensitizing effects (Abdelkarim et al. 2010; Watanabe et al. 2006). The 
enzymes involved in bile acid synthesis are controlled tightly in response to changing 
metabolic conditions and metabolic alterations, along with chronic low-grade 
inflammation, which are characteristics of meta-inflammatory disorders such as obesity, 
type 2 diabetes and MAFLD(Chavez-Talavera et al. 2017; Xie et al. 2015).  
Therefore, the interplay between an individual’s lifestyle factors, combined with their 
microbiota and bile acid profile, shaped in part by their dietary composition and genetic as 
well as epigenetic backgrounds, has a significant impact on an individual’s overall 
metabolic health. This in turn governs the risk for metabolic disorders, including MAFLD. 
Relationship between metabolic health and MAFLD  
Given that metabolic health status (defined as per Table 1) is an integral aspect of MAFLD 
pathophysiology, several studies have investigated the relationship between metabolic 
health and MAFLD. In these, the risk of developing steatohepatitis and significant fibrosis 
increases progressively as the number of metabolic risk factors increases(Ampuero et al. 
2018). Consistently, a cross-sectional study of more than 1,000 patients with biopsy proven 
MAFLD demonstrated that metabolic health has a greater impact on the risk of NASH 
development, significant fibrosis, atherogenic dyslipidaemia and kidney dysfunction than 
obesity or BMI alone(Ampuero et al. 2018). That study also found a similar risk for 
steatohepatitis and fibrosis in a metabolically unhealthy group, regardless of their body 
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weight, suggesting that metabolic health has a greater impact on the severity of liver 
disease than BMI, possibly through unfavourable body fat distribution (and/or as yet 
unknown factors) with a long but important period of subclinical systemic 
inflammation(Ampuero et al. 2018). Similar findings have been demonstrated in Asian and 
Mexican populations (Gutierrez-Grobe et al. 2017; M. K. Lee et al. 2015; Sung et al. 
2014).  
Despite these data, metabolically healthy obesity cannot be considered entirely benign as it 
carries almost double the risk of steatohepatitis compared to individuals who are 
metabolically healthy and normal weight(Sung et al. 2014). This implies that healthy 
obesity (acting through subclinical or as yet be discovered impacts on metabolic health) 
perhaps represents a “honeymoon phase” that in some individuals eventually progresses to 
a metabolically unhealthy obese state (Kramer et al. 2013). Conversely, the presence of 
MAFLD can promote (or at least be associated with) the conversion of an individual’s 
metabolic health from metabolically healthy to metabolically unhealthy, independent of 
age, sex, BMI, lifestyle factors, individual components of metabolic syndrome and insulin 
resistance. The effect is greater in those with a lower BMI and body fat mass compared to 
those with high BMI and body fat mass(Hwang et al. 2019). 
Metabolic adaptation 
The human body has great capacity to maintain body weight homeostasis through effects 
on food intake and energy expenditure. The ability of the body to increase or decrease 
energy expenditure beyond the obligatory energy costs of depositing and maintaining new 
tissues, digesting food, moving and maintaining body mass, without any change in body 
mass is defined as metabolic adaptation(Johannsen et al. 2019). Adaptation is achieved 
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through a fine balance of regulatory systems through the interaction of hormones, 
chemokine signals and the neuroendocrine axis (Johannsen et al. 2019). In response to 
certain nutrition and/or physical activity conditions, several cytokines or peptides secreted 
from muscles (myokines), adipose tissue (adipokines) and liver (hepatokines) engage in 
cross-talk to maintain energy homeostasis by governing lipid and glucose metabolism as 
well as by mediating local and systemic inflammation. Any perturbations in the systems 
involved results in loss of metabolic adaptation, resulting in abnormal expansion of adipose 
tissue and obesity, hepatic fat accumulation, and insulin resistance(Oh et al. 2016).  
In addition, the enterohepatic circulation including bile acids (BA) and their metabolites, as 
well as gut microbiota play important roles in metabolic adaptation which occurs in part 
due to genetic and developmental influences(Wahlstrom et al. 2016a). A number of early 
experiments involving protein overfeeding have shown large variations in weight gain 
among nonrelated subjects but high correlation within twin pairs(Bouchard et al. 1990). 
Further, studies have shown that the change in energy expenditure was due to a change in 
non-exercise activity thermogenesis(Diaz et al. 1992; Leibel et al. 1995). This concept of 
metabolic adaptation may explain why some individuals appear to be obesity resistant 
while others gain weight easily when challenged with caloric abundance.  
Impact of metabolic adaptation on lean MAFLD pathogenesis 
Given the complex and multifactorial pathogenesis of MAFLD(Buzzetti et al. 2016) and 
knowing that not all obese people have MAFLD and not all MAFLD patients are 
obese(Younes and Bugianesi 2019), how an individual adapts to an unfavorable set of 
metabolic circumstances will govern when he/she will manifest fatty liver disease. This 
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adaptive ability is the capability of the body to increase or decrease energy expenditure 
beyond obligatory energy requirements without any change in body mass.  
Thus, an individual may respond to increased dietary cholesterol or caloric intake with 
appropriate metabolic adaptation to maintain body weight, or they may have complete loss 
of metabolic adaptation, resulting in weight gain, with increased adiposity/adiposopathy 
and hepatic fat accumulation. In other individuals, increased caloric intake may only result 
in partial loss of metabolic adaptation, where the outcome is lean MAFLD. In this scenario, 
as outlined in Figure 4 as an example, increased dietary cholesterol in the context of 
perturbed metabolic adaptive capacity (shaped by their background genetic, epigenetic and 
gut microbiota profile), associates with some metabolic adaptation through increased 
production of bile acids, especially secondary bile acids and increased FXR activity to 
maintain body weight and serum cholesterol levels(F. Chen et al. 2019). This metabolic 
adaptation as reflected by higher FXR activity (measured through FGF-19 levels) and 
lower C4 levels (bile acid synthetic marker) may explain why these patients have better 
liver histology, at least in the earlier stages of their disease(F. Chen et al. 2019). 
Interestingly, with regard to nutrients, other studies have suggested that patients with lean 
MAFLD have higher dietary cholesterol and lower dietary polyunsaturated fatty acids 
(PUFAs are associated with lower hepatic TNFα and improved insulin resistance) intake 
compared to non-lean MAFLD patients and healthy controls(Enjoji et al. 2012; Yasutake et 
al. 2009a). Similar findings have been demonstrated in animal models where feeding a 
cholesterol rich diet results in steatohepatitis without obesity or insulin resistance(Kainuma 
et al. 2006). In addition, dietary cholesterol itself, rather than hepatic steatosis is associated 
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with the risk of progression to hepatic inflammation in murine models(Wouters et al. 
2008). 
BMI – A marker of maladaptation?   
Given that metabolic health and metabolic adaptive capacity have an impact on the risk for 
and the progression of MAFLD, equally BMI may be a less robust predictor of MAFLD 
outcomes. In this context, BMI is thus perhaps better considered a marker of 
maladaptation. Consideration in future therefore needs be given to classifying MAFLD 
based on metabolic health and adaptive responses rather than measures of BMI. How this is 
quantified remains an open question.  
Clinical implications and future directions – MAFLD is not a single 
disease entity 
In this review, we have presented data on the complex pathophysiology of MAFLD 
focusing mainly on lean MAFLD, a distinct subset with poor metabolic health but better 
metabolic adaptation. Therefore, lean and non-lean MAFLD represents one of the best 
examples of disease heterogeneity, and the wide spectrum of disease. An obvious 
implication is that future clinical trials should stratify patients into lean and non-lean, as the 
subgroups have a different underlying patho-biology and drivers, and likely differences in 
outcome. In addition, given the importance of metabolic health to MAFLD 
pathophysiology, classification of patients based on their metabolic health status warrants 
further attention. 
Conclusion 
Lean MAFLD presents as a unique phenotype of patients with fatty liver disease with 
distinct characteristics. Metabolic health status plays a major role in the development of 
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MAFLD and among lean individuals with the disease, their genetic, epigenetic, gut 
microbiota and bile acid profiles, enterohepatic circulation and lifestyle factors explain 
their phenotype despite a normal BMI. The distinct and better adaptation of lean patients 
allows them to respond to adverse metabolic inputs to maintain lean body weight despite an 
increase in cardiometabolic risk. Whether or not this partial metabolic adaptation is 
preserved in the long run and what triggers the switch to maladaptation with disease 
progression remains to be elucidated. 
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Figures and legends 
Figure 1. Worldwide prevalence of MAFLD and of lean MAFLD as a proportion of 
total MAFLD 
Worldwide distribution of MAFLD with data on the prevalence of lean MAFLD (light blue; 
where available). Abbreviation: MAFLD – Metabolic associated fatty liver disease. 
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Figure 2. Adiposity phenotype based on metabolic health status and body weight. 
The difference in fat depots, insulin sensitivity, inflammatory marker and hepatic fat content 
in individuals with metabolically healthy lean, metabolically unhealthy lean (lean MAFLD), 
metabolically healthy obese and metabolically unhealthy obese phenotypes. Abbreviations: 
SAT – Subcutaneous adipose tissue; VAT – Visceral adipose tissue; MAFLD – Metabolic 
associated fatty liver disease. 
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Figure 3. The interplay between factors affecting lean MAFLD pathogenesis. 
Environmental, genetic and epigenetic factors, along with the gut microbiota profile 
influence lean MAFLD pathogenesis through regulation of fat accumulation, 
inflammation and bile acid metabolism. Abbreviation: MAFLD – Metabolic 
associated fatty liver disease. 
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Figure 4. The role of metabolic adaptation in lean and obese MAFLD 
pathogenesis. 
Schematic representation of the differences in metabolic adaptation between 
individuals with lean and obese MAFLD on a background of metabolic and genetic 
predisposition. In obese MAFLD patients, there is relatively poor metabolic 
adaptation resulting in adiposity and the development of liver disease. In contrast, 
among lean MAFLD patients there is partial metabolic adaptation at least in the early 
stages of the disease. In the example shown, this is through increased bile acid 
production and FXR activity (other mechanisms may also be operative). This results 
in an “obesity resistant” phenotype”, which appears to be lost as the disease 
progresses. Abbreviations: MAFLD – Metabolic associated fatty liver disease; FXR – 
Farsenoid X receptor.         
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Supplementary Table 1. Summary of a selection of published literature on lean MAFLD 
Author, year, country Definition of lean MAFLD Sample size Main findings 
Kim, HJ, 2004, Korea (H. J. 
Kim et al. 2004) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound  
74 lean and 106 non-lean MAFLD; 
386 lean healthy and 202 non-lean 
healthy controls 
Metabolic disorders are present in MAFLD subjects 
with normal weight 
Chen, CH, 2006, Taiwan (C. 
H. Chen et al. 2006) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
61 lean and 291 non-lean MAFLD; 
1383 lean healthy and 654 non-lean 
healthy controls 
Hypertriglyceridaemia was related to MAFLD in 
non-obese subjects  
Das, K, 2010, India (Das et 
al. 2010) 
Lean BMI  < 25 kg/m2, hepatic 
steatosis on liver ultrasound, 
confirmed on CT 
123 lean and 41 non-lean MAFLD; 
1660 lean healthy and 87 non-lean 
healthy controls 
Lean MAFLD is present in 75% of this 
predominantly non-obese population, with 
potentially significant liver disease 
Younossi, 2012, USA (Z. M. 
Younossi et al. 2012) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
431 lean and 2061 non-lean 
MAFLD; 
4026 lean healthy and 5095 non-
lean healthy controls 
Lean MAFLD patients (20.9%) are younger, have 
lower metabolic syndrome and is more common in 
females 
Margariti, 2012, Greece 
(Margariti et al. 2012) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
19 lean and 143 non-lean MAFLD Lean MAFLD patients (12%) have lower metabolic 
syndrome and higher ALT/AST than non-lean 
MAFLD 
Bhat, 2013, India (Bhat et al. 
2013) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
30 lean and 120 non-lean MAFLD Lean MAFLD present in 20% of patients. Insulin 
resistance is common amongst patients with 
MAFLD, including lean MAFLD (80%) 
Kumar, 2013, India (Kumar 
et al. 2013) 
Lean BMI < 23 kg/m2, biopsy 
proven MAFLD 
27 lean and 141 non-lean MAFLD Lean MAFLD patients (13.2%) have less severe 
histology and lower insulin resistance than non-lean 
MAFLD 
Delacruz, 2014, Australia 
(A. C. e. a. Dela Cruz 2014) 
Lean BMI < 25 kg/m2, biopsy 
proven MAFLD 
125 lean and 965 non-lean MAFLD Lean MAFLD patients (11.5%) have higher mortality 
than patients with non-lean MAFLD despite 
presenting with healthier metabolic profile 
Alam, 2014, India (Alam et 
al. 2014) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound, 
biopsy in some (220/465) 
119 lean and 346 non-lean MAFLD Lean MAFLD patients (25.6%) were metabolically 
and histologically similar to non-lean MAFLD 
patients, with similar rates of NASH and fibrosis 
Feng, 2014, China (Feng et 
al. 2014) 
Lean BMI < 24 kg/m2, hepatic 
steatosis on liver ultrasound 
134 lean and 764 non-lean 
MAFLD; 
597 lean healthy and 284 non-lean 
healthy controls 
Lean MAFLD patients (14.9%) had higher visceral 
adiposity index and comparable metabolic risk 
profile to non-lean MAFLD  
Vendhan, 2014, India 
(Vendhan et al. 2014) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
48 lean and 125 non-lean MAFLD Lean MAFLD patients (27.7%) had better metabolic 
profile but similar association to coronary artery 
disease as non-lean MAFLD  
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Wei, 2015, Hong Kong (Wei 
et al. 2015) 
Lean BMI < 25 kg/m2, liver fat 
assessed by proton-magnetic 
resonance spectroscopy 
135 lean and 127 non-lean MAFLD Lean MAFLD patients (19.3%) had similar 
intrahepatic triglyceride content, but lower 
cytokeratin-18 fragments and liver fibrosis. PNPLA3 
G allele was more common in lean MAFLD. 
Nishioji, 2015, Japan 
(Nishioji et al. 2015) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
411 lean and 394 non-lean 
MAFLD; 
2285 lean healthy and 181 non-lean 
healthy controls 
Lifestyle and metabolic factors (higher triglycerides 
and waist circumference) increases the risk of 
MAFLD, even in lean patients (15.2%) 
Cho, 2016, Korea (Cho 
2016) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
213 lean and 347 non-lean 
MAFLD; 
1498 lean healthy controls 
Lean MAFLD patients (12.4%) had higher 
proportion of females, lower insulin resistance and 
fewer metabolic risk factors than non-lean MAFLD 
Feldman, 2017, Austria 
(Feldman et al. 2017b) 
Lean BMI < 25 kg/m2, hepatic 
steatosis on liver ultrasound 
55 lean and 61 non-lean MAFLD;  
71 lean healthy controls 
Lean MAFLD patients (29.4%) had impaired glucose 
tolerance, low adiponectin concentrations and a 
distinct metabolic profile with increased PNPLA3 
risk allele carriage 
Leung, 2017, Hong Kong (J. 
C. Leung et al. 2017a) 
Lean BMI < 25 kg/m2, biopsy-
proven MAFLD 
72 lean and 235 non-lean MAFLD Lean MAFLD patients (23.5%) had less severe 
disease and better prognosis than non-lean MAFLD. 
Hypertriglyceridaemia and high creatinine were 
associated with advanced liver disease in lean 
MAFLD 
Fracanzani, 2017, Italy 
(Fracanzani et al. 2017) 
Lean BMI < 25 kg/m2, biopsy-
proven MAFLD 
143 lean and 526 non-lean MAFLD Lean MAFLD patients (21.4%) had higher TM6SF2 
risk allele carriage and lower metabolic syndrome, 
less NASH and lower fibrosis but thinner carotid 
intima compared to non-lean MAFLD 
Sookoian, 2017, Argentina 
(Sookoian and Pirola 2018) 
Systematic review, lean BMI ≤ 
25 kg/m2 
493 lean and 2209 non-lean 
MAFLD 
Lean patients tended to have milder histological 
features compared to non-lean MAFLD 
Sookoian, 2017, Argentina 
(Sookoian and Pirola 2017) 
Systematic review with meta-
analysis, lean BMI ≤ 25 kg/m2, 
hepatic steatosis on liver 
ultrasound 
1966 lean and 5938 non-lean 
MAFLD; 9946 lean healthy and 
6027 obese healthy controls 
Lean MAFLD shared common altered metabolic and 
cardiovascular profile compared to non-lean 
MAFLD, although the effect is less severe in lean 
MAFLD 
Hagstorm, 2017, Sweden 
(Hagstrom et al. 2018) 
Lean BMI < 25 kg/m2, biopsy 
proven MAFLD 
123 lean, 335 overweight and 188 
obese MAFLD  
Lean MAFLD patients (19%) had lower fibrosis at 
better metabolic profile at baseline but increased risk 
of development of severe liver disease 
Denkmayr, 2018, Austria 
(Denkmayr et al. 2018) 
Lean BMI ≤ 25 kg/m2, biopsy 
proven MAFLD 
72 lean, 242 overweight and 150 
obese MAFLD 
Lean MAFLD patients (15.9%) had severe 
histological features similar to obese but more 
progressed than overweight MAFLD 
Tobari, 2018, Japan (Tobari 
et al. 2018) 
Lean BMI < 25 kg/m2, biopsy 
proven MAFLD 
116 lean, 173 overweight and 115 
obese MAFLD 
Advanced fibrosis was not associated with BMI but 
histological steatosis was more common in lean 
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MAFLD 
Li, 2019, China (C. Li et al. 
2019) 
Lean BMI < 24 kg/m2, hepatic 
steatosis on liver ultrasound 
84 lean and 85 non-lean MAFLD;  
90 lean healthy and 92 non-lean 
healthy controls 
Lean MAFLD patients had comparable total caloric, 
calorigenic nutrition, iron, sleep duration and 
overtime work as obese MAFLD 
Niriella, 2019, Srilanka 
(Niriella et al. 2019) 
Lean BMI < 23 kg/m2, hepatic 
steatosis on liver ultrasound 
120 lean and 816 non-lean 
MAFLD; 1206 healthy controls 
Lean MAFLD patients (4%) had similar risk of 
developing metabolic comorbidities compared to 
non-lean MAFLD, with higher MAFLD associated 
with PNPLA3 incidence 
Yilmaz, 2019, Turkey 
(Yilmaz et al. 2019) 
Lean BMI < 25 kg/m2, biopsy 
proven MAFLD 
30 lean and 428 non-lean MAFLD Lean MAFLD was present in 6.4% of the study 
sample, with metabolic syndrome present in 63% of 
the sample population 
Wang, 2019, China (Q. 
Wang et al. 2019) 
Lean BMI < 25 kg/m2, biopsy 
confirmed MAFLD 
36 lean and 48 non-lean MAFLD Lean MAFLD patients (42.9%) have a female 
predominance and more advanced fibrosis compared 
to non-lean MAFLD patients 
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9.2 SUPPLEMENTARY PROTOCOLS 
 
9.2.1 AMIDE protocol 
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Introduction 
AMIDE Method 
 
This method measures polar compounds by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) using electrospray ionization (ESI) in the negative ion mode. Positive mode can also be used. 
Analytes include amino acids, nucleotides, nucleosides, nucleotide triphosphates, high energy 
intermediates, organic acids, TCA cycle intermediates, bile acids and vitamins. 
 
Materials 
Chemicals: 
 
Methanol (MeOH) Thermo Fisher FSBA456-4 Methanol OPTIMA LC/MS grade– 4L 
Acetonitrile (ACN) Thermo Fisher FSBA955-4 Acetonitrile OPTIMA LC/MS grade– 4L 
Water Thermo Fisher FSBW6-4 Water OPTIMA LC/MS grade– 4L 
Ammonium Hydroxide Sigma 17837-100ml Fluka, puriss. p.a., ~98% 
Ammonium Acetate Sigma 73594-100G Fluka 
L-Phenylalanine-d8 (98%) CIL* DLM-372-1 Isotopically labeled internal standard 
Thymine-d4    
Inosine-15N4 Sigma  Isotopically labeled internal standard 
*CIL = Cambridge Isotope Laboratories, Inc. 
Equipment: 
 
Pipettors Eppendorf various Research plus 
Multitube vortexer Ratek VM1 Vortex mixer (By CPC) 
Centrifuge Thermo Fisher FRESCO 21 Centrifuge (By CPC) 
Agilent Vial Rack Agilent 5067-0243 Rack for 2 mL glass vials 
 
Consumable supplies: 
 
XBridge Amide column Waters 186004868 XBridge Amide 4.6 x 100mm, 3.5 µm 
Glass Vials Waters 186000273 Clear screw-top vial, 100 per pack 
Glass Vial Inserts Waters WAT072294DV 200 µL deactivated glass insert, 100 per pack 
Vial Caps Waters 186000274 Screw cap with bonded PTFE/silicone septa 
Pipet tips Eppendorf various Tips for Pipettes Research plus 
 
Reagent Preparation 
 
Amide Injection Solvent:  Acetonitrile:Methanol (75:25, v:v) 
1. Add 125 mL of methanol in a 500 mL glass bottle. 
2. Add 375 mL of acetonitrile. 
3. Store the solvent tightly-capped to prevent evaporation. 
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Mobile Phase A: (95:5 H2): Acetonitrile (v:v) with 20mM Ammonium Acetate and 20mM Ammonium Hydroxide 
1. Transfer 1.54g of ammonium acetate to 945 mL of HPLC grade water in a 1L glass bottle 
2. Add 7mL of HPLC grade 10% ammonium hydroxide 
3. Add 50mL of acetonitrile 
4. 4. Confirm pH = 9.0 with pH paper. Store at room temperature, tightly capped. Store for up to 2 weeks. 
 
Mobile phase B: 100% acetonitrile 
1. Add 1000mL of HPLC grade acetonitrile in a 1L glass bottle 
2. 2. Store at room temperature, tightly-capped. Store for up to 6 weeks. 
 
 
 
Stock Solution of Internal Standards:  (10 mM final concentrations) 
1. Weigh out 17.32 mg of isotopically labeled reference standard L-Phenylalanine-d8, 13.01 mg of thymine-d4 
and 12.52 mg of L-Valine-d8  in a 15 mL screw cap vial. 
2. Add 10 mL of methanol to yield a final concentration of 10 mM. 
3. Store at -20°C, tightly-capped to prevent evaporation. 
 
Amide IS-IS: Generic injection solvent with Amide Internal Standards: (10 mM of L-Phe-d8 stock, 10 mM of thymine-d4 
stock, 10 mM of L-Valine-d8  stock solution) 
1. For 500 mL: 
100 µL of 10 mM stock solution of 
Phenylalanine-d8, 100 µL of 10 mM thymine-d4, 
and 
100 µL of 10 mM Valine-d8 
fill bottle with 500 mL of Generic Injection Solvent. 
2. Store at -4°C, tightly-capped to prevent evaporation
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Standards Preparation for LC-MS/MS 
 
Standards: 
1. Add 30 µL of 500 µM analytical standard to 70 µL of Amide IS-SS solution for a final volume of 100 µL in a 
0.6 mL microfuge tube to yield a final concentration of 100 µM. 
2. Vortex the samples to mix both. 
3. Pipet 70 µL of sample into a glass vial with glass insert. Cap each vial tightly and store at 4°C (or 10°C in the 
autosampler stack). 
 
Sample preparation 
 
Extraction for Routine samples for negative mode: 
1. Transfer 20 uL of plasma into a 0.6mL microfuge tube, Add 80uL of amide IS-IS (cooled to -200C) 
for a final volume of 100uL. 
2. Vortex the samples to promote protein precipitation 
3. Centrifuge samples at 14000 rpm for 20 minutes at 4oC 
4. Transfer 75uL of supernatant into glass vial with inserts, taking care to avoid transferring protein 
pellet particles. Cap each vial tightly and store at -30oC (or 10oC in the autosampler stack) 
 
 
For plasma spiked with standards: 
 
1. Transfer each sample into a 0.6 mL microfuge tube. 
2. Add 20 µL of 500 µM analytical standard to 30 µL of plasma to a final volume of 50 µL. 
3. Vortex the samples to mix both. 
4. Pipet 30 µL of the mixture and add to 70 µL of Generic IS-IS solution for a final volume of 100 µL in  another 
0.6 mL microfuge tube. 
5. Vortex the samples to promote protein precipitation. 
6. Centrifuge samples at 14000 rpm for 20 min at 4°C. 
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7. Pipet 75 µL of sample into a glass vial with glass insert, taking care to avoid transferring protein pellet 
particles.  Cap each vial tightly and store at 4°C (or 10°C in the autosampler stack). 
 
Analysis 
 
Analyst 1.5.1 Acquisition Method Name: AMIDE_unsched_MRM.dam 
 
Autosampler settings: 
 
Autosampler: Agilent 1260 Infinity Standard Autosmapler 
Syringe: 50 µL 
Needle Rinse 1: 75:25 HPLC Water:Acetonitrile 
Needle Rinse 2: Acetonitrile 
Sample Stack Temperature 10°C 
 
Cycle Name:  
Delay Time Column 1: 0 sec 
Inject 2 Time: 1200 sec 
Delay Time Column 2: 0 sec 
Pre-clean with Solvent 2: 1 
Pre Inject Delay: 500 ms 
Post Inject Delay: 500 ms 
Column Sample Volume: 10 µL 
Filling Speed: 5 µL/sec 
Injection Speed: 10 µL/sec 
Post Clean with Solution 1: 2 
Post Clean with Solution 2: 2 
Valve Clean with Solution 1: 2 
Valve Clean with Solution 2: 2 
Replicate Count: 1 
 
HLPC settings 
HPLC: Agilent 1260 HPLC 
Guard column: XBridge BEH Amide Van Guard Catridge, 3.5µm, 
2.1x5mm Column: XBridge Amide, 3.5µm, 4.6 x 100mm 
Flow rate: 0.250 – 0.500 mL/min 
Column Sleeve: 25 cm column sleeve 
Column Temp: 30°C 
Injection Volume: 10 µL 
Run Time: 16 minutes 
Mobile Phase A: 95:5 H2O:Acetonitrile (v:v) with 20mM Ammonium Acetate and 
20mM Ammonium Hydroxide (pH 9.0) 
Mobile Phase B: Acetonitrile 
Needle Rinse 1: Water:Acetonitrile (75:25, 
v:v) Needle Rinse 2: Acetonitrile 
 
Step Total Time (min) Flow Rate 
(µL/min) 
% A % B 
0 0.0 250 15 85 
1 8.0 250 65 35 
2 9.0 250 98 2 
  263 
3 10.0 250 98 2 
4 11.0 250 15 85 
5 12.5 500 15 85 
6 15.0 500 15 85 
7 16.0 250 15 85 
 
Mass Spectrometer settings 
Mass Spectrometer: AB Sciex API-5500 QTrap triple quadrupole mass 
spectrometer Interface: Turboionspray, negative ionization mode 
Scan Mode: Scheduled multiple reaction monitoring 
(MRM) MRM Window: 30 sec 
Target Scan Time: 1.0 sec 
Source Temp: 450°C 
Ion Source position: Vertical: 1, 
Horizontal: 5 Parameters 
CAD Gas: High CUR Gas: 25 Ion 
Spray (v): 4500 
TEMP: 350 Gas 1: 33 Gas 2: 33 
Exit Potential (EP): -10 
Resolution Q1: Unit 
Resolution Q3: Unit 
 
Diverter Valve: 
Valve: Valco Diverter Valve 10 port 2 position 
LTG WC027522 (Applied Biosystems), or 
equivalent 
Valve Cable Assembly 2 position actuator, WC024740 
Position A: Flow to waste 
Position B: Flow to ion source 
 
Negative Ionization Mode 
  
Q1 
 
Q3 
QTRAP 
5500 (RT) 
 
Metabolites 
 
DP 
 
EP 
 
CE 
 
CX
 
KEGG 
Identifier 
 
1 
 
146.993 
 
100.9 
 
12.68 
2-hydroxy-2-methylbutyric acid 
(2H2MB) 
 
-55 
 
-10 
 
-20 
 
-13 
 
HMDB01987 
2 146.957 128.8 12.68 2-hydroxyglutarate (2-HG) -55 -10 -18 -7 C02630 
 
3 
 
128.646 
 
101 
 
4.80 
2-ketohexanoic acid (2- 
KH) 
 
-105 
 
-10 
 
-14 
 
-19 
 
C00902 
 
4 
 
910.09 
 
159 
 
12.93 
3-hydroxy-3-methylglutaryl 
coA (3H3MGcoA) 
 
-165 
 
-10 
 
-108 
 
-17 
 
C00356 
5 102.95 58.8 11.78 3-hydroxybutyrate (3-HB) -30 -10 -14 -7 C01089 
 
6 
 
184.885 
 
78.7 
 
13.02 
3-phosphoglycerate (3- 
PG) 
 
-125 
 
-10 
 
-56 
 
-39 
 
C00597 
 
7 
 
190.952 
 
146.8 
 
11.07 
5-hydroxyindoleacetic acid 
(5-HIAA) 
 
-35 
 
-10 
 
-18 
 
-21 
 
C05635 
8 425.576 78.6 13.02 ADP.1 -105 -10 -102 -29 C00008 
9 157.078 42 11.50 Allantoin -30 -10 -46 -7 C02350 
10 505.894 158.9 13.08 ATP.1 -115 -10 -44 -17 C00002 
11 505.894 78.9 13.08 ATP.2 -115 -10 -122 -9 C00002 
 
12 
 
465.163 
 
96.7 
 
3.59 
Cholesteryl sulfate 
(CholSO4) 
 
-220 
 
-10 
 
-94 
 
-31 
 
C18043 
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13 327.982 134.2 11.90 cAMP -60 -10 -46 -13 C00575 
14 407.275 343.4 11.00 Cholic acid -160 -10 -48 -19 C00695 
15 391.225 345.1 6.88 Deoxycholic acid (DCA) -150 -10 -48 -19 C04483 
16 116 74.3 13.10 Guanidoacetic acid (GAA) -25 -10 -16 -11 C00581 
 
17 
 
131.011 
 
84.9 
 
5.23 
Hydroxyisocaproic acid 
(HICA) 
 
-65 
 
-10 
 
-22 
 
-9 
 
HMDB00746 
18 134.971 91.8 11.14 Hypoxanthine -5 -10 -24 -11 C00262 
19 207.012 190 11.99 Kynurenine -50 -10 -12 -27 C00328 
20 132.932 114.9 12.78 Malate -50 -10 -18 -13 C00149 
21 130.005 88 11.75 N-Acetyl-L-Alanine -30 -10 -16 -15 C01073 
22 165.129 147.1 6.49 Phenyllactic -40 -10 -18 -11 C05607 
23 163.123 91.1 4.69 Phenylpyruvate -30 -10 -16 -1 C00166 
24 127.947 82.2 12.23 Pyroglutamic acid -40 -10 -22 -11 C01879 
25 242.949 42.1 11.06 Uridine -75 -10 -44 -9 C00299 
26 150.961 107.9 11.96 Xanthine -20 -10 -24 -5 C00385 
27 282.932 150.9 12.55 Xanthosine -75 -10 -28 -15 C01762 
28 203.939 159.8 11.75 Xanthurenic acid (XAN) -50 -10 -22 -19 C02470 
29 808.099 79.1 12.75 Acetyl-coA -135 -10 -130 -41 C00024 
30 345.905 78.8 12.78 AMP.1 -85 -10 -84 -21 C00020 
31 345.905 134.2 12.78 AMP.2 -85 -10 -50 -13 C00020 
32 242.991 42.2 11.85 Biotin -50 -10 -56 -7 C00120 
33 267.022 135.1 11.96 Inosine -40 -10 -36 -21 C00294 
34 204.819 170.8 6.70 Lipoate -30 -10 -16 -35 C00725 
35 174.999 131.8 13.12 N-carbomyl-aspartate -45 -10 -18 -7 C00438 
36 449.201 434.2 4.07 Phytonadione -30 -10 -42 -25 C02059 
37 283.094 182.9 3.78 Tropisetron (Drug) -135 -10 -44 -29 D02130 
38 88.83 42.94 11.64 Lactate -34 -10 -17 -11 C00186 
 
39 
 
175.055 
 
114.9 
 
12.60 
2-isopropylmalic acid (2- 
IPM) 
 
-65 
 
-10 
 
-20 
 
-13 
 
C02504 
 
40 
 
99 
 
71 
 
6.89 
2-methylacetoacetate (2- 
MAA) 
 
-30 
 
-10 
 
-16 
 
-19 
 
HMDB03771 
41 100.963 57.1 6.90 2-oxobutanoate (2-OB) -60 -10 -12 -9 C00109 
 
42 
 
150.99 
 
106.9 
 
11.04 
4-hydroxyphenylacetic 
acid (4-HPA) 
 
-20 
 
-10 
 
-14 
 
-17 
 
C00642 
43 138.881 78.7 6.30 Acetylphosphate (ACP) -5 -10 -34 -9 C00227 
44 425.576 134 13.02 ADP.2 -105 -10 -34 -13 C00008 
45 128.959 85 12.50 Citraconic acid -5 -10 -16 -11 C02226 
 
46 
 
611.072 
 
306.1 
 
13.08 
Glutathione oxidized (GSSG)  
-85 
 
-10 
 
-36 
 
-17 
 
C00127 
47 167.044 123.1 6.57 Homogentisate -40 -10 -18 -13 C00544 
48 852.062 78.9 12.92 Malonyl-coA -135 -10 -128 -9 C00083 
49 147.187 59.1 11.55 Mevaloate (MEV) -40 -10 -20 -9 C00418 
50 121.652 78.1 11.18 Nicotinate -55 -10 -18 -9 C00253 
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51 
 
176.892 
 
78.9 
14.32 (wider 
MRM-60s) 
 
Pyrophosphate 
 
-35 
 
-10 
 
-46 
 
-9 
 
C00013 
 
52 
 
87 
 
43 
7.90 (wider 
MRM-60s) 
 
Pyruvate 
 
-25 
 
-10 
 
-16 
 
-11 
 
C00022 
53 177.038 128.8 9.15 D-Glucolactone -50 -10 -14 -33 C00198 
54 440.076 174.8 12.75 Folate -95 -10 -50 -11 C00504 
55 130.996 87.9 12.61 Ureidopropionic acid -40 -10 -14 -11 C02642 
 
56 
 
114.985 
 
70.9 
 
7.06 
3-methyl-2-oxobutyrate 
(3M2OB) 
 
-40 
 
-10 
 
-14 
 
-9 
 
C00141 
57 159.059 59.1 12.63 2-oxodipate (2-OD) -30 -10 -20 -5 C00322 
 
58 
 
223.023 
 
206 
 
5.94 
3-hydroxykynurenine (3- 
HK) 
 
-35 
 
-10 
 
-14 
 
-13 
 
C02794 
59 172.821 128.9 13.00 Aconitate -15 -10 -12 -19 C00417 
60 160.002 116.1 12.97 Aminoadipidic acid (AAD) -60 -10 -20 -7 C00956 
61 174.999 115 12.74 Ascorbic acid -50 -10 -18 -7 C00072 
62 343.982 149.9 12.47 cGMP -75 -10 -34 -27 C00942 
 
63 
 
212.933 
 
79 
 
12.88 
Deoxyribose-phosphate (DRP)  
-115 
 
-10 
 
-58 
 
-9 
 
C00672 
64 338.925 78.8 13.19 Fruc-1,6-bP -55 -10 -92 -9 C00354 
65 259.089 78.7 13.14 Fruc-6-P -65 -10 -84 -11 C00085 
 
66 
 
305.92 
 
142.8 
 
12.70 
Glutathione reduced 
ss(GSSH) 
 
-55 
 
-10 
 
-30 
 
-19 
 
C00051 
67 89 59 6.98 D/L-Glyceraldehyde -25 -10 -10 -5 C02426/C00577 
68 181.944 79.8 12.80 Homocysteic acid (HCA) -70 -10 -38 -13 C16511 
69 190.913 72.9 13.04 Isocitrate -35 -10 -36 -35 C00311 
70 187.975 144 8.30 Kynurenic acid -105 -10 -24 -15 C01717 
71 114.531 70.982 13.15 Fumarate -22 -10 -13 -10 C00122 
72 154.936 111 7.04 Orotate -25 -10 -16 -13 C00295 
 
73 
 
135.974 
 
92.2 
 
5.51 
p-aminobenzoic acid (p- 
AB) 
 
-80 
 
-10 
 
-16 
 
-11 
 
C00568 
 
74 
 
167.047 
 
79 
 
13.03 
Phosphoenolpyruvate 
(PEP) 
 
-10 
 
-10 
 
-46 
 
-13 
 
C00074 
75 274.797 257.1 13.13 Saccharopine -40 -10 -22 -19 C00449 
 
76 
 
383.063 
 
133.9 
 
13.07 
S-adenosyl-L- 
homocysteine 
 
-40 
 
-10 
 
-40 
 
-21 
 
C00021 
77 866.034 158.6 12.89 Suc-coA -180 -10 -90 -27 C00091 
78 124 80 12.61 Taurine -50 -10 -22 -55 C00245 
 
79 
 
497.727 
 
79.8 
 
6.90 
Taurodeoxycholic acid 
(TDCA) 
 
-280 
 
-10 
 
-108 
 
-25 
 
C05463 
 
80 
 
423.946 
 
78.9 
 
13.26 
Thiamine pyrophosphate 
(TPP) 
 
-50 
 
-10 
 
-80 
 
-9 
 
C00068 
81 241.037 42.1 8.10 Thymidine -80 -10 -60 -11 C00214 
82 111.05 42.1 8.24 Uracil -35 -10 -24 -11 C00106 
 
 
83 
 
 
182.983 
 
 
149.9 
 
 
6.94 
3-methoxy-4- 
hydroxyphenylglycol 
(3M4HPG) 
 
 
-50 
 
 
-10 
 
 
-20 
 
 
-25 
 
 
C05594 
84 135.913 91.8 5.21 Anthranilic acid (AA) -50 -10 -22 -27 C00108 
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85 289.046 271 13.20 Arginosuccinate -75 -10 -18 -19 C03406 
 
86 
 
198.852 
 
79.1 
 
13.04 
Erythrose 4-phosphate 
(E4P.1) 
 
-50 
 
-10 
 
-62 
 
-13 
 
C00279 
87 198.852 97 13.04 E4P.2 -50 -10 -16 -3 C00279 
 
88 
 
168.879 
 
78.9 
 
12.87 
Glyceraldehyde 3- 
phosphate (G3P) 
 
-5 
 
-10 
 
-40 
 
-15 
 
C00118 
89 273.993 130.8 12.82 Glutarylcarnitine (C5-DC) -30 -10 -18 -15 HMDB13130 
90 102.945 59 12.77 Malonate -15 -10 -14 -15 C00383 
91 120.712 42.2 7.18 Niacinamide -30 -10 -70 -9 C00153 
92 130.974 86.9 12.72 Oxaloacetate -40 -10 -16 -13 C00036 
93 224.988 162.8 12.72 Prephenate -40 -10 -12 -9 C00254 
94 300.924 151 6.82 Quercetin -80 -10 -34 -25 C00389 
 
 
95 
 
 
454.988 
 
 
79.1 
 
 
12.77 
Riboflavin 5'- 
monophosphate (R5'MP.1) 
 
 
-90 
 
 
-10 
 
 
-106 
 
 
-9 
 
 
C00061 
96 454.988 96.8 12.76 R5'MP.2 -90 -10 -46 -15 C00061 
 
97 
 
605.994 
 
78.7 
 
12.89 
UDP-N-acetyl- 
glucosamine 
 
-140 
 
-10 
 
-128 
 
-9 
 
C00043 
 
98 
 
402.972 
 
79 
 
13.06 
Uridine 5'-diphosphate 
(U5'dP) 
 
-100 
 
-10 
 
-30 
 
-15 
 
C00015 
99 123.78 76.9 13.03 Val-d8 -85 -10 -18 -13  
100 172.075 154.2 12.55 Phe-d8 -130 -10 -20 -9  
101 129.026 42.1 7.95 Thymine-d4 -100 -10 -30 -15  
102 258.988 78.9 13.32 Glucose-6-phosphate -75 -10 -80 -9 C00092 
103 116.72 72.98 13.43 Succinate -24 -10 -17 -10 C00042 
 
104 
 
230.9 
 
80 
 
6.48 
CSA (Camphor-10- 
sulfonic acid) 
 
-170 
 
-10 
 
-40 
 
-13 
 
 
105 
 
664.42 
158.893 
(514, 649) 
 
13.17 
 
NADH 
 
-110 
 
-10 
 
-69 
 
-16 
 
C00004 
106 179.037 32 13.56 Glucose -45 -10 -26 -15 C00031 
 
107 
 
663.606 
78.9(158.9, 
540.4) 
 
13.19 
 
NAD 
 
-70 
 
-10 
 
-124 
 
-11 
 
C00003 
108 743.939 158.919 13.39 NADPH -88 -10 -77 -15 C00005 
109 743.293 621.079 13.52 NADP.1 -72 -10 -27 -28 C00006 
110 743.293 158.895 13.52 NADP.2 -72 -10 -55 -22 C00006 
111 190.843 110.970 12.89 Citrate -50 -10 -19 -12  
112 152.016 107.900 7.20 3-hydroxyanthralinic acid -85 -10 -20 -11  
 
**FROM JOHN (We use HILIC method for +ve Ionization) 
Ionization Q1 Q3 RT eV Metabolite name KEGG 
 
mode 
 
Precursor 
 
Product 
Retention 
time 
Collision 
energy 
 
gray boxes are isobaric 
 
Identifier 
+ 61.1 44.2  25 Urea C00086 
+ 62.1 44.2  12 ethanolamine C00189 
+ 69 42.24  23 Imidazole C01589 
+ 76 48  10 glycine_HILIC  
+ 76.1 30.5  18 glycine C00037 
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+ 76.1 42  50 trimethylamine-N-oxide  
+ 78 61  20 cysteamine  
+ 89 72  12 putrescine C00134 
+ 90.01 72  13 beta-alanine  
+ 90.04 44.1  20 sarcosine C00213 
+ 90.1 44.2  13 alanine C00041 
+ 93 57  12 glycerol  
+ 102 58  21 betaine aldehyde C00576 
+ 104 60  21 choline C00114 
+ 104.1 60  27 choline_HILIC  
+ 104.01 69  22 4-aminobutyrate C00334 
+ 104.02 58  21 dimethylglycine C01026 
+ 104.1 87  17 GABA  
+ 104.1 86  16 aminoisobutyric acid  
+ 106 60  15 serine C00065 
+ 112 95  26 histamine  
+ 112.1 95  19 cytosine C00380 
+ 114 44.2  19 Creatinine C00791 
+ 116.1 70.1  13 proline C00148 
+ 118 91  26 indole C16074 
+ 118.02 58  36 betaine C00719 
+ 118.1 55.2  13 valine C00183 
+ 118.1 72  18 valine_HILIC  
+ 118.1 58  41 betaine  
+ 119.1 87  8 methyl-hydroxyisobutyric acid  
+ 120 74  13 threonine C00188 
+ 120.15 44.2  32 homoserine C00263 
+ 121 94  25 purine C00465 
+ 122.1 59.1  29 cysteine C00491 
+ 123 80  30 niacinamide  
+ 123.1 80  22 nicotinamide C00153 
+ 126.1 68.1  29 1-methylhistamine  
+ 126.2 44.1  31 taurine  
+ 127.002 81  15 Imidazoleacetic acid C05828 
+ 127.1 110  19 thymine C00178 
+ 130 84  18 DL-Pipecolic acid C00408 
+ 131.001 114  12 N-Acetylputrescine C02714 
+ 132.004 68.2  19 hydroxyproline C01157 
+ 132.1 86  13 leucine-isoleucine C00123 
+ 132.1 90  17 creatine  
+ 132.1 86.2  18 cis/trans hydroxyproline  
+ 133 70  14 ornithine C00077 
+ 133.4 70  30 ornithine_HILIC  
+ 133.1 74  19 asparagine C00152 
+ 133.1 115  12 N-carbomoyl-beta-alanine  
+ 134 74  17 aspartate C00049 
+ 136 119  26 adenine C00147 
+ 136 90  20 homocysteine  
+ 136.02 119.02  12 Methylcysteine C00155 
+ 136.12 90.1  17 homocysteine C00155 
+ 137.001 94  20 methylnicotinamide C02918 
+ 138 120  18 anthranilic acid  
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+ 142 44  22 phosphoethanolamine  
+ 142.1 95  20 histidinol C00860 
+ 146 112  15 spermidine C00315 
+ 146.1 87  21 acetylcholine  
+ 146.2 72  22 spermidine  
+ 147 67  32 lysine C00047 
+ 147.1 84  25 lysine_HILIC  
+ 147.1 84.1  17 glutamine C00064 
+ 148 106  14 O-acetyl-L-serine C00979 
+ 148.1 84.1  17 glutamate C00025 
+ 150.1 133  12 methionine C00073 
+ 150.1 61  31 methionine_HILIC  
+ 152.2 110  20 guanine C00242 
+ 153 135  9 xanthine  
+ 153 108  16 cystamine  
+ 154 136.2  18 3-hydroxyanthranilic acid  
+ 156.1 110.1  14 histidine C00135 
+ 159 116  11 allantoin  
+ 160 55.3  21 2-Aminooctanoic acid HMDB00991 
+ 162.1 103  20 carnitine C00318 
+ 162.1 85  29 carnitine-HILIC  
+ 163.1 85  29 glucose  
+ 166 74  14 Methionine sulfoxide HMDB02005 
+ 166.1 103  30 phenylalanine C00079 
+ 166.1 120.2  19 phenylalanine_HILIC  
+ 169 134  25 Pyridoxamine C00534 
+ 170 134  24 pyridoxine C00314 
+ 170.1 124  20 1-Methyl-Histidine C01152 
+ 174.2 128  19 phenylalanine-d8  
+ 175 115.1  16 N-acetyl-L-ornithine C00437 
+ 175.02 60  16 arginine C00062 
+ 175.1 70  32 arginine_HILIC  
+ 176 159  14 citrulline C00327 
+ 176 113.2  20 citrulline_HILIC  
+ 177.05 74  19 N-carbamoyl-L-aspartate C00438 
+ 177.1 80  34 cotinine  
+ 177.1 160  18 serotonin  
+ 180 162  12 glucosamine C00329 
+ 182.1 77  39 tyrosine C00082 
+ 182.5 136.1  19 tyrosine_HILIC  
+ 184.001 125  23 Phosphorylcholine C00588 
+ 186 88  12 3-phospho-serine C01005 
+ 189.001 84.2  26 N6-Acetyl-L-lysine C02727 
+ 189.002 84  23 Acetyllysine C02727 
+ 189.1 130  17 N-acetyl-glutamine HMDB06029 
+ 189.1 70  40 NMMA  
+ 190.1 84.1  24 N-acetyl-glutamate C00624 
+ 190.2 144  29 kynurenic acid  
+ 192.3 146.2  18 5-HIAA  
+ 202.1 129.1  19 spermine C00750 
+ 203.2 129.3  20 spermine_HILIC  
+ 203 70  24 Ng,NG-dimethyl-L-arginine C03626 
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+ 203.1 70.3  40 ADMA/SDMA  
+ 204 85  19 Acetylcarnitine DL C02571 
+ 204.4 85.1  28 C2-carnitine  
+ 205 146  18 tryptophan C00078 
+ 205.5 188.3  16 tryptophan_HILIC  
+ 206 160  30 xanthurenate  
+ 209 146  25 Kynurenine C00328 
+ 218.4 85.1  28 C3-carnitine  
+ 221.1 204  18 5-hydroxytryptophan  
+ 222 138  18 N-acetyl-glucosamine C00140 
+ 223 121  29 Flavone C15608 
+ 223 134  13 cystathionine C00542 
+ 225 208  30 3-hydroxy kynurenine  
+ 227.1 110  33 carnosine  
+ 228.1 112.1  15 2'-deoxycytidine  
+ 231 216  27 Visnagin  
+ 232.003 90  14 creatine C00300 
+ 232.4 85.1  28 C4-butyryl-carnitines  
+ 234.2 113.2  33 carnosine-d7  
+ 235 176  22 5-methoxytryptophan HMDB02339 
+ 241.002 74  32 Cystine C00491 
+ 241.1 109.1  33 anserine  
+ 243.1 127  16 thymidine  
+ 244.1 112  14 cytidine C00475 
+ 245.1 227  20 biotin C00120 
+ 245.2 113.1  17 uridine  
+ 246.5 85.1  27 C5-valeryl-carnitines  
+ 248.4 85.1  28 C3-malonyl-carnitine  
+ 252 136  22 deoxyadenosine C00559 
+ 258.1 104  16 Glycerophosphocholine C00670 
+ 259 110  24 acadesine D02742 
+ 260 126  17 D-glucosamine-6-phosphate C00352 
+ 260.1 162.1  17 D-glucosamine-1-phosphate C03783 
+ 260.5 85.1  27 C6-carnitine  
+ 262.4 85.1  28 C4-methylmalonyl-carnitine  
+ 265 122  19 thiamine C00378 
+ 267.2 190.3  27 atenolol  
+ 268 88  31 S-ribosyl-L-homocysteine_pos C03539 
+ 268.1 152  17 deoxyguanosine C00212 
+ 268.15 136.1  29 adenosine C00212 
+ 268.2 116.3  30 metoprolol  
+ 274.5 85.1  27 C7-carnitine  
+ 276.5 85.1  27 C5-glutaryl-carnitine  
+ 281.8 150  27 1-Methyladenosine C02494 
+ 284.1 135  35 guanosine C00387 
+ 285.1 153  18 xanthosine  
+ 288.5 85.1  27 C8-carnitine  
+ 291 70  37 L-arginino-succinate C03406 
+ 291.1 70  54 arginosuccinate_HILIC  
+ 298 136  29 S-methyl-5-thioadenosine C00170 
+ 298.002 166  24 7-methylguanosine HMDB01107 
+ 302.5 85.1  27 C9-carnitine  
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+ 308 112  18 dCMP C00239 
+ 308.1 162  21 glutathione C00051 
+ 309.2 251  20 Warfarin  
+ 316.6 85.1  27 C10-carnitine  
+ 323 81  19 dTMP C00364 
+ 324 112  18 CMP C00055 
+ 325 97  14 UMP C00105 
+ 330.3 136.2  30 cAMP  
+ 332.1 136  23 dAMP C00360 
+ 335 123  30 Nicotinamide ribotide C00455 
+ 339 110  32 C9H15N4O8P  
+ 344.6 85.1  31 C12-carnitine  
+ 345.2 122  15 thiamine-phosphate C01081 
+ 348.1 135  38 dGMP C00362 
+ 348.15 136  23 AMP C00020 
+ 348.2 62.3  37 anandamide  
+ 349 137  21 IMP C00130 
+ 355 250  20 S-adenosyl-L-methioninamine C01137 
+ 357.9 139  20 Indomethacin  
+ 364 152  21 GMP C06193 
+ 365 97  13 xanthosine-5-phosphate C00655 
+ 372.7 85.1  31 C14-carnitine  
+ 377 243  26 riboflavin C00255 
+ 385.1 136  21 S-adenosyl-L-homoCysteine_pos C00021 
+ 399.1 250  15 S-adenosyl-L-methionine C00019 
+ 400.7 85.1  35 C16-carnitine  
+ 406.2 84  60 lisinopril  
+ 407.2 100  30 carvedilol  
+ 424.7 85.1  35 C18:2-carnitine  
+ 426.7 85.1  35 C18:1-carnitine  
+ 428.7 85.1  35 C18-carnitine  
+ 442 295  18 folate C00504 
+ 444.2 178  32 7,8-dihydrofolate C00415 
+ 455.3 165.3  40 verapamil  
+ 460.1 313.1  21 5-methyl-THF C00440 
+ 475.2 100.2  45 sildenafil  
+ 489.3 184.2  55 citicholine  
+ 494.1 169.1  51 glyburide  
+ 505.8 85.1  35 C24:4-carnitine  
+ 525.5 352.8  31 Diiodothyronine HMDB00582 
+ 540.9 85.1  35 C26-carnitine  
+ 559.3 440.3  30 atorvastatin  
+ 613 231  35 glutathione disulfide_pos C00127 
+ 651.9 606.1  35 triiodothyronine  
+ 664.1 428  32 NAD+_pos C00003 
+ 666.1 514  28 NADH C00004 
+ 678.3 147.3  52 cobalamin  
+ 688 348  27 dephospho-CoA_pos C00882 
+ 744.2 136  50 NADP+_pos C00006 
+ 746.15 729  18 NADPH C00005 
+ 768 261  39 coenzyme A_pos C00010 
+ 777.8 732  35 thyroxine  
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+ 786 348  26 FAD C00016 
+ 810 303  30 acetyl-CoA_pos C00024 
+ 824.1 317.1  35 propionyl-CoA_pos C00100 
+ 852 345  36 acetoacetyl-CoA_pos C00332 
+ 854 347  28 malonyl-CoA_pos C00083 
+ 868.1 361.1  40 succinyl-CoA_pos C00091 
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9.2.2 HILIC protocol 
 
 
 
 
Introduction 
HILIC Method 
 
This method measures polar compounds by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) using electrospray ionization (ESI) in the positive ion mode. Analytes include amino acids, 
nucleotides, neurotransmitters and selected medications and vitamins. 
 
Materials 
 
Chemicals: 
 
Methanol (MeOH) Thermo Fisher FSBA456-4 Methanol OPTIMA LC/MS grade– 4L 
Acetonitrile (ACN) Thermo Fisher FSBA955-4 Acetonitrile OPTIMA LC/MS grade– 4L 
Water Thermo Fisher FSBW6-4 Water OPTIMA LC/MS grade– 4L 
Formic Acid Sigma 06440 Fluka, puriss. p.a., ~98% 
L-Phenylalanine-d8 (98%) CIL* DLM-372-1 Isotopically labeled internal standard 
L-Valine-d8 (98%) Sigma 486027 Isotopically labeled internal standard 
*CIL = Cambridge Isotope Laboratories, Inc. 
Equipment: 
 
Pipettors Eppendorf various Research plus 
Multitube vortexer Ratek VM1 Vortex mixer (By CPC) 
Centrifuge Thermo Fisher FRESCO 21 Centrifuge (By CPC) 
Agilent Vial Rack Agilent 5067-0243 Rack for 2 mL glass vials 
*ASP = Analytical Sales & Products 
Consumable supplies: 
 
HPLC HILIC column Waters 186002015 Atlantis HILIC Silica 2.1 x 150mm, 3 µm 
Glass Vials Waters 186000273 Clear screw-top vial, 100 per pack 
Glass Vial Inserts Waters WAT072294DV 200 µL deactivated glass insert, 100 per pack 
Vial Caps Waters 186000274 Screw cap with bonded PTFE/silicone septa 
Pipet tips Eppendorf various Tips for Pipettes Research plus 
 
 
Reagent Preparation 
 
Extraction Medium:  Acetonitrile:Methanol:Formic Acid (75:25:0.2, v:v:v) 
1. Add 1 mL of formic acid to 125 mL of methanol in a 500 mL glass bottle. 
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2. Add 375 mL of acetonitrile. 
3. Store the solvent tightly-capped to prevent evaporation. 
 
Mobile Phase A:  0.1% Formic acid, 10 mM Ammonium Formate 
1. Transfer 0.631 g of Ammonium formate to 999 mL of HPLC grade water in a 1 L glass bottle. 
2. Add 1 mL of HPLC grade formic acid. 
3. Store at room temperature, tightly capped. 
 
Mobile Phase B:  0.1% Formic acid in Acetonitrile 
1. Add 1 mL of HPLC grade formic acid to 999 mL of HPLC grade acetonitrile in a 1 L glass bottle. 
2. Store at room temperature, tightly-capped. 
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Stock Solution of Internal Standards:  (10 mM of L-Valine-d8  stock and 10 mM of L-Phe-d8 stock solution) 
1. Weigh out 17.32 mg of isotopically labeled reference standard (L-Phenylalanine-d8) and 12.52 mg of L- 
Valine-d8  in a 15 mL screw cap vial. 
2. Add 10 mL of methanol to yield a final concentration of 10 mM. 
3. Store at -20°C, tightly-capped to prevent evaporation. 
 
HILIC IS-SS: Extraction Medium with Internal Standard: 
1. Pipet 100 µL of the stock solution containing 10 mM L-Phenylalanine-d8 and 10 mM L-Valine-d8 into a 500 
mL glass bottle containing 500 mL of Extraction Medium. 
2. Final concentration of each internal standard is 0.002 mM. Store at -4°C, tightly-capped to 
prevent evaporation. 
 
Master Mix of Reference Compounds: (0.2 µg/mL) 
1. To validate the HPLC retention times and tandem MS/MS transitions of the target analytes, a single 
master mix can be made. 
2. The final concentration of each analyte is 0.2 µg/mL, which corresponds to a 1:500 dilution from 
each standard’s stock solution. 
3. Store at -20°C, tightly-capped to prevent evaporation. 
 
Calibration Curve: 
1. A calibration curve for a specified analyte can be constructed from a stable isotope-labeled standard in 
pooled plasma, using serial dilutions. 
2. Starting with the 1000 µg/mL stock solution, make serial dilutions of the standard in Extraction Medium 
to achieve a final concentration of the standard of 0, 0.05, 0.1, 0.5, 1, 10, 50 and 100 µg/mL in pooled 
plasma. 
 
Standards Preparation for LC-MS/MS 
 
Standards: 
1. Add 20 µL of 500 µM analytical standard to 80 µL of HILIC IS-SS solution for a final volume of 100 µL in a 
0.6 mL microfuge tube to yield a final concentration of 100 µM. 
2. Vortex the samples to mix both. 
3. Pipet 70 µL of sample into a glass vial with glass insert. Cap each vial tightly and store at 4°C (or 10°C in the 
autosampler stack). 
 
Sample Preparation 
Extraction: 
1. Transfer 10uL of plasma into a 0.6mL microfuge tube. Add 90uL of HILIC IS-IS (cooled to -30oC) for 
a final volume of 100uL. 
2. Vortex the samples to promote protein precipitation. 
3. Centrifuge samples at 14000 rpm for 20 min at 4oc 
4. Transfer 75uL of supernatant into glass vial with inserts, taking care to avoid transferring protein 
pellet particles. Cap each vial tightly and store at -30oC (or 10oC in the autosampler stack) 
 
For making pooled plasma: 
1. Transfer 20 µL of each plasma from different groups (preferably from the same study mice/patient) into a 0.6 
mL microfuge tube. Vortex to mix the samples. Aliquot the required amount and stored the remains in -80°C. 
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2. Add 90 µL of HILIC IS-SS/ 70 µL of Amide IS-SS solution and 10 µL of the pre-mixed plasma/ 30 µL of the pre-
mixed plasma for Amide method to a new 0.6 mL microfuge tube to make up a final volume of 100 µL. 
3. Vortex the samples to promote protein precipitation. 
4. Centrifuge samples at 14000 rpm for 20 min at 4°C. 
5. Pipet 75 µL of sample into a glass vial with glass insert, taking care to avoid transferring protein pellet  
particles.  Cap each vial tightly and store at -20°C (or 10°C in the autosampler stack). 
 
For plasma spiked with standards: 
 
1. Transfer each sample into a 0.6 mL microfuge tube. 
2. Add 20 µL of 500 µM analytical standard to 30 µL of plasma to a final volume of 50 µL. 
3. Vortex the samples to mix both. 
4. Pipet 30 µL of the mixture and add to 70 µL of HILIC IS-SS solution for a final volume of 100 µL in another 
0.6 mL microfuge tube. 
5. Vortex the samples to promote protein precipitation. 
6. Centrifuge samples at 14000 rpm for 10 min at 4°C. 
7. Pipet 70 µL of sample into a glass vial with glass insert, taking care to avoid transferring protein pellet 
particles.  Cap each vial tightly and store at 4°C (or 10°C in the autosampler stack). 
 
Equilibration 
Equilibration is required for brand new columns or when you switch columns. New HILIC columns must  be 
equilibrated with 50:50 ACN:Water for 100 min at 0.25 ml/min followed by 40 minutes of the initial mobile phase 
conditions. If just switching between columns, then equilibrate with initial mobile phase conditions for 60 minutes. 
 
Analysis 
Analyst 1.5.1 Acquisition Method Name: HILIC_MRM_CNY_New.dam 
Autosampler settings: 
Autosampler: Leap CTC Pal or equivalent system 
Syringe: 50 µL 
Needle Rinse 1: 75:25 HPLC Water:Acetonitrile 
Needle Rinse 2: Acetonitrile 
Sample Stack Temperature 10°C 
 
Cycle Name:  
Delay Time Column 1: 0 sec 
Inject 2 Time: 1200 sec 
Delay Time Column 2: 0 sec 
Pre-clean with Solvent 2: 1 
Pre Inject Delay: 500 ms 
Post Inject Delay: 500 ms 
Column Sample Volume: 10 µL 
Filling Speed: 5 µL/sec 
Injection Speed: 10 µL/sec 
Post Clean with Solution 1: 2 
Post Clean with Solution 2: 2 
Valve Clean with Solution 1: 2 
Valve Clean with Solution 2: 2 
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Replicate Count: 1 
 
HLPC settings 
HPLC: Agilent QTRAP 5500 
Guard column: XBridge BEH Amide Van Guard Catridge, 3.5µm, 
2.1x5mm Column: Atlantis HILIC Silica, 3µm, 2.1x150mm 
Flow rate: 0.250 – 0.400 mL/min 
Column Sleeve: 25 cm column sleeve 
Column Temp: 30°C (can be modified to optimize separation and peak 
shape) Injection Volume: 10 µL 
Run Time: 25 minutes 
Mobile Phase A: 0.1% Formic acid in 10 mM Ammonium Formate (pH 
~2.5) Mobile Phase B: 0.1% Formic Acid in Acetonitrile 
Needle Rinse 1: Water:Acetonitrile (75:25, 
v:v) Needle Rinse 2: Acetonitrile 
 
Step Total Time (min) Flow Rate 
(µL/min) 
% A % B 
0 0.0 250 5 95 
1 0.5 250 5 95 
2 6.0 250 60 40 
3 9.0 250 60 40 
4 10.0 250 5 95 
5 11.0 400 5 95 
6 23.5 400 5 95 
7 24.5 250 5 95 
6 25.0 250 5 95 
 
Mass Spectrometer settings 
 
  
Q1 
 
Q3 
QTRAP 5500 
(RT) 
 
Metabolites 
 
DP 
 
EP 
 
CE 
 
CX
 
KEGG/HMDB 
Identifier 
1 76.018 30 10.14 Glycine 40 10 9 13 C00037 
2 90.23 44.069 10.15 Alanine 41 10 16 8 C00041 
3 116.095 70.04 10.49 Proline 51 10 24 13 C00148 
4 118.076 72.03 9.87 Valine 61 10 16 15 C00183 
5 120.099 74.055 10 Threonine 44 10 15 8 C00188 
6 121.94 59.1 11.01 Cysteine 63 10 26 9 C00491 
7 132.17 86.06 9.81 Isoleucine_Leucine 37 10 16 22  
8 132.17 69.01 9.63 Isoleucine 46 10 25 16 C00407 
9 132.17 43 9.52 Leucine 46 10 44 10 C00123 
10 134.14 73.97 10.23 Aspartate 85 10 19.5 12.5 C00049 
11 147.14 84.007 11.97 Lysine 51 10 25 12 C00047 
12 147.14 44 10.24 Glutamine_spec 51 10 73 10 C00064 
13 150.088 61.072 9.55 Methionine 44 10 33 10 C00073 
14 166.117 120.04 9.38 Phenylalanine 40 10 21 14 C00079 
15 182.139 91.066 9.41 Tyrosine 41 10 40 10 C00082 
 
16 
 
182.1 
 
136 
 
9.80 
Methionine sulfone 
(MetSul) 
 
51 
 
10 
 
15 
 
8 
 
HMDB02005 
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17 196.12 100 9.01 Methylsulfone (MES) 140 10 31 25  
18 205.114 188.047 9.21 Tryptophan 43 10 15 12 C00078 
19 133.15 74 10.2 Asparagine 56 10 22 10 C00152 
20 203.069 70.3 12.12 ADMA/SDMA 41 10 41 12 C03626 
21 118.013 58 11.09 Betaine 66 10 43 16 C00719 
22 232.076 85.1 10.84 C4-butyrl-carnitine 51 10 29 4  
 
23 
 
329.93 
 
135.9 
 
9.52 
Adenosine 3',5'-cyclic 
phosphate (cAMP) 
 
41 
 
10 
 
47 
 
16 
 
C00575 
24 104.808 59.8 11.28 Choline 111 10 31 12 C00114 
25 176.062 113.1 10.56 Citrulline 36 10 27 8 C00327 
 
26 
 
103.893 
 
57.9 
 
10.79 
Gamma aminobutyric 
acid (GABA) 
 
296 
 
10 
 
27 
 
26 
 
C00334 
27 189.974 144 8.23 Kynurenic acid 36 10 29 16 C01717 
28 132.92 70.1 11.48 Ornithine 46 10 25 8 C00077 
29 177.086 159.9 9.14 Serotonin 1 10 19 16 C00978 
30 125.901 44.1 9.26 Taurine 41 10 29 10 C00245 
31 777.623 731.8 8.71 Thyroxine 71 10 43 42 C01829 
32 651.783 605.8 8.71 Triidothyronine 31 10 31 16 C02465 
 
33 
 
75.87 
 
58 
 
10.81 
Trimethylamine N-oxide 
(TMAO) 
 
96 
 
10 
 
27 
 
8 
 
C01104 
34 267.004 135 9.81 3-deaazadenosine 106 10 35 14  
35 204.066 85 11.72 Acetylcarnitine 46 10 31 16 C02571 
36 147.059 88.2 11.3 Acetylcholine 51 10 21 14 C01996 
37 162.106 60 11.54 Carnitine 41 10 23 8 C00318 
38 120.086 74 9.73 L-Homoserine 51 10 17 10 C00263 
39 189 130 9.33 N-acetylglutamine 46 10 19 12 C00624 
 
40 
 
189.036 
 
70 
 
11.67 
NG-monomethyl-L- arginine 
(L-NMMA) 
 
56 
 
10 
 
35 
 
14 
 
C03884 
41 379.391 105.2 4.98 2-Arachidonyl glycerol 151 10 61 20 C13856 
42 305.298 77.1 5.01 Arachidonic acid 21 10 95 10 C00219 
43 162.079 98.1 10.67 Aminoadipic acid (AAD) 1 10 21 14 C00956 
44 268.002 136 8.30 Adenosine 26 10 29 18 C00212 
45 202.013 70.3 10.25 DMGV 46 10 23 8  
46 90.092 72 10.66 beta-Alanine 51 10 11 10 C00099 
47 131.928 62.8 8.95 Creatine 66 10 29 10 C00300 
48 184.964 98.9 11.77 Phosphocholine 61 10 29 12 C00588 
 
49 
 
131.753 
 
63.1 
 
8.98 
trans-hydroxyproline (t- 
HYP) 
 
51 
 
10 
 
51 
 
6 
 
C01157 
50 104.024 85.9 10.24 BAIBA 61 10 11 12 C05145 
51 106.074 88.094 10.08 Serine 46 10 15 10 C00065 
52 163.123 45.068 12.12 GlucosePos2 54 10 28 9 C00031 
53 175.139 70.02 11.27 Arginine 43 10 32 10 C00062 
54 126.1 80 0 Valine-d8 40 10 18 15  
55 174.2 128 0 Phe-d8 40 10 19 15  
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56 126.002 85.1 11.61 1-methylhistamine 41 10 27 10 C05127 
57 252.068 57 8.48 2'-deoxyadenosine 46 10 57 16 C00559 
58 227.976 111.9 9.02 2'-deoxycytidine 71 10 21 52 C00881 
 
59 
 
191.966 
 
146 
 
5.25 
5-hydroxyindoleacetic acid 
(5-HIAA) 
 
61 
 
10 
 
27 
 
24 
 
C05635 
60 158.926 117.9 11.56 Allantoin 41 10 17 12 C01551 
61 241.033 109.2 12.67 Anserine 31 10 35 16 C01262 
62 177.059 80.2 8.51 Cotinine 41 10 35 12 HMDB01046 
63 152.907 65.1 7.80 Cystamine 51 10 33 10  
64 78.858 61 12.64 Cysteamine 16 10 29 8 C01678 
65 243.977 112.1 8.5 Cytidine 71 10 29 28 C00475 
66 112.004 95 9.19 Cytosine 101 10 23 10 C00380 
67 92.83 75 12.47 Glycerol 46 10 15 10 C00116 
68 112.921 68.1 12.59 Histamine 36 10 45 8 C00388 
69 202.977 70.1 11.9 Spermine 56 10 37 10 C00750 
70 265.916 122 12.96 Thiamine 36 10 29 14 C00378 
71 242.985 127.2 6.27 Thymidine 26 10 29 6 C00214 
72 244.982 113.1 6.84 Uridine 66 10 23 10 C00299 
 
73 
 
190.001 
 
129.9 
 
4.92 
3-indolepropionic acid 
(3-IPA) 
 
56 
 
10 
 
31 
 
14 
 
HMDB02302 
74 120.977 94.2 7.99 Purine 56 10 31 14 C15587 
75 169.988 151.9 9.75 Pyridoxine 36 10 21 18 C00314 
76 377.047 243 7.71 Riboflavin 21 10 33 18 C00255 
77 348.133 67 5.67 Anandamide 76 10 30 15 C11695 
78 148.15 84 9.95 Glutamate 54 10 23 10 C00025 
79 156.072 110 11.34 Histidine 49 10 21 12 C00135 
 
80 
 
224.996 
 
208.1 
 
9.35 
3-hydroxykynurenine 
(3HK) 
 
61 
 
10 
 
13 
 
6 
 
C02794 
81 227.002 110 12.48 Carnosine 51 10 33 14 C00386 
82 141.868 58 11.31 Phosphoethanolamine 291 10 37 6 C00346 
83 400.141 358.3 7.58 Colchicine 116 10 31 16 HMDB15466 
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Mass Spectrometer: AB Sciex API-5500 QTrap triple quadrupole mass 
spectrometer Interface: Turboionspray, positive ionization mode 
Scan Mode: Scheduled multiple reaction monitoring 
(MRM) sMRM Window: 30 sec 
Target Scan Time: 1.0 sec 
Source Temp: 450°C 
Ion Source position: Vertical: 1, Horizontal: 
5 Parameters 
CAD Gas: High CUR Gas: 
25 Ion Spray (v): 4500 
TEMP: 350 Gas 1: 30 
Gas 2: 30 Exit Potential (EP): 
10 Resolution Q1: Unit 
Resolution Q3: Unit 
 
Diverter Valve: 
Valve: Valco Diverter Valve 10 port 2 position LTG 
WC027522 (Applied Biosystems), or 
equivalent 
Valve Cable Assembly 2 position actuator, 
WC024740 Position A: Flow to waste 
Position B: Flow to ion source 
 
 
Notes when integrating peaks: 
 
Leucine and isoleucine in same window. Leucine is first and isoleucine is second peak. 
ADMA/SDMA. Integrate both peaks 
Glutamate: 1st peak 
Glutamine: 2nd peak 
5 OH tryptophan: 1st peak 
Cytosine: middle peak
